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Abstract
Apoptosis is the programmed cell death mechanism responsible for regulation of cell 
number during tissue development and maturity. However, dysregulation of 
apoptosis has pathological consequences, particularly in the brain, where 
‘inappropriate’ apoptosis leads to neurodegeneration.
Neuronal apoptosis is primarily initiated by release o f  the respiratory protein 
cytochrome c from mitochondria, the organelles responsible for aerobic respiration. 
Considerable interest has been focussed on the mechanism o f  cytochrome c release, 
but surprisingly little on the nature o f  the cytochrome c signal itself. It has been 
claimed that release is all-or-none, however this ;is inconsistent with accumulating 
evidence o f  cytosolic mechanisms for ‘buffering’ cytochrome c.
This study has addressed two primary methodological weaknesses in the field, by 
modelling an underlying disease pathology, rather than artificially inducing apoptosis, 
and by using a truly quantitative assay for measuring cytochrome c concentration. 
These experimental advantages have yielded the first demonstration that cytochrome 
c is released in proportion to the severity o f  pathological insult. The model adopted 
was reduced activity o f  the mitochondrial NADH:ubiquinone oxidoreductase, a 
recognised feature o f  Parkinson’s disease, induced in this case by rotenone titration.
The controlled, proportional release observed invited the hypothesis that a low level 
o f  cytochrome c release is insufficient to induce apoptosis. In support of this 
suggestion, the mechanism o f  release was determined to be conducive to cell survival
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given hypothetical ‘sub-threshold’ release. It was also demonstrated that release is 
likely to be induced following mitochondrial generation o f  reactive oxygen species, 
o f  which there is believed to be a constitutive basal level. Finally it was established 
that in primary cortical neurons, respiratory inhibition can induce cytochrome c 
release which is sub-threshold for induction o f  apoptosis.
The study has generated considerable support for therapeutic exploitation of the 
cytosolic ‘Inhibitor o f  Apoptosis Proteins’, for delaying progression o f  Parkinson’s 
and other neurodegenerative diseases.
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CHAPTER 1
General Introduction
1.1 Mitochondria
1.1.1 Origin
Mitochondria are discrete organelles found in the cytosol o f  most eukaryotic cells. 
They are thought to have evolved from free-living bacteria. These early prokaryotes 
are suggested to have been engulfed by larger cells, with which they forged a 
symbiotic relationship. Now dependent on their host cells, mitochondria still display 
evidence to suggest a former prokaryotic existence, for instance retaining their own 
DNA and bacteria-like ribosomes. This ‘Endosymbiont Hypothesis’ was popularised 
by Lynn Margulis (1981) and is now widely accepted.
1.1.2 Respiratory function
Mitochondria have evolved to contribute the facility o f  aerobic respiration in 
eukaryotic cells. They are contained within two membranes, an outer (OM) and an 
inner (IM) membrane. The OM is permeable to molecules o f  less than lOkDa, due to 
the presence o f  porin channels within the phospholipid bilayer. This means that ATP, 
ADP and ions (plus other small proteins) can all freely translocate between the ‘inter­
membrane space’ (IMS) and the cytosol. The IM, in contrast, is impermeable to most 
ions and solutes, except through specific carriers, eg. the adenine nucleotide 
translocator (ANT) which allows ADP and ATP to move between the matrix and the 
IMS. The IM is highly invaginated, with folds organised into layers known as cristae. 
The IM therefore has a much larger surface area than the OM. It also has a 
significantly greater protein concentration. In addition to requiring numerous
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transporter proteins, the IM also encompasses the machinery required for ‘oxidative 
phosphorylation’, the process which underlies aerobic respiration (reviewed by 
Scheffler, 1999).
This machinery makes up the ‘Electron Transport Chain’, or ETC. This is a series of 
anchored protein complexes and mobile electron carriers, which together serve to 
create a proton electrochemical gradient. This has two components: a pH difference 
and a membrane potential (Avj/m) which is due to charge separation. Dissipation of 
this ‘proton motive force’ can be used to power the phosphorylation o f  ADP to form 
ATP (Mitchell, 1961). The components o f  the ETC are used in order o f  increasing 
reduction potential, such that an electron flows spontaneously through the chain (see 
Figure 1.1). Electrons are accepted initially from NADH and succinate, and at the 
site o f  the final complex in the chain, donated to molecular oxygen to form water. In 
three o f  the four complexes o f  the ETC, electron transfer is coupled to movement of 
protons from the matrix to the IMS. This leads to generation o f  the proton motive 
force across the IM. Experimentally, this gradient can be approximated to A\|/m<and it 
is this parameter which is generally referred to in the literature.
Movement o f  protons back down the gradient via the ATP synthase provides energy 
for the phosphorylation o f  ADP to ATP, at the expense of Ai|/m. In addition, protons 
appear to ‘leak’ back down the gradient, crossing the IM by a means other than the 
ATP synthase (reviewed by Kadenbach, 2003). This leak reduces the efficiency of 
oxidative phosphorylation.
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ADP ATP
Figure 1.1
Schematic diagram of the mitochondrial ETC. Electrons, donated by nicotinamide 
adenine dinucleotide (NADH) and succinate, pass down a series o f protein complexes 
and electron carriers o f  increasing reduction potential. The passage o f electrons is 
coupled to the generation of a proton gradient (extrusion o f protons is coupled to 
electron transfer through complexes I, III and IV), which can be used to power the 
ATPase, also known as complex V of the ETC. Electrons are donated to molecular 
oxygen at the end of the chain, forming water.
7.7
The individual complexes will now be described in more detail (general references 
Heales et al, 2002, Lehninger et al, 1993) with particular emphasis on complexes I 
and IV, which will feature most prominently in this study. A number o f  universal 
electron carriers are also used in the ETC. In addition to NADH, flavin 
mononucleotide (FMN) and flavin adenine dinucleotide (FAD) can both act as 
electron acceptors and donators. They shuttle electrons in pairs (as FMNH2 and 
FADH 2 ), using ‘semiquinone’ forms as intermediates (FMNH and FADH). Fe-S 
centres, in contrast, are single electron carriers, containing Fe and S atoms in 1:1 
stoichiometry. Their function relies on the single electron oxidation or reduction of 
the Fe ions.
1.1.2.1 Complex I (EC 1.6.5.3)
Complex I is commonly known as the NADH dehydrogenase or NADH:ubiquinone 
oxidoreductase. It is the largest o f  the ETC enzyme complexes, the mammalian 
enzyme comprising 45 subunits (Carroll et al, 2002). It contains two types of 
prosthetic groups: an FMN group and at least 6 Fe-S centres. It is thought to exist as 
a dimer. The complex has an L formation, with a short arm (the NADH 
dehydrogenase) extending into the matrix and a long arm (the ubiquinone 
hydrogenase) which is largely held within the IM. The two are connected by a 
narrow stalk.
The process o f  electron transport through complex I is shown schematically in Figure 
1.3. Electrons are donated by NADH, which is present in the matrix as a product of 
the TCA cycle. NADH produced by glycolysis is imported from the cytosol by the 
malate-aspartate shuttle (primary mechanism in liver, kidney and heart mitochondria),
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and the glycerol-3-phosphate shuttle (primary mechanism in brain and skeletal 
muscle mitochondria). The FMN group o f  complex I accepts hydrogen atoms from 
NADH, and is reduced to FMNH 2 . This species is recycled to the oxidised form, 
donating two electrons to the Fe-S cluster, and releasing two protons back into the 
matrix. The Fe-S cluster donates the two electrons to ubiquinone (UQ), which on 
accepting two protons from the matrix along with the electrons, becomes reduced to 
ubiquinol (UQH 2 ), via a semiquinone intermediate (UQH). The UQ in this stage of 
the pathway is anchored within complex I. UQH 2 then donates the two electrons to a 
second cluster o f  Fe-S groups, releasing the two associated protons into the IMS. 
Now in the ubiquinone hydrogenase region o f  the complex, electrons are passed from 
the Fe-S centres onto UQ, which in this case is freely mobile within the IM. Once 
again, via a UQH intermediate, the electron carrier is reduced to UQH 2 , taking up two 
protons from the matrix in the process. UQH 2 then migrates through the IM and 
passes on the two electrons to complex III.
The net reaction catalysed by complex I is:
NADH + UQ + 5H+j -------► NAD+ + UQH2 + 4H+0
where H+, are internal protons, ie. in the matrix, and H+0 are external protons, ie. in 
the IMS. Therefore there is a net extrusion o f  four protons per NADH oxidised. This 
contributes to the generation o f  Av|/m across the IM.
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Figure 1.2
Schematic diagram to demonstrate the structure and function o f  complex I (NADH 
dehydrogenase). Electrons are donated by NADH in the matrix, and via FMN, 
clusters o f Fe-S centres and anchored ubiquinone, are ultimately passed on to 
ubiquinone in the IM to form ubiquinol, which can then diffuse from the complex. 
There is a net translocation o f  four protons from the matrix to the IMS for every 
NADH oxidised.
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Complex I can be inhibited using a variety of compounds. The most commonly used 
of these experimentally is rotenone, a commercially used pesticide, whose structure is 
shown in Figure 1.3. Rotenone is a ‘class IF inhibitor of complex I, meaning that it 
inhibits in a non-competitive manner (as opposed to ‘class V inhibitors such as 
piericidin A, which are partially competitive with UQ). Like all other known 
inhibitors o f  complex 1, rotenone acts on the matrix-embedded long arm of the 
complex, arresting electron transfer from the Fe-S cluster to the free UQ in the IM 
(Friedrich et al, 1994).
o
OCH
Figure 1.3
The structure o f rotenone, class II inhibitor of complex I.
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1.1.2.2 Complex II (EC 1.3.5.1)
Complex II is commonly known as succinate dehydrogenase or succinate:ubiquinone 
oxidoreductase. In addition to its role in the ETC, this enzyme complex also 
functions in the TCA cycle upstream of oxidative phosphorylation.
Complex II is composed o f  four subunits, and contains two types o f  prosthetic 
groups: a covalently bound FAD and Fe-S centres. The enzyme can accept electrons 
from succinate via the FAD group. The electrons are then passed through the Fe-S 
centres and donated to free UQ in the IM to form UQH 2 .
The net reaction catalysed by complex II is:
succinate + U Q ---------------► fumarate + UQH 2
and there is no net transfer o f  protons from the matrix to the IMS.
UQH 2 migrates to complex III, where it donates a pair o f  electrons and is therefore 
oxidised.
Complex II can be inhibited using malonate.
1.1.2.3 Complex III (EC 1.10.2.2)
Complex III is also known as the cytochrome bc\ complex, or ubiquinone- 
cytochrome c oxidoreductase. It exists as a homodimer and is composed o f  eleven
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subunits. Complex III contains two types o f  prosthetic groups: hemes and Fe-S 
centres. The cytochrome b proteins {b ^ i and b5()(y) span the IM, while cytochrome c\ 
and the Fe-S centre are localised to the IMS face o f  complex III.
Electrons are donated by UQH 2 , which enters a ‘Q cycle’ within the enzyme
complex. This is as a result o f  the Fe-S centre being only a single electron carrier. 
Following acceptance o f  one electron from UQH 2 , the Fe-S centre cannot be further 
reduced. The resulting UQH is therefore forced into donating the second electron to 
the heme b group. UQ can then re-enter the soluble membrane pool. Meanwhile, 
within complex III, the electron is passed onto a second heme b group, which can 
reduce UQ from the membrane pool back to semiquinone. When a second electron is 
passed through the system, this UQH can be reduced to UQH 2 and returned to the 
membrane pool. The effect o f  this Q cycle is to enable the net efflux o f  four protons 
into the IMS for every UQH 2 which is oxidised. This again contributes to generation 
of  Ai|/m (Reviewed by Hunte et al, 2003).
The net reaction catalysed by complex III is therefore:
UQH2 + 2cyt c3++ 2H+i . ^  UQ + 2cyt c2+ + 4H+„
Cytochrome c is released from complex III in the reduced form, and migrates to
complex IV, where it is oxidised.
Complex III can be inhibited using myxothiazol or antimycin A.
28
1.1.2.4 Complex IV (EC 1.9.3.1)
Complex IV is commonly known as cytochrome c oxidase. The mammalian enzyme 
is composed o f  thirteen subunits, and contains two types o f  prosthetic groups: hemes 
and copper ions. The hemes are incorporated within cytochromes a and cij. Both of 
these cytochromes are in rapid redox equilibrium with a copper centre (Cua and Cur, 
respectively). Electrons are donated by reduced cytochrome c (which has migrated 
from complex III) and are passed, via the two bimetallic redox centres, to oxygen. A 
simplified diagram o f  the currently understood mechanism o f  electron transfer 
through complex IV is shown in Figure 1.4.
The mechanism by which electrons are transferred through complex IV has been the 
subject o f  considerable interest. In particular, the role o f  the bimetallic Cu- 
cytochrome a centre in causing the four-electron reduction o f  oxygen has been 
investigated. A basic scheme for this process is shown in Figure 1.5. The process is 
suggested to create a kind o f  ‘oxygen trap’. As soon as the heme is reduced (ie. Fe3+ 
reduced to Fe2+), oxygen can be bound. On binding, the reduced heme and Cu 
centres very rapidly donate an electron to each o f  the oxygen atoms, themselves being 
oxidised back to Fe3+ and Cu2+ respectively. Once this rapid phase has been 
completed, the reaction is irreversible, therefore the process effectively ‘traps’ 
oxygen.
The net reaction catalysed by complex IV is:
4cyt c2* + 8H+| + 0 2---------► 4cyt <?3+ + 4H+0 + 2H20
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Figure 1.4
Schematic diagram to demonstrate the structure and function o f  complex IV 
(cytochrome c oxidase). Electrons are donated by cytochrome c, and ultimately 
passed on to oxygen in the matrix to form water. This is the point of oxygen 
consumption during mitochondrial respiration. There is a net translocation o f one 
proton from the matrix to the IMS for every cytochrome c oxidised, and a further 
proton is consumed chemically.
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There is a net efflux o f  one proton per cytochrome c oxidised. However, due to the 
influx o f  one electron, there is a net two charge transfer per cytochrome c oxidised. 
Complex IV is therefore the third complex able to contribute to the generation of 
A\|/m.
Complex IV can be inhibited experimentally using cyanide. Nitric oxide and carbon 
monoxide are also recognised inhibitors. The inhibition o f  complex IV by cyanide is 
not fully understood. It appears that the CN" ion may bridge the heme oj-Cub 
bimetallic centre in its fully oxidised form, thus forming a Fe3+-CN'-Cu2+ moiety 
(Gardner et a l, 1996). Assuming that this complex has a lower reduction potential 
than the bimetallic centre alone, then electron transfer through complex IV and 
therefore the generation o f  A\pm would be inhibited.
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Figure 1.5
Schematic diagram to demonstrate the mechanism utilised by complex IV to 
complete the four-electron reduction o f oxygen to water without the generation of 
free radical intermediates. This is achieved by the bimetallic Fe-Cu group. (Adapted 
from Babcock & Wikstrom, 1992).
1.1.2.5 Complex V
Complex V is more commonly known as the ATP synthase. Structurally, the enzyme 
contains two major sectors, Fi and F0. Fc is a transmembrane complex spanning the 
IM, is composed of  four polypeptides and forms the channel for proton translocation. 
The ‘o’ notation refers to the sensitivity o f  this region to oligomycin. F| projects into 
the matrix, and contains the catalytic machinery for ATP synthesis.
Functionally, the complex is tripartite. The first region to act is a motor or turbine 
which converts the energy generated from the flow o f  protons through F| down the 
gradient into rotational energy. Following this, a ‘rotating transmission device’ 
transmits the rotational energy to the catalytic sites. Finally, there are three catalytic 
sites which transform rotational energy into the chemical energy required for 
formation o f  the bond between ADP and Pj.
The ATP synthase enzyme can function in reverse to hydrolyse ATP at the expense of 
Ai|/m. It has been proven that this function is associated with subunit rotation within 
the complex. It is believed that the reverse rotation mediates the phosphorylation of 
ADP.
1.1.3 The ETC and reactive oxygen species
The ETC is a site where oxygen and unpaired electrons are permanently in close 
proximity. Incomplete reduction o f  molecular oxygen results in the generation of 
reactive oxygen species (ROS) instead o f  water. It is perhaps not surprising, 
therefore, that an estimated 1 -  3% of the total oxygen consumed at the ETC is
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converted to ROS (Boveris et al, 1972). Monoelectronic reduction o f  oxygen yields 
the superoxide radical (C^*"). Complexes I and III are thought to be the major sites of 
production o f  superoxide in the ETC. It has been suggested that if generated at 
complex I, superoxide is released on the matrix side o f  the IM (St-Pierre et al, 2002). 
Either the Fe-S centres (Genova et al, 2001) or the active site flavin (Liu et al, 2002) 
are thought to be the major site o f  electron leak to oxygen within complex I. 
Conversely, complex III is thought to release superoxide on the cytosolic face of the 
IM. The UQH in the Q cycle o f  complex III (see l.l .2.3) is thought to be the primary 
site o f  electron leak to oxygen within complex III (Turrens et al, 1985).
The role o f  reduced intermediates in the mitochondrial generation o f  superoxide may 
be an explanation for the observed dependence o f  the process on Avj/m. It has been 
suggested that dissipation o f  A\|/m, and therefore maximal oxidation o f  electron 
carriers such as UQ, reduces the potential for reduction o f  oxygen to superoxide 
(Skulachev, 1996). Indeed in Drosophila mitochondria, a 10% decrease in A\|/m was 
sufficient to abolish approximately 70% o f  the ROS generation by reverse electron 
flow through complex I (Miwa & Brand, 2003). The relationship has been 
specifically demonstrated in brain mitochondria, where ROS generation is decreased 
by opening the mitochondrial ATP-sensitive K+ channel (and therefore reducing Avpm) 
(Ferranti et al, 2003).
Superoxide is rapidly converted to hydrogen peroxide (H2 O 2 ), a reaction accelerated 
by four orders o f  magnitude by superoxide disniutase (SOD). H2 O 2 can then be 
oxidised to water by glutathione peroxidase, using reduced glutathione (y- 
glutamylcysteinylglycine, GSH) as an electron donor. As a result, GSH is oxidised to
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glutathione disulphide (GSSG) but can be recycled to GSH via the glutathione 
reductase reaction. Alternatively, H2 O 2 can be oxidised to water and molecular 
oxygen in a reaction catalysed by catalase (see Figure 1.6).
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Figure 1.6
Cellular disposal o f  superoxide. Superoxide is rapidly converted to hydrogen 
peroxide in the presence o f superoxide dismutase. This may then be reduced to water 
either by glutathione peroxidase (GPx) 0 1* catalase. Alternatively, hydrogen peroxide 
can form the hydroxyl radical via a Fenton reaction. This is one of a number of 
possible alternative fates; reactions with other proteins or iron in heme proteins can 
also occur.
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1. 1.4 Brain mitochondria
1.1.4.1 Mitochondrial heterogeneity
Mitochondria differ in their properties depending on the tissue from which they 
originate. Indeed in some regions there is variation within one tissue type and even 
within one cell. The brain is an example o f  a tissue in which such diversity in 
mitochondrial properties is observed. Brain mitochondria differ from those from 
heart, liver, muscle, kidney etc. in many ways, eg. susceptibility for calcium-induced 
damage (Kristian et al, 2000), extent o f  ROS generation and antioxidant capacity (Liu 
et al, 2000), and proton leak (Rolfe et al, 1994). Further to this, discrepancies in 
mitochondrial function have been observed between different regions and cell types 
o f  the brain eg. in sensitivity to calcium (Brustovetsky et al, 2003a), response to 
oxygen and glucose deprivation (Almeida et al, 2002), ETC complex activities 
(Battino et al, 1991) and other enzyme activities (Lai et al, 1994).
1.1.4.2 Experimental isolation o f  brain mitochondria
The heterogeneity o f  brain mitochondria is taken into account when isolating these 
organelles for experimentation. Methods have been developed by Lai and Clark 
(1989) for the isolation o f  both ‘non-synaptic’ and ‘synaptic’ brain mitochondria. 
Mitochondria classified as non-synaptic are more plentiful in the brain, since the term 
encompasses all brain mitochondria excepting those from the synaptic terminals of 
neurons. This excluded population are the synaptic mitochondria, o f  which the yield 
is relatively much smaller per unit mass o f  brain.
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The isolation procedure involves a series o f  centrifugation steps, including an 
ultracentrifugation o f  a density gradient, which is used to separate myelin, 
synaptosomes (from which synaptic mitochondria can be released) and ‘free’ (or non- 
synaptic) mitochondria. Throughout the preparation, yield is sacrificed for purity. 
Brain tissue has a particularly high lipid content. The presence o f  lipids such as 
myelin during the mitochondrial preparation allows vesicle formation during 
homogenisation, which contaminates a preparation o f  otherwise isolated 
mitochondria. Due to the need to eliminate non-mitochondrial material, the isolation 
o f  brain mitochondria is a process o f  longer duration than that for their heart or liver 
counterparts, for example. The yield is also much lower per unit mass o f  original 
tissue. This would explain the relative lack o f  literature concerning isolated brain 
mitochondria as compared to those from other sources.
However, as described, there are important differences in properties between 
mitochondria from different tissues, hence the importance o f  using the relevant 
source. The isolation o f  synaptic mitochondria is an even more arduous procedure 
than that o f  non-synaptic mitochondria, involving a larger number o f  centrifugation 
steps including two density gradient ultracentrifugation spins. O f those isolated 
mitochondria studies which use brain mitochondria, a low percentage o f  this subset 
are o f  synaptic origin. The understanding that synaptic mitochondria have distinctive 
properties (Almeida et al, 1995; Davey et al, 1998) and their particular importance in 
the pathology o f  neurodegeneration underlie the need to make more frequent use of 
them as an experimental tool.
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1.1.4.3 Brain mitochondria in neurodegenerative disease
As described later (1.3.3), mitochondria have an important role in initiating cell death. 
This implicates the organelles in the neuronal loss observed in neurodegenerative 
disease. However, there is a more clinically recognised link between brain 
mitochondria and neurodegenerative pathologies which relates to the activities o f  the 
ETC enzyme complexes. The majority o f  neurodegenerative diseases are associated 
with reduced activity o f  at least one o f  the complexes. For example, complex I 
activity is reduced in the brains o f  patients with Parkinson’s disease (Schapira, 1990), 
Alzheimer’s disease and Down syndrome (Kim et al, 2001), complex II/II1 deficiency 
is detected in Huntington’s disease brain (Gu et al, 1996), and complex IV deficiency 
in brain tissue from Leigh disease patients (Cacic et al, 2001).
1.2 Cytochrom e c
This study will focus on the particularly important and contradictory roles o f  the 
electron carrier cytochrome c (see 1.2.3).
1.2.1 Structure
Cytochrome c is a 12.1kDa protein consisting o f  a single polypeptide chain of 104 
amino acids, covalently attached to a heme group. It is one o f  a family o f  
cytochromes, all o f  which are iron-containing electron transfer proteins. The three 
classes o f  cytochromes within this family, a, b and c, are defined by their light
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absorption spectra. The longest wavelength absorption band is approximately 600nm 
for type a , 560nm for type b and 550nm for type c cytochromes.
The redox properties are afforded by the heme group which is present in all 
cytochromes. The heme group is a porphyrin ring structure, composed of four, 
smaller, nitrogen containing rings. The porphyrin ring is centred around an Fe ion, 
which can exist in the oxidised (or ferricytochrome c, Fe3") or reduced (or 
ferrocytochrome c, Fe2+) state, hence the redox properties o f  the cytochrome. Each 
class o f  cytochrome has a different form o f heme. Cytochrome c, which contains 
heme C, is unique within the family in its covalent attachment to the heme group; 
cytochromes a and b form tight but non-covalent associations with heme A and heme 
B, respectively.
The amino acid sequence o f  cytochrome c has been determined in a wide range of 
species, including human (Matsubara & Smith, 1962) and rat (Scarpulla et al, 1981). 
The structure o f  heme C is shown in Figure 1.7.
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Figure 1.7
Structure o f  heme C. The areas shaded in blue are the sites o f covalent attachment 
with the cytochrome protein. Thioether bonds are formed with the two cysteine 
residues.
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1.2.2 The biometabolism o f  cytochrome c
1.2.2.1 Synthesis
Cytochrome c. is encoded by nuclear DNA. However, it is constitutively localised to 
the IMS and IM of mitochondria (or the lumen o f  chloroplasts or outside the 
cytoplasmic membrane in bacteria, depending on the system). A crucial factor in the 
biogenesis o f  cytochrome c is therefore its translocation to the target location. It is 
understood that cytochrome c is synthesised at the site o f  cytosolic ribosomes as 
‘apocytochrome c \  which is the protein without the heme moiety. Apocytochrome c 
is converted to ‘holocytochrome c? (or simply cytochrome c) by ligation o f  heme at 
the site to which it has been targeted. The heme ligation process varies depending on 
the system (ie. mitochondria, chloroplast or bacteria). O f interest in this study is 
cytochrome c which is located at the IMS and IM o f  eukaryotic mitochondria, 
therefore this is the system which will be described.
Apocytochrome c, having been synthesised on cytosolic ribosomes as described, 
translocates to mitochondria due to an internal (rather than N-terminal) targeting 
sequence. It is ‘trapped’ in the IMS of mitochondria by the enzyme cytochrome c 
heme lyase (CCHL). The action o f  the enzyme, as the name suggests, is to attach the 
heme group onto the apo-protein. Prior to the association o f  heme, apocytochrome c 
has a protease-sensitive unfolded conformation. This may be a crucial factor in the 
import process across the OM (Jordi et al 1992). However, once heme has been 
covalently attached via the CCHL, cytochrome c adopts a protease-resistant, folded 
form, which is then released from CCHL into the IMS. It then appears to exist in 
dynamic equilibrium between freely soluble and IM-associated states (1.2.2.2).
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Generally, mitochondrial proteins which are encoded by the nucleus, and therefore 
synthesised in the cytosol, require the translocase o f  the mitochondrial OM, known as 
the TOM complex (Li 11 & Neupert, 1996) or other protease-sensitive OM 
components for targeting and import into the mitochondria. It has been claimed that 
activity o f  the CCHL enzyme on the peripheral surface o f  the OM is sufficient to 
cause import o f  apocytochrome c into the IMS (Mayer et al, 1995), independently of 
the TOM complex. This is disputed by Diekert et al (2001), who claim that the TOM 
complex is in fact required for import o f  cytochrome c. Aside from this debate, it is 
accepted that cytochrome c appears to employ a unique import pathway.
It should be noted that the initial and final stages o f  heme biosynthesis take place in 
the mitochondrial matrix. The last stage o f  the heme synthesis process is the insertion 
o f  ferrous iron into the protoporphyrin ring by ferrochelatase (reviewed by Ferreira, 
1995). Heme must be in the reduced form during covalent attachment to 
apocytochrome c, therefore heme must be maintained in this ferrous form. Yet to be 
identified are the components o f  the heme translocation and membrane transport 
processes and the IMS mechanisms for maintenance o f  the reduced form of heme.
1.2.2.2 Constitutive localisation
Following heme attachment, it is recognised that cytochrome c is constitutively 
localised to the IMS. However, it has become increasingly apparent that there is a 
certain extent o f  anchoring o f  cytochrome c to the IMS face o f  the IM. This may be 
mediated by the IM phospholipid cardiolipin (Cortese et al, 1998; Nicholls, 1974). It 
is thought that the varying levels o f  association o f  cytochrome c with the IM via
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cardiolipin have important implications for the susceptibility o f  the protein to be 
released into the cytosol (see 1.3.5.3).
1.2.2.3 Degradation
Cellular proteins which are constitutively localised to the cytosol or nucleus are 
generally degraded in the cytosol by the action o f  the proteasome. Prior to this 
process, proteins are attached to a 76-residue ubiquitin protein via an isopeptide bond. 
Ubiquitination signals that the bound protein should be targeted for degradation by 
the proteasome. Mitochondria, however, do not express the proteasome. 
Nonetheless, proteins which are constitutively localised to the mitochondrial matrix 
can be degraded in the same compartment, by a variety o f  ATP-dependent and ATP- 
independent proteases (reviewed by Bota and Davies, 2001).
There is, however, very little information available in the literature on the fate o f  IMS 
proteins with respect to degradation. Bearing in mind the limited permeability o f  the 
IM, it would appear more likely that IMS proteins would be subject to cytosolic, 
rather than matrix-based degradation. In accordance with this, it has been shown that 
yeast cytochrome c, in either the oxidised or reduced form, readily undergoes 
ubiquitination in vitro (Sokolik & Cohen, 1992). It appears that the understanding of 
cytochrome c degradation has not progressed from this point. It is possible that the 
cytochrome c protein is degraded by the proteasome, and that the heme groups are 
excreted. However, it is unclear whether there are specific protective mechanisms in 
place to prevent cytochrome c which is released from mitochondria for the purpose of 
degradation from exhibiting its pro-apoptotic role (as described in 1.3.3.1).
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1.2.3 Roles o f  cytochrome c
1.2.3.1 Electron carrier in the ETC
The longest established role o f  cytochrome c is as an electron carrier in the 
mitochondrial ETC. This chain o f  enzyme complexes was described in 1.1.2. 
Cytochrome c accepts an electron from complex III (ubiquinone:cytochrome c 
oxidoreductase), and is released as ferrocytochrome c. On encountering complex IV 
(cytochrome c oxidase), cytochrome c donates the electron, thus returning to the ferri 
form.
1.2.3.2 Pro-apoptotic signalling protein
Relatively recently, cytochrome c has been exposed to have somewhat o f  a “Jekyll 
and Hyde” character. In addition to its vital role in the ETC, it has become apparent 
that cytochrome c can actively initiate the programmed cell death mechanism known 
as apoptosis (see 1.3.3.1) (Liu et al, 1996). If released from the IMS into the cytosol 
o f  the host cell, cytochrome c induces an amplifying cascade o f  proteolytic enzyme 
activity, which ultimately is fatal to the cell. (Importantly, this capacity is limited to 
holocytochrome c -  apocytochrome c has no pro-apoptotic properties - Yang et al, 
1997). The apoptotic process is an essential part o f  development and physiological 
regulation o f  cell number, however dysregulation can have pathological consequences 
such as tumourigenesis and neurodegeneration.
1.2.3.3 Anti-oxidant
The two main roles o f  cytochrome c are described above. However, it is also 
recognised that cytochrome c has anti-oxidant properties. It has been known for some
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time that cytochrome c can oxidise superoxide back to oxygen (Nakano, 1990). An 
intriguing study by Korshunov and co-workers (1999) demonstrates that 
submicromolar concentrations o f  cytochrome c external to the mitochondria are 
capable o f  inhibiting ROS generation at complex I.
1.3 Apoptosis
1.3.1 The definition o f  apoptosis
Apoptosis is a term coined in 1972 by Kerr, Wyllie and Currie. In contradiction to 
the title o f  this much-cited paper, the process is far from basic. It describes a form of 
cell death which can be seen as suicide. In response to a pro-apoptotic stimulus, a 
cell undergoes a controlled sequence o f  events, depending on the presence of 
sufficient ATP, culminating in chromatin condensation, nuclear fragmentation, cell 
shrinkage and plasma membrane blebbing. The cell carefully packages its contents 
into small, membrane-bound vesicles, which can then be phagocytosed. By 
committing itself to death in this way, the cell prevents the generalised release o f  its 
contents, including lysosomal enzymes etc., to the extracellular environment. The 
process does not initiate any localised inflammation (Arends & Wyllie, 1991). This 
is in contrast to necrotic cell death, where massive and uncontrolled membrane 
breakdown leads to non-specific release o f  potentially dangerous cellular contents 
into the surroundings o f  neighbouring cells. Death by apoptosis provides significant 
‘damage limitation’ with respect to the remaining cells.
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1.3.2 Physiological versus pathological apoptosis
This ‘damage limitation’ aspect o f  apoptotic cell death is crucial to its role as a 
mechanism o f  regulating cell number during development and, in some tissues, 
during maturity also. The brain is a particular example o f  the physiological role of 
apoptosis in development. As the brain develops, neurons are vastly overproduced. 
As connections form between the more active neurons, cells which remain latent can 
be removed via apoptosis to shape the developed brain structure (Oppenheim, 1991).
Apoptosis also has important physiological roles long into maturity. Organs or 
tissues in which cells are rapidly proliferating, eg. the liver and the skin, use apoptosis 
as a means o f  regulating cell number while new cells are produced. However, failure 
o f  apoptosis-mediated regulation o f  cell number is the basis o f  a tumour. Cancerous 
cells display a resistance to undergo apoptosis (reviewed by Igney & Krammer, 
2002). Many lines o f  investigation for cancer therapy aim to exploit the apoptotic 
machinery (Jansen et a l, 1998; Keane et al, 1999 among many others).
A second route via which apoptosis can exert pathological effects is in the brain. In 
this organ, once maturity is reached, the cells are not turned over as in the liver, for 
example. The complement o f  neurons at maturity is, for the most part, not 
replenished (although it has been suggested that regeneration o f  pyramidal neurons in 
the hippocampus is possible -  Nakatomi et al, 2002). If neurons are lost through 
apoptosis or any other form o f  death, they are unlikely to be replaced.
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Apoptotic cell death is thought to be a major mechanism of cell loss during 
neurodegenerative disease (Hirsch et al, 1999; Smale et al, 1995; Thomas et al, 1995 
and reviewed by Yuan et al, 2000). Inappropriate apoptosis in response to genetic or 
environmental factors can lead to the loss o f  adult neurons, which may never be 
replaced. In addition to neuronal loss during disease, a gradual decline in neuronal 
number due to apoptosis with evidence o f  oxidative stress is suggested to be a major 
factor contributing to aging (Anglade et al, 1997).
This particular feature o f  mature brain tissue is a very good example o f  a reason for 
studying brain mitochondria. Given the role o f  mitochondria in initiating apoptosis
(1.3.3) and the unique implications o f  apoptosis for neurons in mature brain, the 
features o f  brain mitochondria with respect to apoptotic induction may be highly 
individual.
1.3.3 Initiation o f  apoptosis
There are two major routes by which apoptosis may be triggered in a cell. The first is 
via receptors on the surface o f  the cell membrane. These ‘death receptors’ are 
members o f  the tumour necrosis factor receptor (TNFR) family, whose major role 
aside from the induction o f  apoptosis is in regulating the function o f  the immune 
system. Ligands o f  these receptors, either soluble or membrane-bound, can provide 
‘communication’ between cells, passing on the message to commit to apoptosis. This 
process is tightly regulated. Specific criteria might exist for the conformation o f  a 
pro-apoptotic ligand, with respect to the extent o f  homopolymerisation for example.
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In addition, soluble or membrane-bound ‘decoy’ receptors can quench the pro- 
apoptotic signal.
The second route appears to be the dominant one for neuronal apoptosis (Pettmann & 
Henderson, 1998) and is the process o f  interest in this study. Relatively recently, it 
was found that mitochondria, in addition to being the ‘powerhouse’ o f  the eukaryotic 
cell, could also actively trigger its death (Newmeyer et a l, 1994). Mitochondria can 
provide a pro-apoptotic signal to the host cell, and importantly, are then required to 
provide sufficient ATP for the apoptotic program to be completed. This signal, as 
was indicated in 1.2.3.2 is the redox protein cytochrome c, more commonly 
associated with electron transport in the ETC.
There are other IMS proteins which, when released from mitochondria, have pro- or 
anti-apoptotic influences on the cytochrome omediated pathway (1.3.6). One, 
however, appears to induce apoptosis in a manner independently o f  cytochrome c. 
Apoptosis Inducing Factor (or AIF) is a flavoprotein which, when present in the 
cytosol, can induce the same apoptotic endpoint as cytochrome c (chromatin 
condensation, DNA fragmentation, etc.) (Cande et a l, 2002). However, it bypasses 
the proteolytic enzyme cascade which is a feature o f  cytochrome oinduced apoptosis 
(1.3.3.1, 1.3.4). The relative importance o f  AIF-induced apoptosis is not yet 
determined, but it appears that it may be required for death occurring in response to 
some stimuli (Joza et al, 2001).
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1.3.3.1 Induction o f  apoptosis by cytochrome c
Under physiological conditions, the OM is impermeable to the 12.1kDa cytochrome 
c.. However, certain insults experienced by the mitochondria can cause cytochrome c 
to be released from the IMS, where a proportion o f  the protein is freely mobile, to the 
cytosol (Yang et a l, 1997). It has been estimated that the cytochrome c concentration 
of an apoptotic cell could range from 5 to 150pM (Waterhouse et al, 2001). Once in 
the cytosol, cytochrome c is potentially lethal (Liu et a l, 1996).
Although there are protective mechanisms in place (see 1.3.6), the pro-apoptotic 
target o f  cytochrome c in the cytosol is a soluble cytosolic protein o f  approximately 
130kDa called Apaf-1 (Apoptosis Protease Activating Factor-1). The association of 
these two proteins forms a complex known as the ‘apoptosome’. Binding of 
cytochrome c increases the affinity o f  Apaf-1 for 2 ’ deoxyATP (dATP) (Jiang and 
Wang, 2000).'
Binding o f  dATP to the apoptosome causes the complex to oligomerise. A non- 
hydrolysable analogue o f  dATP appears sufficient to exert the same effect as dATP 
(Jiang & Wang, 2000), likewise dADP can substitute (Liu et al, 1996). It therefore 
appears to be the binding o f  dATP which promotes assembly o f  the apoptosome, 
rather than the hydrolysis o f  dATP. There is debate as to whether ATP can substitute 
for dATP and initiate apoptosis via the apoptosome (Liu et a l, 1996; Zou et al, 1999).
1 T his  is the d e o x y n u c le o s id e  triphosphate which incorporates 2 ’ d eo x y r ib o se ,  and is used in the 
co m p o si t io n  o f  the D N A  backbone.  This  form o f  dA T P  is therefore present in v iable  cells ,  unlike 3 ’ 
d e o x y A T P ,  wh ich  is the ‘m im ic ’ nu cleoside ,  unable to be incorporated into D N A .  This latter can be  
used to treat d i sea ses  such as A I D S  and chicken pox ,  by  halting D N A  synthesis.
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The oligomerised apoptosome complex is then responsible for the activation of  a 
cascade o f  protease activity which executes the apoptotic program. These aspartate- 
specific cysteine proteases are known as caspases. They operate in a hierarchical 
sequence, with ‘initiator’ caspases responsible for the activation o f  their downstream 
‘effector’ counterparts. Prior to activation, they exist in zymogen form, ie. inactive 
pro-enzymes. The zymogen comprises a prodomain with two catalytic subunits. It is 
generally considered that release o f  the catalytic subunits by cleavage at the site of 
aspartic acid residues is required in order for the caspase to be activated (Thomberry 
& Lazebnik, 1998), with the notable exception o f  caspase-9 (Stennicke et al, 1998).
The death receptor pathway resulting from extrinsic signals, as described above
(1.3.3), is generally initiated by caspase 8 (Boldin et al, 1996). Apoptosis which 
occurs via the mitochondrial pathway, in contrast, utilises caspase-9 at the head o f the 
‘caspase cascade’. This caspase is the exception to the general rule o f  activation by 
cleavage. A study by Stennicke et al (1999) demonstrated that the activity of 
caspase-9 was primarily mediated not by proteolytic processing, but by the presence 
o f  cytosolic factors. Recombinant caspase-9 (the ‘activated’, cleaved form) was 
found to be maximally active (2000-fold increase) in cells when in the presence of 
cytochrome c and dATP. Mutated recombinant procaspase-9 which could not be 
proteolytically cleaved was able to support apoptosis with ‘equal vigour’ to the wild- 
type protein, providing that cytosolic factors were present.
The reliance on cytosolic factors for the activation o f  procaspase-9 is explained by the 
function o f  the apoptosome complex. Procaspase-9 is recruited to the oligomerised 
apoptosome, where it associates and appears to stimulate further or stabilise existing
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dATP binding. It is docked by the N-terminal 1 -  97 amino acids o f  Apaf-1, which 
form a CARD domain (caspase recruitment domain, a recognised sequence common 
to several caspases and adaptor proteins which activate them -  Hofmann et al, 1997). 
The association is o f  a homophilic nature, since procaspase-9 also has a CARD 
region. The CARD domain on Apaf-1 appears to remain inaccessible to procaspase-9 
except in the presence o f  dATP and cytochrome c , which promote conformational 
changes in Apaf-1 (Li et al, 1997). It is believed that the WD repeat domain at the C- 
tenninal o f  Apaf-1 is responsible for blocking the CARD domain, and that interaction 
o f  the WD repeat region (which is thought to be involved in protein-protein 
interactions -  Komachi et al, 1994) with cytochrome c and dATP induces this 
conformational change.
Procaspase-9 is thought to associate in a 1:1 stoichiometry with Apaf-1, forming a 
1.4MDa complex, with eight Apaf-1 subunits per apoptosome (Zou et al, 1999,). 
However, a smaller, 700kDa complex can also be detected and appears to be more 
active (Cain et al, 2000). Procaspase-9 is seldomly detected when associated with the 
apoptosome complex. It is thought that the zymogen is rapidly processed on 
recruitment, and that perhaps clustering o f  the zymogen allows autoactivation by 
proteolytic cleavage (Srinivasula et al, 1998).
However, caspase-9 appears to be unique within the family in that it does not require 
proteolytic processing in order to be activated (Stennicke et al, 1999). Active 
caspase-1 and -3 are composed of  two catalytic subunits, thought to arise from 
dimerization o f  monomeric zymogens (Stennicke & Salveson, 1998). It is suggested 
therefore that the apoptosome could induce proximity o f  procaspase-9 zymogens,
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driving homodimerization o f  monomers and therefore activation without proteolytic 
cleavage (Stennicke et al, 1999).
It has been determined that caspase-9 is only active when associated with the 
apoptosome (Rodriguez & Lazebnik, 1999), and it has been suggested that the 
complex may not only serve to activate the zymogen, but also to recruit previously 
activated caspase-9 in order that it may be functional (Cain et al, 2002).
It has been suggested that other CARD-containing caspases, eg. -1, -2, -4, -8 and -10, 
may be able to substitute for caspase-9 in the apoptosome if their level o f  expression 
is sufficient (Li et al, 1997). However, Pan et al (1998) have used an in vitro system 
to demonstrate that this is not the case, and that the apoptosome-mediated activation 
o f  caspase-9 appears to be specific for that enzyme.
1.3.4 The caspase cascade
There are at least 14 mammalian caspases recognised to date (2003). Whilst it was 
assumed that caspase-9 was responsible for the activation o f  downstream caspases, a 
study by Slee et al (1999) simply but elegantly demonstrated that this was the case 
using caspase inhibitors and immunodepletion in cell free extracts. This approach 
enabled the authors to deduce the order of activation o f  caspases in response to 
cytochrome c. Not only did they demonstrate a hierarchy o f  caspase activity 
(reproduced in Figure 1.8), but they also confirmed that caspase-9 was indispensable 
for cytochrome c-initiated triggering o f  the death program, a conclusion consistent 
with the claim o f  Pan et al (1998) as mentioned above (1.3.3.1).
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The branched sequential nature o f  the cascade results in considerable amplification 
between activation o f  procaspase-9 and the terminal effector caspases. This 
amplification is augmented by the postulated positive feedback by active caspase-3 
onto the upstream activation o f  procaspase-9. This feature o f  the apoptotic program 
emphasises the importance o f  the cytochrome c-mediated formation o f  the 
apoptosome complex. It highlights the necessity to buffer ‘accidental’ cytochrome c 
release, potential mechanisms for which are described in 1.3.6.
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Cytochrome
Apaf-1 Caspase-9
Caspase-7 Caspase-3
Caspase-6 Caspase-2^)
Caspase-8 Caspase-10
Figure 1.8
The postulated caspase cascade, reproduced from Slee et al (1999). The cascade is 
branched, with at least one feedback loop -  caspase-3 activity provides positive 
feedback to the activation o f  caspase-9. It is interesting to note that caspase-8 
features as an effector caspase in this pathway, bearing in mind the initiator role it 
plays in the death receptor-mediated apoptosis (1.3.3).
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1.3.5 Mechanisms o f  release o f  cytochrome c
In order for cytochrome c to bind to Apaf-1 and trigger the events described above, it 
must be present in the cytosol, which clearly necessitates the release o f  cytochrome c 
from its IMS location, through the OM. Apocytochrome c is not able to substitute for 
the holo- form (Yang et al, 1997), therefore release o f  the mature protein is required. 
The mechanism by which cytochrome c release (CCR) occurs has been the subject of 
huge debate, not least due to the clinical implications o f  determining the mechanisms 
o f  apoptosis and how they might be exploited.
1.3.5.1 Swelling-dependent release mechanisms
As the importance o f  the CCR event emerged, there was renewed interest in the 
description by Hunter and Haworth in (1979) o f  a large proteinaceous pore which 
spanned the IM and OM o f  mitochondria, and whose opening rendered the membrane 
envelope permeable to solutes with a molecular mass below approximately 1.5kDa. 
It became apparent that this ‘permeability transition pore’ (PTP) could cause CCR. 
Opening o f  the PTP leads to influx o f  solutes and water into the mitochondrial matrix, 
and therefore swelling o f  the matrix contents. This forces the IM outwards. Since the 
surface area o f  the IM is greater than that o f  the OM, the outward force exerted by the 
former causes generalised rupture o f  the latter. As a result, IMS proteins such as 
cytochrome c can be released in a non-specific manner.
Evidence for occurrence o f  this ‘Mitochondrial Permeability Transition’ (MPT) was 
found in many cases o f  CCR (Borutaite et al, 2003; Yang & Cortopassi, 1998; Zhu et 
al, 2002; among others). Much interest was invested in determining the structure of
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the PTP, with clinical exploitation in mind. There have been numerous proposed 
components, although three proteins are most commonly associated with the 
megachannel. The first is the OM ‘voltage dependent anion channel’, or VDAC. 
Also known simply as ‘porin’, this channel has a physiological role in regulating 
metabolite flow across the OM. However, it is also thought to associate with other 
proteins to form the major OM component o f  the PTP. The adenine nucleotide 
translocator (ANT) is thought to constitute the primary IM component o f  the PTP, in 
addition to its role as the translocator o f  ADP and ATP across the IM. The third PTP 
protein is cyclophilin cl, found in the matrix. Aside from a role in apoptosis, 
cyclophilin d  belongs to a family o f  molecular chaperones, capable o f  peptidyl-prolyl 
isomerase mediated protein folding.
In addition to these three main components, other postulated players are the 
peripheral benzodiazepine receptor (PBR, McEnery et a l, 1992) and mitochondrial 
hexokinase (Beutner et a l, 1996). A role is also suggested for the Bcl-2 family of 
proteins. This group includes both pro- and anti-apoptotic members. Pro-apoptotic 
Bax (Marzo, 1998) is thought to be a peripheral pore component, rendering the MPT 
sensitive to inhibition by anti-apoptotic family members (Narita et al, 1998).
The inclusion o f  cyclophilin d  in the PTP is widely accepted, and it is this protein 
which confers sensitivity o f  MPT to the immunosuppressive drug cyclosporin A. 
(CsA). This drug is widely used as an experimental tool to identify occurrence o f  the 
MPT. However, it has numerous targets other than the PTP-associated cyclophilin cl 
(Capano et al, 2002; Kim et al, 2003; Sanchez et al, 2003; among others). The
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effects o f  the drug are therefore notoriously non-specific and must be interpreted with 
caution.
A further feature o f  MPT often used as a tool for its detection is the dissipation of 
Avj/m. Loss o f  the integrity o f  the IM inevitably causes a loss o f  ability to support a 
proton gradient.
Another major experimental tool for detection o f  MPT is the monitoring of 
mitochondrial volume. Evidence o f  mitochondrial swelling is usually taken as 
indication o f  MPT. However, there is another, less recognised, ‘swelling-dependent’ 
CCR mechanism which leads to generalised OM rupture. Vander Heiden & 
Thompson (1999) report that inappropriate closure o f  the VDAC (described in 
1.3.5.1) can also mediate CCR. Closure o f  this channel leads to a defect in the 
exchange o f  ATP and ADP across the OM. As ADP levels in the matrix decline, 
ADP becomes less available as a substrate for the ATP synthase (complex V). In 
fact, if the ATP:ADP ratio increases sufficiently within the matrix, the ATP synthase 
can function in reverse, catalysing the dephosphorylation o f  ATP to ADP (Oster & 
Wang, 2000). In contrast to the dissipation o f  A\j/m associated with the MPT, the 
effect o f  this dysregulation is to hyperpolarize the A\j/m. It is claimed by the authors 
that this hyperpolarisation leads to matrix swelling and non-specific OM rupture as 
described for the MPT. However, the authors did not provide justification for their 
suggested link between hyperpolarisation o f  A\|/m and matrix swelling.
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1.3.5.2 Swelling-independent release mechanisms
Whilst non-specific rupture o f  the OM would inevitably cause CCR (at least o f  the 
proportion which is freely soluble in the IMS -  see 1.2.2.2), a major discrepancy has 
arisen in recent years. An increasing number o f  studies are reporting CCR in the 
absence o f  any detectable swelling o f  the mitochondria. There is little argument that 
MPT would lead to CCR, but it would appear that it is not the sole mechanism 
capable o f  doing so.
It has been claimed that MPT is in fact a reversible event, with ‘flickering’ opening of 
the PTP occurring prior to the permanent loss o f  membrane integrity described above 
(1.3.5.1). This has been suggested as a possible reconciliation o f  swelling- 
independent CCR with MPT as the mechanism (Scarlett & Murphy, 1997). However, 
there has been no explanation o f  how the IMS cytochrome c could be liberated by a 
channel which spans both the IM and OM, and has a permeability limit o f  1.5kDa 
(note that cytochrome c is 12.1kDa). The crucial event in the MPT theory o f  CCR 
was rupture o f  the OM, which is inextricably linked to matrix swelling.
Attention has switched, therefore, to potential CCR mechanisms which leave the IM 
unperturbed, but instead rely on permeability changes in the OM alone. This 
approach has identified a number o f  channels in the OM which may be implicated in 
CCR. One o f  these is the postulated OM component o f  the PTP, the VDAC. This 
channel is constitutively present as an OM channel, as described (1.3.5.1). It has 
however been identified as a potential route by which CCR may occur (Madesh & 
Hajnoczky, 2001). The argument has been put forward, however, that the pore 
diameter o f  this channel is insufficient to permit CCR (Mannella, 1998). This led to a
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new line o f  investigation involving the Bcl-2 family o f  proteins, referred to in 1.3.5.1. 
One pro-apoptotic member in particular has been implicated. Bax has been seen to 
translocate through the cytosol to the mitochondrial OM during apoptosis (Wolter et 
al, 1997; Zhang et a l, 1998) and has sequence homology with known channel- 
forming proteins (Montessuit et al, 1999). It is subject to regulation by 
heterodimerisation with anti-apoptotic members o f  the Bcl-2 family, which are 
thought to be constitutively present in the OM. However, providing that these 
regulatory systems allow, Bax is now thought to be able to form OM channels of 
sufficient pore diameter to permit CCR (Antonsson et al, 2000).
In order to reconcile this data with reports o f  VDAC being required for CCR, work 
has been earned out into the possible association o f  Bax and VDAC. It has been 
demonstrated that Bax can coimmunoprecipitate with VDAC (Narita et al, 1998), and 
modulate its permeability (and a Bax-VDAC channel is now considered a strong 
candidate for a swelling-independent CCR channel (Shimizu et al, 2000)). It is 
possible that there may be substitution o f  Bax by other pro-apoptotic Bcl-2 family 
members in some cases (Brustovetsky et al, 2003b).
A third possible OM channel hypothesis also implicates Bax. It has been shown that 
Bax can cause membrane instability by reducing the linear tension o f  phospholipid 
bilayers (Basanez et al, 1999). It has been suggested that this induced instability 
could lead to the formation o f  lipidic pores or lipid-protein complexes which could 
permit CCR. However, this hypothesis has attracted significantly less interest to date.
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A summary o f  the major recognised swelling-dependent and swelling-independent 
CCR mechanisms can be seen in Figure 1.9.
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solutes, water ADP
B
D
Figure 1.9
Summary of the currently recognised possible CCR mechanisms. A and B show 
swelling-dependent release mechanisms, due to opening of the PTP and closure of the 
VDAC, respectively. C, D and E demonstrate swelling-independent mechanisms, 
caused by Bax oligomerisation, Bax oligomerisation and association with VDAC, and 
Bax-mediated lipidic pore formation, respectively. For details, see text.
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1.3.5.3 Implications o f  the release mechanism
Due to the implications o f  the suggested CCR mechanisms, swelling-independent 
processes are gaining support. The recognised apoptotic program is energy- 
dependent. The loss o f  IM integrity associated with swelling-dependent CCR 
mechanisms, and inevitable dissipation o f  Aij/m are inconsistent with the sustained 
generation o f  ATP required for apoptosis. It is possible that there are releasable and 
non-releasable pools o f  cytochrome c, and that sufficient cytochrome c is retained in 
the event o f  MPT to support the apoptotic program. It is also suggested that released 
cytochrome c may be capable of maintaining Ai|/m and ATP production (Waterhouse 
et al, 2001). However, as Crompton alludes to in his 2000 review, this highly 
disruptive process appears poorly matched with the tightly regulated apoptotic 
program, designed to tidily package cellular contents so as to prevent further damage 
(see 1.3.1).
There has been discussion of  the apoptosis and necrosis programs not being 
independent events, but rather that cell death occurs by mechanisms which fall along 
a continuum between the two extremes (Zeiss, 2003). It is possible that MPT is 
associated with more necrotic forms o f  cell death, where the energy requirement is 
reduced.
One recent study has suggested a very interesting possible reconciliation o f  the MPT 
with swelling-independent apoptosis. De Giorgi et al (2002) report that ‘flickering’ 
openings o f  the PTP can signal for the redistribution o f  Bax to the mitochondrial OM. 
Bax oligomerisation at the OM then allows CCR as described in 1.3.5.2. In this
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sense, the PTP is not an intrinsic component o f  the CCR machinery, but an upstream 
trigger which can induce release by another means.
The mechanism responsible for CCR during apoptosis has implications other than 
simply allowing the redistribution o f  cytochrome c. Downstream o f  CCR, defence 
mechanisms exist in the cytosol to prevent ‘inappropriate’ apoptosis. If the death 
program is to be arrested at a ‘post-mitochondrial’ stage, the extent o f  disruption 
afforded by the CCR mechanism becomes vitally important. It is essential for cell 
survival that it retains energetic viability (highly dependent on the functional capacity 
o f  the mitochondria). Preservation o f  mitochondrial respiratory function is of 
particular importance in neurons, which have limited glycolytic capacity (Walz & 
Mukerji, 1988). Therefore disruptive release mechanisms such as MPT render the 
post-mitochondrial defence processes somewhat redundant.
1.3.6 Post-mitochondrial regulation o f  apoptosis
It would appear that even following activation o f  the caspase cascade, a cell has not 
reached the ‘point o f  no return’ in its survival. A number o f  mechanisms have been 
identified whereby apoptosis can be prevented at a stage downstream of CCR.
1.3.6.1 IAPs
Inhibitor o f  apoptosis (‘IAP’) proteins belong to a family known as the BIR- 
containing proteins (‘BIRPs’). The BIR domain is the ‘baculovirus IAP repeat’, and 
is essential to the anti-apoptotic properties o f  IAPs (Duckett et a l, 1998). Some IAPs
64
also contain a zinc-binding ‘ring finger’ domain (Verhagen et al, 2001). Since the 
discovery o f  the first IAP in 1993 (Crook et a l, 1993), eight human IAPs have been 
identified: XIAP, ILP-2, c-IAPl, C-1AP2, ML-IAP, NAIP, survivin and apollon. The 
best characterised o f  these, and apparently the most potent (Deveraux et al, 1999) is 
XIAP. From the study o f  this protein, understanding has grown about how IAPs act 
to regulate apoptosis by direct inhibition o f  caspases.
XIAP is thought to regulate at least seven caspases, however a detailed understanding 
o f  the mechanism o f  inhibition only exists at present for its interaction with caspases 
-3 , -7 and -9 . Interestingly, although proteolytic cleavage o f  procaspase-9 is not 
required for its activation (Stennicke et a l, 1999), only the cleaved form is subject to 
regulation by XIAP (Srinivasula et al, 2001). XIAP binds directly via its BIR3 
domain to the smallest cleavage product o f  caspase-9. In contrast, caspases-3 and -7  
are inhibited by steric occlusion by XIAP following binding o f  the caspase by a 
region adjacent to BIR2 (Riedl et al, 2001).
Other IAPs most likely operate by similar mechanisms, although no other IAP has as 
large a repertoire o f  recognised target caspases as XIAP. Interestingly, there is an 
IAP specific to neuronal cells, NAIP (neuronal apoptosis inhibitory protein). To date, 
NAIP is only thought to regulate the activities o f  caspases-3 and -7  (Maier et al, 
2002), but bearing in mind the sequential, non-redundant nature o f  the caspase 
cascade, this inhibition may still be significant. With respect to the role o f  apoptosis 
in neurodegeneration (1.3.2), it has been shown that NAIP levels are decreased in 
adult patients with Down syndrome and Alzheimer’s disease (Seidl et al, 1999). It
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has also been demonstrated that NAIP has a protective role in an in vivo model of 
Parkinson’s disease (Crocker et al, 2001).
1.3.6.2 Smac
The ‘second mitochondria-derived activator o f caspase’ (Smac) protein was identified 
in 2000 by Du et al (and also concurrently by Verhagen et al, who named the protein 
‘direct IAP binding protein with low p l \  or DIABLO). The name assigned by the 
latter group reveals the role o f Smac in the regulation of apoptosis. It serves as an 
inhibitor o f  the IAP proteins described above (1.3.6.1), and therefore by a 
disinhibition mechanism, promotes apoptosis:
S m a c ---------------------1 IAP -------------------- 1 C a s p a s e  activity
(Indirect promotion)
Smac was found to be a 23-25kDa protein which co-localised with cytochrome c 
under normal conditions. It was identified in several tissue types, although 
interestingly was only present at low levels in brain (Verhagen et al, 2000). It was 
found to be synthesised with an N-terminal mitochondrial targeting sequence, which 
was cleaved off to form the mature protein. It has been repeatedly proven that Smac 
is an IMS protein, released to the cytosol during apoptosis (Adrain et al, 2001; Deng 
et al, 2002; Rehm et al, 2003; among others). This is clearly reminiscent of 
cytochrome c, however it appears that the two proteins are not necessarily released by 
the same mechanism during apoptosis (Kandasamy et a!, 2003; Rehm et al, 2003).
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In the study by Verhagen et al (2000), Smac interacted with all o f the IAPs tested 
(XIAP, c-IAPl, C-IAP2 and the baculoviral OpIAP). It is likely therefore that the 
interaction is mediated by the conserved BIR domains and that Smac will inhibit any 
IAP family member.
Smac will therefore potentiate the pro-apoptotic effects induced by cytochrome c. 
Clearly, it is not required for the activation of procaspase-9 by the apoptosome system 
(Liu et al, 1996). However, it has been claimed by Deshmukh et al (2002) that Smac 
release is required for the full apoptotic program to be completed in primary neurons. 
As yet, there are no reports which confirm the repeatability of this finding.
An interesting report by MacFarlane et al (2002) lends added complexity to the 
regulation o f  caspase activity by the IAP/Smac system. The authors claim that XIAP 
functions as a ubiquitin-protein ligase for the ubiquitination and therefore subsequent 
degradation of Smac. Therefore, XIAP creates a form of negative feedback loop on 
the pro-apoptotic Smac, overall strengthening its own anti-apoptotic capacity.
S m a c -------------------- 1 IAP  1 C a s p a s e  activity
(Indirect promotion)
(Prom otes  degradation)
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1.3.6.3 Omi
Omi, also known as HtrA2 (Gray et al, 2000), is very similar in localisation and role 
to Smac. Although the bacterial homologue HtrA has roles as a protease and as a 
chaperone, the proven role o f  mammalian Omi lies in its ability to inhibit IAPs 
(Suzuki et a l, 2001). The mature Omi is a 37kDa protein, synthesised, like Smac, 
with a mitochondrial targeting sequence which is cleaved off upon mitochondrial 
transport. It is released from mitochondria during apoptosis, and via inhibition o f  
IAPs potentiates the other pro-apoptotic signals (van Loo et al, 2002). Unlike Smac, 
Omi does not interact with all the IAPs tested (Verhagen et al, 2002), however it does 
appear to have a more ubiquitous expression pattern than Smac (Gray et al, 2000). 
There is evidence that Omi exerts a more severe inhibition o f  IAPs than Smac, by 
catalysing their irreversible catalytic cleavage (Yang et al, 2003). The serine protease 
activity o f  Omi is also thought to induce an atypical caspase-independent form o f cell 
death (van Gurp et al, 2003).
1.3.6.4 Hsps
The cytosolic heat shock proteins (Hsps) have been known for some time to have 
anti-apoptotic properties (Jaattela et al, 1992; Mosser et al, 1997). It has now been 
revealed that this effect is, at least in part, due to the capacity o f  Hsps to chaperone 
Apaf-1 in the cytosol. Both Hsp70 (Saleh et al, 2000) and Hsp90 (Pandey et al,
2000) have been shown to sequester Apaf-1, preventing the formation o f  the 
oligomerised apoptosome. This in turn prevents association with and activation of 
procaspase-9. Saleh et al (2000) demonstrate that the association o f  Hsp70 with 
Apaf-1 occurs via the CARD domain on Apaf-1 (1.3.3.1). It is suggested that Hsp- 
mediated inhibition o f  apoptosome oligomerisation may be due to a conformational
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change in the dATP-binding site on Apaf-1. Pandey et al (2000) demonstrated that a 
range o f  DNA-damaging agents relieved the protective effects o f  Hsp90 by 
dissociating the Hsp90-Apaf-1 complex.
1.3.6.5 GSH
It has been suggested that only ferricytochrome c is capable o f  initiating apoptosis 
(Hancock et al, 2001). Provided that cytosolic GSH levels (1.1.3) are sufficient, 
cytochrome c released into the cytosol would be rapidly reduced to the ferro form, 
and therefore according to the theory o f  Hancock et al (2001) be prevented from 
activating caspase-9. However, if either the cytosolic cytochrome c concentration 
rises high enough, or the GSH concentration falls low enough, there will be an 
increasing presence o f  ferricytochrome c.
1.3.6.6 Potassium
It has been reported that physiological concentrations o f  intracellular K+ inhibit 
cytochrome c-dependent caspase activation (Hughes et al, 1997). A mechanism of 
this inhibition has since been determined by Cain et al (2001). It appears that K+ can 
inhibit the binding o f  cytochrome c to Apaf-1, and therefore the formation o f  the 
active 700kDa apoptosome complex. Clearly, this will prevent activation o f  caspase- 
9 and the subsequent caspase cascade. It is suggested that this may be a protective 
mechanism employed by the cell to prevent inappropriate apoptosis resulting from 
accidental release o f  small quantities o f  cytochrome c. Interestingly, the inhibition is 
antagonised in a concentration-dependent manner by cytochrome c, although the 
kinetics o f  K+ mediated inhibition are not truly competitive with the pro-apoptotic 
protein. It has been reported that intracellular levels o f  K+ are reduced during
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apoptosis (Hughes et al, 1997). This would lower the threshold cytochrome c 
concentration required for apoptosis to proceed.
Regulation o f  the cytosolic K+ concentration would therefore appear to be a very 
important post-mitochondrial control mechanism for protection against apoptosis.
1.3.6.7 Phosphorylation
It has been noted that cells in which activity o f  the protein kinase Akt is increased by 
transfection show reduced susceptibility to apoptosis (Nakashio et al, 2000). 
Cytosolic extracts from such cells are resistant to cytochrome c-induced caspase 
activation (Cardone et al, 1998). These authors determined that the Akt-mediated 
protection from apoptosis is due to phosphorylation o f  both procaspase-9 and active 
caspase-9. It is hypothesised that Akt-induced phosphorylation o f  either form results 
in blocking o f  the Apaf-1 binding site by a non-cleavable zymogen (in the case of 
procaspase-9) or a cleaved but inactive enzyme (in the case o f  caspase-9). This 
would reduce the availability o f  the site to non-phosphorylated procaspase-9 or 
caspase-9, thus inhibiting apoptosis.
1.3.6.8 Ubiquitination
The conjugation o f  ubiquitin to a protein leads in the majority o f  cases to degradation 
by the proteasome (see 1.2.2.3). Ubiquitin-mediated degradation and change in 
activity o f  proteins involved in the apoptotic machinery are thought to be important in 
vivo mechanisms o f  regulating the death process (Yang & Yu, 2003). Regulation of 
the activity o f  caspases (Chen et al, 2003) and Bcl-2 proteins (Marshansky et al,
2001) by ubiquitination has been reported. It has even been suggested that
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degradation o f  IAPs via ubiquitination might be essential for apoptosis to proceed 
(Yang et a l, 2000).
An interesting twist to the regulation o f  apoptosis is that the IAPs which have the 
carboxy-terminal ring finger motif (1.3.6.1) have E3 activity. E3 is the enzyme 
responsible for recognising target proteins and transferring activated ubiquitin to them 
(reviewed by Pickart, 2001). As a result, these IAPs can catalyse their own 
autoubiquitination (Yang et al, 2000) as well as the ubiquitination o f  other players in 
the apoptotic program such as caspases (Huang et al, 2000; Suzuki et al, 2001b) and 
Smac (MacFarlane et al, 2002). Interestingly it has been suggested that Smac may in 
return be capable o f  catalysing the ubiquitination o f  XIAP (Yang & Yu, 2003).
Proteasome-mediated degradation o f  ubiquitinated proteins therefore has considerable 
influence over the pro/anti-apoptotic balance within the cytosol.
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CHAPTER 2
Materials and Methods
2.1 Materials
2.1.1 Chemicals and reagents
Ficoll 400 was purchased from Amersham Pharmacia Biotech (Bucks., UK). 
Deoxyribonuclease type I (DNAse, EC 3.1.21.1, from bovine pancreas), cytochrome 
c (from horse heart), pyruvate kinase (PK, EC 2.7.1.40, from rabbit muscle) and 
lactate dehydrogenase (LDH, EC 1.1.1.27, from rabbit muscle) were purchased from 
Roche Diagnostics (East Sussex, UK). L-valine based minimal essential medium 
(MEM), neurobasal medium, foetal bovine serum (FBS) and B27 with antioxidants 
were purchased from Gibco BRL (Renfrewshire, UK). Anti-Bak (rabbit polyclonal 
G-23), anti-Smac (goat polyclonal V-17), anti-AIF (goat polyclonal D-20) and the 
secondary anti-goat horseradish peroxidase-conjugated antibody were purchased from 
Santa Cruz Biotechnology Inc. (Heidelberg, Germany). Adenosine 5’-diphosphate 
(ADP, potassium salt) and cyclosporin A (from Tolypocladium inflatum) were 
purchased from Merck Biosciences Ltd. (Nottingham, UK). Anti-tubulin (mouse 
monoclonal TU-20) was purchased from AbCam (Cambridge, UK). The secondary 
anti-mouse FITC-conjugated antibody was purchased from Molecular Probes Europe 
BV (Leiden, The Netherlands). All other chemicals and reagents were o f  analytical 
grade and purchased from Sigma-Aldrich (Poole, UK).
2.1.2 Assay kits
The rat/mouse Quantikine M Immunoassay kit for cytochrome c and the colorimetric 
caspase-9 assay kit were purchased from R&D Systems (Abingdon, UK). The
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Detergent Compatible Protein Assay reagents were purchased from Bio-Rad (Herts., 
UK).
2.1.3 Equipment.
Sterile six-well culture plates (for neuronal cultures) were purchased from Costar 
(Corning Costar, High Wycombe, UK). Sterile 80cm2 flasks (for astrocytic cultures) 
were purchased from Nalge Nunc International (Naperville, IL, USA). Glass 
coverslips were purchased from Chance-Proper (Smethwick, UK). Microscope slides 
(1-1.2mm super premium) and 50ml screw-top centrifuge tubes were purchased from 
BDH Laboratory Supplies (Poole, UK). 96-well microtiter plates were purchased 
from Thermo LabSystems (Vantaa, Finland). Ultra-Clear centrifuge tubes for 
ultracentrifugation were purchased from Beckman Instruments (CA, USA). The 
oxygen electrode was purchased from Rank Bros. (Cambridge, UK). The TPP+ 
electrode was purchased from World Precision Instruments (Herts., UK).
2.1.4 Animals
Rats used for isolated mitochondria preparations were male, approximately 250g and 
o f  the Wistar strain. Embryonic day 17 Wistar rat pups were used for primary 
neuronal culture, and 1-2 day old neonates used for the astrocyte primary culture. All 
animals were purchased from A.J. Tuck & Son Ltd. (Rayleigh, Essex, UK). Animals 
were kept under 12 hour light/dark cycles, fed a stock laboratory diet and provided 
with water ad libitum.
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2.2 Preparation o f  sample material
2.2.1 Isolation o f  brain mitochondria from  adult rat whole brain
2.2.1.1 Preparation o f  Ficoll gradients
The isolation o f  mitochondria from whole brain tissue requires that contaminating 
subcellular elements be removed. A series of simple centrifugation steps yields a 
crude mitochondrial pellet, but separation by density gradient is required in order to 
remove contaminating myelin and to distinguish the synaptosomal fraction from the 
non-synaptic mitochondria.
Traditionally, this density gradient separation was achieved using sucrose solutions 
(Gray & Whittaker, 1962; Blokhuis & Veldstra, 1970). However, this involved 
subjecting the mitochondria to extremely hypertonic sucrose concentrations, and 
centrifugation was at very high speed and o f  long duration. These factors had 
detrimental effects on the metabolic activity o f  mitochondria isolated in this manner.
A preferable alternative is now available. Ficoll 400 (Amersham Pharmacia Biotech, 
Bucks, UK) is a high molecular mass (average M r 400g .m ofl) polymerised sugar. 
Since its molecular mass is significantly greater than that o f  sucrose, Ficoll solutions 
o f  the same concentration (in g per unit volume) have relatively lower osmolarity 
(since a lower number o f  moles per unit volume is required). Consequently, the use 
o f  Ficoll allows contaminating elements such as myelin to be filtered out whilst not 
exerting osmotic stress on organelles such as mitochondria.
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Ficoll 400 was prepared for use in mitochondrial isolation procedures as follows. 
Ficoll was dissolved in deionised water at a concentration o f  500g.l_1. This solution 
was dialysed against deionised water overnight at 4°C. The specific gravity o f  the 
dialysed Ficoll was then measured. Using the manufacturer's standard curve, this 
specific gravity was then used to determine the Ficoll concentration. The volume of 
deionised water required to reduce this concentration to 20% (w/v) was calculated 
and the necessary dilution made.
10% and 7.5% Ficoll solutions were prepared by dilution of  the 20% solution using 
isolation medium, to give final concentrations 10% or 7.5% (w/v) Ficoll, 0.32M 
sucrose, 50pM K+EDTA, lOmM Tris-HCl pH 7.4.
6% and 4.5% Ficoll solutions were prepared by dilution o f  the 20% solution using 
modified isolation medium, to give final concentrations 6% or 4.5% (w/v) Ficoll, 
0.24M mannitol, 60mM sucrose, 50pM K+EDTA, lOmM Tris-HCl pH 7.4.
3% Ficoll was prepared by diluting 6% Ficoll (made as above) 1:1 with deionised 
water.
All Ficoll solutions were brought to pH 7.4 immediately prior to use with HC1 and 
Tris.
Gradients were made up by slow layering o f  Ficoll in Beckman Ultra-Clear 
Centrifuge Tubes (Beckman Instruments Ltd, California). The first gradient consisted
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o f  18ml 10% Ficoll, 9ml 7.5% Ficoll and 9ml isolation medium. The second gradient 
(synaptic preparation only) consisted o f  9ml 6% Ficoll, 4.5ml 4.5% Ficoll and 3ml 
3% Ficoll. Visible clear interfaces provided verification o f  discrete density layers.
The procedure for separation by the first gradient (10% / 7.5% / isolation medium) 
differed between the non-synaptic and the synaptic mitochondria isolation protocol 
(see Figure 2.1). For the former, a 'spin-down' method was used. This means that the 
homogenate to be separated is suspended in the top layer, ie. the isolation medium. 
Centrifugation results in the required fraction (the non-synaptic mitochondria) 
passing down through the gradient. The parameters o f  the spin are such that some 
non-synaptic mitochondria remain in the synaptosomal layer, but no synaptosomes 
reach the pellet. Thus yield is sacrificed for purity.
For the isolation o f  synaptic mitochondria, a 'spin-up' method is used. The 
homogenate to be separated is this time resuspended in the bottom layer. The volume 
o f  homogenate is known exactly, and used to dilute a 12% Ficoll solution to 10% 
(w/v). This mixture is then used as the bottom layer o f  the gradient, and the top layer 
is isolation medium alone. The centrifugation then results in the required fraction 
(the synaptosomes) passing up through the gradient. Again, yield is sacrificed for 
purity, as the spin-up process leaves some residual synaptosomes in the pellet, but 
avoids contamination o f  the synaptosomal layer by non-synaptic mitochondria.
77
17.5%
10%
isolation medium containing 
resuspended cmde 
mitochondria! pellet
99000 x g
‘SPIN DOWN’
Isolation
medium
Myelin
Synaptosomes (some 
contamination by non- 
synaptic uiilocltoiidria)
Pellet of non-synaptic 
mitochondria (pure)
Isolation
medium
7.5%
99000 x g
‘SPIN UP'
10% Ficoll containing 
resuspeuded crude 
mitochondrial pellet
Isolation
medium
7.5%
10%
Myelin
Synaptosomes (pure)
Pellet o f non-synaptic 
mitochondria (some 
contamination by 
synaptosomes)
Figure 2.1
Schematic diagram to demonstrate the advantages o f ‘spin down’ and ‘spin up’ 
techniques for density gradient separation of non-synaptic and synaptic mitochondria, 
respectively. Photograph shows contamination o f  non-synaptic mitochondrial pellet 
with white synaptosomes following ‘spin-up’ procedure.
2.2.1.2 Isolation o f  non-synaptic rat brain mitochondria
The isolation o f  non-synaptic rat brain mitochondria was carried out according to the 
method o f  Lai and Clark (1989), which is demonstrated schematically in Figure 2.2. 
Three male Wistar rats were killed by cervical dislocation and decapitated. The 
whole brains were removed and placed in approximately 30ml isolation medium 
(0.32M sucrose, ImM K+EDTA, lOmM Tris-HCl, pH 7.4) at 4°C. From this point 
the isolation procedure was carried out at this temperature. The brains were rapidly 
chopped manually. The tissue was allowed to settle and the isolation medium was 
gently poured away and replaced with fresh medium. This was repeated three times 
to remove as much contaminating blood as possible.
The chopped brain tissue was then diluted 1:10 with isolation medium in a Dounce 
homogeniser. The suspension was homogenised using eight up-and-down strokes. 
The resulting homogenate was centrifuged in two tubes at 1500xg for 3 minutes in a 
pre-cooled Beckman J2-21M/E centrifuge (Beckman RIIC Ltd., High Wycombe, UK) 
with a Beckman JA-20 fixed angle rotor. The supernatants were decanted off into 
clean centrifuge tubes. Isolation medium was added to the pellets, and these were 
homogenised in the Dounce homogeniser using four up-and-down strokes. The 
resulting homogenate was centrifuged for a second time under the conditions above. 
Again, the supernatants were decanted off into clean tubes.
The pellets were discarded, and the pooled supernatants centrifuged at 17000xg for 
10 minutes in the pre-cooled Beckman J2-21M/E centrifuge. The supernatants were 
this time discarded, and the 'crude mitochondrial pellets' resuspended in a total of
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18ml isolation medium. The pellets were resuspended by five up-and-down strokes 
in a Potter homogeniser.
Ficoll gradients o f  18ml 10% Ficoll and 9ml 7.5% Ficoll were set up in two Beckman 
Ultra-Clear Centrifuge Tubes. 9ml o f  the mitochondrial homogenate was layered 
gently onto each o f  these gradients (as described in 2.2.1.1). The two tubes were then 
placed into matched rotor buckets from a Beckman SW28 swing-out rotor. Isolation 
medium was used to bring the two buckets to equal mass, as determined by a digital 
balance. The buckets were attached to the rotor, and the tubes centrifuged at 99000x<g 
for 30 minutes in a pre-cooled Beckman L8-70M ultracentrifuge. The layers o f  Ficoll 
and the myelin and synaptosomal bands were removed carefully by pipetting, (see 
Figure 2.1). The mitochondrial pellet was washed very gently with isolation medium.
The pellet was then resuspended in approximately lml isolation medium by five up- 
and-down strokes in a 2m 1 Potter homogeniser. The homogenate was centrifuged in a 
1.5ml eppendorf tube in a pre-cooled centrifuge (Sigma Laborzentrifugen 3K10, 
Osterode, Germany) at 9800xg for 10 minutes. This process allowed removal of any 
residual Ficoll. The supernatant was discarded, and the pellet resuspended in 
isolation medium to a concentration o f  approximately 15mg.mr' (determined by 
observation) using 3 up-and-down strokes in the 2ml Potter homogeniser. The final 
mitochondrial suspension was stored on ice in a 1.5ml eppendorf tube prior to 
experimentation.
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Figure 2.2
Schematic diagram to demonstrate the procedure for isolating non-synaptic 
mitochondria from whole rat brains.
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2.2.1.3 Isolation o f  synaptic rat brain mitochondria
The isolation procedure for synaptic rat brain mitochondria is the same as for the non- 
synaptic population to the point o f  obtaining the crude mitochondrial pellet. 
However, due to the relatively poor yield o f  synaptic mitochondria, it was necessary 
to use whole brains from four, instead o f  three, animals. The whole procedure is 
demonstrated schematically in Figure 2.3.
On obtaining the four crude mitochondrial pellets, 6ml isolation medium was used to 
pool them. This was then homogenised together with some o f  a 30ml volume of 12% 
Ficoll, using five up-and-down strokes in a Potter homogeniser. This homogenate 
was then transferred to a 50ml falcon tube, and mixed thoroughly with the remaining 
12% Ficoll to make 36ml o f  a 10% (w/v) Ficoll / mitochondrial suspension. 18ml of 
this was used in each o f  two ultra-clear tubes as the bottom layer o f  the gradient, and 
9ml 7.5% Ficoll and 9ml isolation medium gently layered on top (as described in
2.2.1.1). The samples were prepared for ultracentrifugation as in the non-synaptic 
preparation.
After the 30 minute spin at 99000xg, the top two layers o f  Ficoll and the myelin band 
were carefully removed. The synaptosomal band was then decanted using a Pasteur 
pipette. The synaptosomal layers from both tubes were pooled in a clean centrifuge 
tube and diluted 1:3 with isolation medium. This was then centrifuged at 18500xg for 
10 minutes in the pre-cooled Beckman J2-21M/E centrifuge, using the Beckman JA- 
20 fixed angle rotor. The supernatant was removed, and 10ml 6mM Tris-HCl (pH
8.1) was added to lyse the synaptosomes. The pellet was resuspended in the aqueous 
Tris solution using four up-and-down strokes in a small Dounce homogeniser. 20ml
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additional 6mM Tris-HCl (pH 8.1) was then added, and the suspension mixed gently. 
It was then centrifuged at 11800xg for 10 minutes. The supernatant was very 
carefully decanted off, ensuring that the loose pellet was not disturbed. 10ml 6mM 
Tris-HCl (pH 8.1) was added to the pellet, and again resuspension was achieved by 
four up-and-down strokes in the small Dounce homogeniser. The homogenate was 
centrifuged at 8300xg for 10 minutes. The supernatant was then sharply decanted, so 
that the loose white part o f  the pellet was lost.
The remaining darker pellet was resuspended using a pipette in 6ml 3% Ficoll. 3ml 
o f  this mixture was layered onto each o f  two gradients o f  9nil 6% and 4.5ml 4.5% 
Ficoll. These tubes were prepared for ultracentrifugation as before, and centrifuged 
in the pre-cooled Beckman L8-70M ultracentrifuge using the Beckman SW28 swing- 
out rotor at 11300xg for 30 minutes. After separation, the top fraction was carefully 
removed using a Pasteur pipette. The band between the 6% and 4.5% Ficoll layers 
was removed from each tube, pooled in a clean centrifuge tube and diluted 1:3 with 
isolation medium. This was centrifuged at 12000xg for 10 minutes.
The pellet from this spin, along with the two pellets from the ultracentrifugation were 
pooled in approximately 1ml isolation medium and resuspended in a 2ml Potter 
homogeniser. This suspension was centrifuged in a 1.5ml eppendorf at 9800xg for 10 
minutes in a pre-cooled centrifuge (Sigma Laborzentrifugen 3K10, Osterode, 
Germany). The supernatant was removed, and the pellet resuspended in isolation 
medium to a concentration o f  approximately lOmg.ml'1 (determined by observation) 
using the 2ml Potter homogeniser. The final mitochondrial suspension was stored on 
ice in a 1.5ml eppendorf tube prior to experimentation.
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Figure 2.3
Schematic diagram to demonstrate the procedure for isolating synaptic mitochondria 
from whole rat brains.
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2.2.2 Cell culture
The methods for both neuron-rich and astrocyte-rich cultures were adapted from 
Almeida & Medina (1998).
2.2.2.1 Neuron-rich primary culture from foetal rat cortex
Sterile plastic 6-well plates were coated with poly-L-ornithine and incubated for 1
hour at 37°C. Following this, the wells were washed twice with sterile distilled water
and then UV treated. The plates were then incubated at 37°C during the cell
preparation.
Embryonic day 17 foetuses were extracted from the uterus o f  a time-mated Wistar rat 
following cervical dislocation o f  the adult. The cortices were dissected out in a petri 
dish containing EBSS and then rolled on a sterile piece o f  filter paper to remove 
meninges. They were transferred to a small petri dish containing 10ml o f  neuronal 
‘solution A ’ (EBSS containing 26.5pg.mF1 DNAse and 3m g.m rl fatty acid free 
BSA), and chopped gently using scissors. The contents o f  the dish were moved to a 
50ml falcon tube using a 10ml pipette. The dish was then washed using a further 
10ml o f  solution A, and this also added to the falcon tube. The tissue was left to 
settle for 2 minutes.
The supernatant was then carefully decanted off, and replaced with 10ml neuronal 
‘solution B ’ (EBSS containing 3.25mg.ml"1 fatty acid free BSA, 66.25pg.mF1 DNAse 
and 250pg.ini'1 trypsin). This was incubated at 37°C for 15 minutes. After this time,
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1ml cold (4°C) FBS was added to arrest the trypsinisation. The tissue was again 
allowed to settle for 2 minutes.
The supernatant was carefully removed and replaced with 12ml solution A. The 
tissue was gently triturated 5 times using a P I 000 Gilson pipette and then a P200 
Gilson pipette. The mixture was allowed to settle for 4 minutes. The supernatant was 
moved to a clean tube, ensuring that the pellet was not disturbed. 12ml solution A 
was added to the pellet and the trituration procedure repeated. After letting the 
mixture settle for 4 minutes once more, the supernatant was removed and combined 
with the first. This solution was then centrifuged at 500xg- for 5 minutes at 4°C.
The supernatant was removed and the pellet resuspended in lml neuronal media 
(neurobasal media containing 1% (v/v) antibiotic-antimycotic solution, 2mM 
glutamine, 25pM glutamate and 2% (v/v) B27 with antioxidants). The cell 
suspension was passed through a pre-wetted nylon mesh strainer (pore size 100pm) 
and the volume brought to 3ml with neuronal media.
The cells were then counted. This was done by adding lOpl cell suspension to 40pl 
trypan blue and 30pl HBSS, and then applying lOpl o f  this mixture to a 
haemocytometer (Weber Scientific International, Middlesex, UK). The number of 
cells able to extrude trypan blue from their cytosol was counted over 4 separate grid 
sections, and the overall number o f  cells in 3ml media counted. Neuronal media was 
added to the suspension to bring it to 106 cells.ml'1 media. The cells were then seeded 
onto the poly-L-ornithine coated plates at a density o f  2 x 106 cells.well'1, ie.
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2ml.well'1. The plates were placed in an incubator (B5060EK/C02, Heraeus
Instruments, Hanau, Germany) at 37°C with 5% C 0 2/95% air and >90% humidity.
Taking the day o f the preparation as Day 0, on Day 3, 1ml o f the media in each well 
was substituted for conditioned media (see below) containing 20jnM cytosine 
arabinoside (so final concentration in each well o f  lOpM) to prevent growth of 
dividing cells. The cells were treated on Day 6. Neurons at this stage are shown in 
Figure 2.4.
Figure 2.4
Primary cortical neurons at day 6 of culture. Phase contrast micrograph, X20 
objective. Scale bar represents 40pm.
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2 2 .2 2 .  Astrocyte-rich primary culture from neonatal rat cortex
It is now well recognised that interaction with surrounding glia is an important aspect 
o f  the physiology o f  neurons in vivo (reviewed by Hatton, 2002), and it is therefore 
somewhat artificial to culture neurons in isolation. Co-culture systems can be used, 
but it is difficult to regulate the ratio o f  astrocytes to neurons over any significant 
period of  time due to the constant proliferation o f  the glia. An alternative is to 
‘condition’ the neuronal media by exposing it to astrocytes prior to use on the 
neurons. Neurobasal media supplemented with 1% (v/v) antibiotic-antimycotic 
solution, 2mM glutamine and 2% B27 with antioxidants was therefore added onto 
confluent astrocyte cultures (12ml per 80cm2 flask) and incubated for 24 hours. This 
was then used on Day 3 o f  the neuronal culture, supplemented with cytosine 
arabinoside (see 2.2.2.1).
The astrocyte-rich primary culture was prepared as follows. 1-2 day old Wistar rat 
pups were decapitated. The cortices were dissected out in a petri dish containing 
EBSS and then rolled on a sterile piece o f  filter paper to remove meninges. They 
were transferred to a petri dish containing 10ml o f  astrocytic ‘solution A ’ (EBSS 
containing 20jj,g.ml‘l DNAse and 3m g.m rl fatty acid free BSA), and chopped gently 
using scissors. The tissue was triturated using a P I000 Gilson pipette, then moved to 
a 50ml falcon tube using a 10ml pipette. The petri dish was washed with a further 
10ml solution A and this added to the falcon tube. The tube was then centrifuged at 
500xg for 5 minutes at 4°C.
The supernatant was carefully removed, and replaced with 20ml astrocytic ‘solution 
B ’ (EBSS containing 3m g.m r1 fatty acid free BSA, O.lmg.ml'1 DNAse and
0.25mg.mr' trypsin). The mixture was incubated for 10 minutes at 37°C. Towards 
the end o f  this incubation, the tissue was triturated using a P I 000 and then a P200 
Gilson pipette, lml cold (4°C) FBS was then added to arrest the trypsinisation. The 
mixture was centrifuged at 500xg for 5 minutes at 4°C.
The supernatant was removed and the pellet resuspended in 10ml solution A. The 
tissue was allowed to settle for 2 minutes. The supernatant was carefully decanted, 
and then centrifuged at 500xg- for 5 minutes at 4°C.
The supernatant was removed and the pellet resuspended in astrocyte media (L-valine 
based MEM containing 1% (v/v) antibiotic-antimycotic solution, 10% (v/v) FBS and 
2mM glutamine). The cells were then plated into 80cm plastic flasks, and the 
volume o f  media brought to 10ml in each. The number o f  flasks was equated to the 
number o f  neonates dissected. The flasks were incubated at 37°C as described in 
2 .2 .2 . 1 .
The media was completely changed every 3 days. Once the astrocytes reached 
confluency (approximately 6 or 7 days after the preparation), they were exposed for 
24 hours to 12ml neurobasal media per flask. After this time, the cells were removed 
from the flasks by trypsinisation and re-plated in double the number o f  flasks. The 
cells were allowed to proliferate and the media changed every 3 days as before. Once 
the cells achieved confluency for a second time, neurobasal media was once again 
conditioned. After this treatment, the astrocytes were discarded.
Astrocytes at confluency are shown in Figure 2.5.
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Figure 2.5
Primary cortical astrocytes at confluency. Neurobasal media was conditioned by 24 
hours exposure to astrocytes at this stage. Phase contrast micrograph, X20 objective. 
Scale bar represents 40pm.
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2.3 M easurement of mitochondrial respiratory function
2.3.1 Mitochondrial incubations
An 800jli1 glass chamber with a Clark-type oxygen and TPP+ electrode with 
silver/silver chloride reference were used for determination o f  the respiratory 
parameters oxygen consumption rate and Avj/m. A schematic diagram o f  the chamber 
and electrode arrangement is shown in Figure 2.6.
2.3.1.1 Measurement o f  oxygen consumption rate
The oxygen electrode detects the falling oxygen concentration in the electrode 
chamber as mitochondria consume oxygen for the process o f  oxidative 
phosphorylation. A silver/silver chloride reference anode and a platinum cathode are 
immersed in a concentrated potassium chloride solution, which is separated from the 
mitochondria suspension by a thin Teflon membrane. The oxygen tension in the 
mitochondrial suspension equilibrates across the membrane. Oxygen is then reduced 
at the cathode:
4H+ + 4e' + 0 2 2H20
The electrons for this reaction are produced at the anode, to which chloride ions 
migrate and are oxidised:
4Ag + 4CF 4AgCl + 4e‘
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The current generated by this electron movement is measured, and is directly 
proportional to the oxygen tension. The rate o f  reduction in this current therefore 
represents the rate o f  oxygen consumption by the mitochondria.
The electrode must be calibrated before use at the temperature at which experiments 
will be carried out so that the measured current can be converted to absolute oxygen 
consumption rate. The current detected by the oxygen electrode is directly 
proportional to the oxygen tension in the mitochondrial suspension. Because o f  this 
linear relationship, only two calibration points are necessary - zero and 100%. In 
order to do this, aerated respiration buffer alone was added to the electrode chamber, 
which was maintained at 37°C. The steady state electrode reading at this point was 
taken as 100%. ImM sodium dithionite was added to the chamber, and the oxygen 
concentration allowed to rapidly fall to zero. This reading was taken as 0%. 199 
nmoles C^.m ! ' 1 was taken as the partial pressure o f  oxygen at saturation point in 
buffer at 37°C (Chappell, 1964). This calibration therefore established two known 
oxygen concentrations (0 and 199 nmoles C^-ml'1), from which all subsequent 
recorded consumption rates could be calculated.
Each experiment yielded a straight line trace during state 3 respiration, the gradient of 
which represented the rate o f  oxygen consumption. The rate o f  oxygen consumption 
before the addition o f  mitochondria was subtracted in each case to correct for 
background signal. The resulting corrected reading was converted to nmoles 0 2 .min' 
' .m g '1, by means o f  the calibration points described above.
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2.3.1.2 Measurement o f  mitochondrial membrane potential
v|/m was measured using a tetraphenylphosphonium ion (TPP+) electrode. The 
principle o f  the technique is that TPP+ is taken up by mitochondria as a function of 
v)/m. The electrode itself consists o f  an inert tube containing lOmM TPP+, separated 
from the surrounding chamber by a membrane. 4pM TPP+ is added to the respiration 
medium in the chamber. The concentration gradient o f  the charged ion between the 
inside and outside o f  the electrode (across the membrane) causes a potential 
difference, and this is the parameter which is measured (in mV) with respect to a 
silver/silver chloride electrode.
Prior to each experiment which involved measurement o f  i|/m, three calibration 
curves were created. Each o f  these involved adding TPP+ in lpM  increments 
between 0 and 6 pM. The signal in mV resulting from each [TPP+] was recorded. 
This was repeated for all three calibration curves, and the mean o f  the three readings 
calculated. This mean signal was then plotted against [TPP+], and a second order 
polynomial equation was fitted to the resulting curve (since the relationship between 
[TPP+] and measured voltage is non-linear). This equation could then be used to 
convert mV signals to [TPP+] (pM).
It was necessary to correct for background binding o f  TPP+ to mitochondria which 
was independent o f  \j/m. In order to do this, before each experiment mitochondria 
were incubated with BSA in aerated respiration buffer in the electrode chamber at 
37°C. (The BSA used throughout is fatty acid free. It is included for the purpose of 
binding free fatty acids in the incubation medium, which have mitochondrial
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uncoupling properties (Samartsev et al, 2000)). State 3 respiration was induced by the 
addition o f  excess substrates and ADP, and the mitochondria allowed to consume all 
o f  the oxygen present. v|/m was taken to be zero after an anaerobic state was 
reached. The signal in mV at this point was translated to [TPP+] using the best fit 
polynomial equation described above. This [TPP+] was the maximum possible free 
[TPP+], and was always slightly lower than 4pM due to the background binding.
Signals in mV from the experimental traces were converted to [TPP+] in the same 
way. They were then expressed as \|/m (mV) by applying the following adaptation of 
the Nernst Equation:
v|/m = (2.3RT)/nF x logI0 (A[TPP+(nlt] / A[TPP+in])
ie. i|/m = -61.5 x logio([TPP+] / ([TPP+]con. - [TPP+]) x 2650)
where [TPP+] is the measured parameter for each experiment and [TPP+]con is the 
maximum possible free [TPP+] corrected for background binding as described above. 
The volume o f mitochondria is estimated as being 2650 (derived from 0.755pl.mg'', 
Brand, 1995) times smaller than the volume of the buffer in which it is suspended. 
The '([TPP+]con - [TPP+]) x 2650' term o f the equation therefore estimates the change 
in [TPP+] inside the mitochondria, given the measured change outside.
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To pH meter
TPP+ and 
reference electrodes
800|j] mitochondrial 
suspension + 4pM TPP+ 
stirrer 
oxygen electrode *
magnetic stirrer
injection groove 
37°C water jacket
37°C water out
37°C water in
* Oxygen electrode consists 
of platinum cathode 
surrounded by ring 
reference anode of 
silver/silver chloride. Both 
are immersed in saturated 
KC1 solution, separated 
from chamber by thin teflon 
membrane
Figure 2.6
Schematic diagram to show the arrangements o f  oxygen and TPP+ electrodes with the 
glass chamber.
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2.3.1.3 Incubation schemes
All respiration experiments were earned out according to one o f  three ‘incubation 
schemes’. These involve the addition o f  mitochondria to respiration buffer (lOOmM 
KC1, 75mM mannitol, 25mM sucrose, lOmM Tris-HCl, 50p.M K+EDTA, lOmM 
phosphate-Tris (pH 7.4)) at 37°C containing BSA (2mg.mg'' protein). They allow a 
period o f  equilibration for the mitochondrial sample, before the later addition of 
substrates and ADP to induce state 3 respiration. Sufficient time was also allowed 
during the incubations for inhibitors to exert their effect before respiration was 
induced (Davey & Clark, 1996). A longer incubation time was provided where the 
series o f  experiments was to involve an antibody as the inhibitor (Brustovetsky et al, 
2003b).
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0  mins Respiration buffer (37°C)
Fatty acid free BSA (2mg.mg'' mitochondrial protein) 
TPP+ (4pM)
Isolated mitochondria (0.5mg.mrl)
(Buffer volume corrected to give total volume 800pl)
2  mins Rotenone (0 -  0.45nmoles.mg'' protein for non-synaptic mitochondria, 
0 0.25nmoles.mg'' protein for synaptic mitochondria)
or
KCN (0-400nmoles.mg l protein for non-synaptic mitochondria)
7 mins Glutamate (lOmM) 
Malate (2.5mM) 
Pyruvate (lOmM) 
ADP (2mM)
1 0  mins Remove aliquots to be assayed
Tabic 2.1
The protocol for Incubation Scheme 1, as referred to in the text.
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0  mins
Respiration Buffer (37°C)
Fatty acid free BSA (2mg.mg’' mitochondrial protein) 
Inhibitor (given concentration)
Isolated mitochondria (0.5mg.ml )
(Buffer volume corrected to give total volume 800pl)
1 0  mins Rotenone (0 or O ^Snm oles.m g ’ 1 protein)
15 mins Glutamate (1 OmM)
Malate (2.5mM)
Pyruvate (lOmM)
* ADP (2mM)
18 mins Remove aliquots to be assayed
Table 2.2
The protocol for Incubation Scheme 2, as referred to in the text.
0  mins Respiration Buffer (37°C)
Fatty acid free BSA (2mg.mg"' mitochondrial protein) 
Isolated mitochondria (0.5mg.ml )
(Buffer volume corrected to give total volume 800pl)
1 0  mins Remove aliquots to be assayed
Table 2.3
The protocol for Incubation Scheme 3, as referred to in the text.
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2.3.2 Respiratoiy enzyme complex assays
2.3.2.1 Complex I assay
NADH ubiquinone oxidoreductase (complex I; EC 1.6.99.3) activity was measured 
using a method adapted from Ragan et al (1987). As Complex I serves to accept 
reducing equivalents from NADH and donate them to ubiquinone, its activity can be 
measured by monitoring the loss o f  NADH. This was done by determining the loss 
of  absorbance at 340nm in a Uvikon 940 spectrophotometer (Kontron Instruments 
Ltd., Watford, UK).
The assay was carried out in 1ml o f  25mM potassium phosphate buffer with lOmM 
M gC f, ImM KCN, and 2 .5m g.m fl fatty acid free BSA at 30°C and pH 7.2. 5mM 
NADH was added to the cuvette. The mitochondrial sample was frozen (in liquid 
nitrogen) and thawed three times and then 10pg protein added into the cuvette. The 
cuvette was placed in the spectrophotometer and allowed to equilibrate to 30°C. 
After two minutes, the reaction was initiated by the addition o f  50pM CoQi. The 
absorbance at 340nm was read against blank cuvettes (identical except CoQi 
omitted). lOpM rotenone was added after a further five minutes, and the absorbance 
monitored for a further five minutes.
The rotenone-inhibited rate o f  change o f  absorbance was subtracted from the initial 
rate. This rotenone-sensitive component was then converted to Complex I activity in 
nmoles.min'1.mg ' 1 using the Beer-Lambert Law and an extinction coefficient o f  6.81
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x 103 IVr'.cirr1 for NADH. (The generally accepted value for the extinction 
coefficient o f  NADH at 340nm is 6.22 x 103 M'Vcm'1. However, in the presence of 
CoQi, this is shifted to the value used in this case (Ragan et, al, 1987)).
2.3.2.2 Complex IV assay
Cytochrome c oxidase (complex IV; EC 1.9.3.1) was measured using the method of 
Wharton & Tzagoloff (1967). As Complex IV serves to accept reducing equivalents 
from reduced cytochrome c and donate them to molecular oxygen to form water, its 
activity can be measured by monitoring the rate o f  oxidation o f  cytochrome c. This 
was done by determining the loss o f  absorbance at 550nm in a Uvikon 940 
spectrophotometer (Kontron Instruments Ltd., Watford, UK).
For this assay, reduced cytochrome c is required as a reagent. A lOnig.mf1 solution 
o f  oxidised cytochrome c was initially reduced by adding approximately 5mg sodium 
ascorbate. In order to remove the ascorbate from the solution, the reduced 
cytochrome c was then passed down a PDio gel filtration column. The concentration 
o f  this reduced cytochrome c solution was then determined by measuring the 
absorbance at 550nm against cytochrome c which was fully oxidised by the addition 
o f  lOOpM potassium ferricyanide. The Beer Lambert Law was applied to this 
absorbance difference, using the extinction coefficient for reduced cytochrome c 19.2 
x 103 M ' W .
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The assay for Complex IV activity was then carried out in lml o f  10mM potassium 
phosphate buffer with 50pM reduced cytochrome c at 30°C and pH 7.0. The cuvette 
was placed in the spectrophotometer and allowed to equilibrate for 2 minutes. The 
mitochondrial sample was frozen (in liquid nitrogen) and thawed three times and then 
10pg protein added to the cuvette. The absorbance at 550nm was measured against a 
cuvette containing no sample but with the reduced cytochrome c fully oxidised by the 
addition o f  lOOpM potassium ferricyanide.
The rate o f  change o f  absorbance at 550nm is non-linear. The reaction shows first 
order dependence on the concentration o f  reduced cytochrome c. By plotting the 
natural log o f  absorbance over time for each sample, a straight line relationship was 
obtained. The gradient o f  each the line was taken as the first order rate constan t, and 
the activity o f  Complex IV expressed as /unin'1.mg'1.
2.4 Assay of mitochondrial proteins
2.4.1 Cytochrome c concentration
Cytochrome c concentration can be measured accurately and quantitatively by 
immunoassay. The Quantikine M Rat/Mouse Cytochrome c Immunoassay kit from 
R&D Systems (Abingdon, UK) was used for this purpose. The assay works by a 
'sandwich' method, immobilising a labelled monoclonal antibody by attachment to a 
second antibody, via mutual binding to cytochrome c. The mechanism is explained in 
Figure 2.7.
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All reagents were brought to room temperature before use, having been stored at 4°C. 
75jliI o f  the conjugate monoclonal antibody was added to each of  the wells, which had 
been pre-coated with a non-labelled monoclonal antibody. Samples were diluted 
according to their estimated cytochrome c concentration, in order that they should fall 
within the limits o f  the standard curve (0.78 - 25ng/ml). 50 j l l 1 of  sample or standard 
were added to the wells. A known mass o f  cytochrome c was also dissolved in 
deionised water and assayed in the same way as a control. The well contents were 
then mixed by gently tapping the plate for 1 minute. The plate was covered and 
incubated for 2  hours at room temperature to allow the antibodies to bind any 
cytochrome c present. The wells were then washed thoroughly 5 times, ensuring that 
wells were emptied completely each time. The plate was inverted and blotted against 
clean paper towels. lOOpI substrate solution (H2 O 2 + tetramethylbenzidine) was 
added to each well, and the plate incubated at room temperature in the dark for 30 
minutes. After this time, lOOpl stop solution (dilute HC1) was added to each well. 
The plate was tapped gently to ensure thorough mixing. The absorbance o f  each well 
was determined at 450nm and 540nm in a plate-reading spectrophotometer 
(SpectraMaxPlus, Molecular Devices, Sunnyvale, CA). The latter was subtracted 
from the former to correct for background absorbance.
A standard curve was plotted as log([cyt c]) versus log(A4 5 o - A 5 4 0 ). The linear 
equation o f  best fit was used to translate the absorbance readings obtained from the 
samples to concentrations o f  cytochrome c. Finally, these were corrected for the
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initial dilution factor, and expressed as nmoles.mg ' 1 mitochondrial protein. A typical 
standard curve is shown in Figure 2.8.
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Each well of a 96-well microplale has been pre-coated with a 
monoclonal antibody specific for rat/mouse cytochrome c. The 
antibody is immobile.
Monoclonal antibody for cytochrome c
y  a m  y  y y
A solution containing a second monoclonal antibody for 
cytochrome c is added into the well. Unlike the first, this antibody 
is freely mobile in the solution and is conjugated to the enzyme 
horseradish peroxidase (HRP).
*  Monoclonal antibody for cytochrome c 
^  conjugated to HRP ( * )
The sample solution is added. Any cytochrome c present can bind 
to both antibodies (which are in excess). This ‘sandwich’ process 
immobilises the conjugated antibody to an extent directly 
proportional to the concentration of cytochrome c. Other proteins 
within the sample solution and surplus conjugated antibody remain 
free in the solution.
£  Cytochrome c in sample solution 
A Other proteins in sample solution
•  Thorough washing removes all free proteins, leaving only the 
cytochrome c and bound antibodies.
•  A substrate solution is added immediately after washing. This 
consists of hydrogen peroxide (H20 2) and the chromagen 
tetramethylbenzidine (TMB), which are mixed immediately prior 
to this stage. HRP catalyses the oxidation of TMB by H20 2 to 
form a soluble blue product.
•  Hydrogen peroxide 
o  Tetramethylbenzidine 
B Soluble blue product
•  The addition of weak hydrochloric acid stops the HRP-catalysed 
reaction, and converts the blue product to a stable yellow product. 
The concentration of this product is directly proportional to the 
concentration of cytochrome c in the original sample, and can be 
determined by measuring the absorbance at 450nm (corrected for 
background signal by subtraction of absorbance at 540nm).
Stable soluble yellow product
•  A standard curve is created by applying the same procedure to 
standards of [cytochrome c] from 0.78 - 25ng/ml. This is then 
used to convert the absorbance reading to [cytochrome c] for the 
samples.
Figure 2.7
The mechanism underlying the cytochrome c immunoassay
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Figure 2.8
Typical standard curve from cytochrome c immunoassay. Log [cytochrome c] is 
plotted versus the log of the optical density measurement. The resulting best fit line 
can be used to calculate all experimental readings to cytochrome c concentrations. 
For example, this standard curve has the best Fit equation:
log OD = 1.071og[cyt c] 1.27 (R2 = 0.996)
This rearranges to:
[cyt c]»i o <,ogOD+
105
2.4.2 Citrate synthase activity
Citrate synthase (EC 4.1.3.7) was measured using the method o f  Shepherd and 
Garland (1969). The enzyme catalyses the following reaction:
Acetyl-CoA + oxaloacetate + H2 O -------- ► citrate + free CoA
If 5,5’-dithiobis(2-nitrobenzoic acid) (or DTNB) is present, it can react with the free 
CoA product to form a 77-nitrothiophenol anion, which absorbs at 412nm. The basis 
o f  this ‘linked’ assay is therefore to provide the reagents required for the citrate 
synthase-catalysed reaction along with DTNB and monitor the increase in absorbance 
at 412nm.
The assay was carried out in 96-well plate. Each well contained 250pl o f  lOOmM 
Tris-HCl buffer with 0.1 mM acetyl-CoA and 0.2mM DTNB at 30°C and pH 8.0. 
20pl o f  sample was added. The plate was positioned in a plate-reading
spectrophotometer (SpectraMaxPlus, Molecular Devices, Sunnyvale, CA), and the 
absorbance at 412nm monitored for 5 minutes to establish the background rate. After 
this time, 0.2mM oxaloacetate was added to initiate the reaction. The absorbance at 
412nm was again monitored for 5 minutes. The background rate was subtracted from 
the stimulated rate o f  absorbance change. Using the Beer Lambert Law and a p -  
nitrothiophenol anion extinction coefficient o f  13.6 x 103 M 'l.cm‘l, citrate synthase 
activity was expressed in nmoles.min'1.mg'1. For analysis o f  released citrate 
synthase, activity o f  the enzyme in the supernatant samples was shown as a
percentage o f  the mean total mitochondrial activity.
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2.4.3 Adenylate kinase activity
Adenylate kinase (EC 2.7.4.3) was measured using a method adapted from Kluck et 
al (1999) and Doran & Halestrap (2000). The enzyme catalyses the following 
reaction:
In this linked assay, phosphoenolpyruvate (PEP) is added with pyruvate kinase, 
generating pyruvate and ATP. Lactate dehydrogenase (LDH) then catalyses the 
conversion o f pyruvate to lactate, using NADH. ATP is present in the buffer. This 
system therefore increases the ATP:ADP ratio. Adenylate kinase is required to 
restore the balance, by catalysing the reaction shown above in the forward direction. 
AMP is added as the substrate for the assay, allowing the reaction to proceed. The 
rate o f adenylate kinase activity is measured by the rate o f decrease in NADH levels, 
used at the LDH-catalysed step. The scheme for the assay is therefore:
AMP + ATP ^  2ADP
AMP
ADP ATP NADH NAD
PEP >  Pyruvate >• Lactate
PK LDH
Rotenone and oligomycin are included in the buffer to prevent ETC-mediated 
changes in the ATP:ADP ratio. This is necessary for assaying the whole
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mitochondria] adenylate kinase activity, and is retained for the measurements on 
supernatants for consistency.
The assay was earned out in a 96-well plate. Each well contained 250pl o f  130mM 
KC1, 6 m M M g S 0 4, lOOmM Tris, 1.5mM NADH, 0.5mM ATP, 0.5mM 
phosphoenolpyruvate, 5pM rotenone, 7.5pM oligomycin, 0.2U.ini ' 1 pyruvate kinase 
and 0.2U.ini ' 1 lactate dehydrogenase, at 30°C and pH 7.5. 20 j l i 1 o f  the supernatant 
sample was added. The plate was then positioned in a plate-reading 
spectrophotometer (SpectraMaxPlus, Molecular Devices, Sunnyvale, CA) and 
allowed to equilibrate for 2 minutes. 0.6mM AMP was then added to each well, and 
the absorbance at 366nm monitored for 5 minutes. The normal wavelength for 
monitoring a loss o f  NADH is 340nm. However, for this assay it was found that 
monitoring absorbance at 340nm gave a highly unreliable signal. One or more 
components o f  the reaction mixture presumably interfere with this reading. 
Therefore, as in Kluck et al (1999), NADH was monitored at 366nm. Using a diode 
array spectrophotometer, it was confirmed that NADH showed significant absorbance 
at 366nm.
After 5 minutes incubation with AMP, 0.4mM di-adenosine pentaphosphate (specific 
adenylate kinase inhibitor) was added to each well, and the absorbance measured for 
a further 5 minutes. The inhibited rate was subtracted from the stimulated rate of 
change in absorbance. Adenylate kinase activity was expressed as rate o f  change of 
absorbance per mg o f  mitochondrial protein (Brustovetsky et a l, 2003b). For analysis
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of released enzyme, this rate was then converted to a percentage o f  the mean total 
mitochondrial activity.
2.4.4 M itochondrial glutathione content
Mitochondrial GSH concentration was measured using reverse-phase HPLC, coupled 
to a dual-electrode electrochemical detector (Riederer et al, 1989).
Samples from mitochondrial incubations which had been acid extracted using 
orthophosphoric acid were injected (20pl) by a Kontron HPLC 360 autosampler 
(Watford, UK). A guard column was used to clean the sample (octadecasilyl, 3mm x 
10mm). The signal was resolved using a reverse-phase Techsphere octadecasilyl 
column (particle size 5pm, 4.6mm x 250mm). The column was maintained at 30°C 
using a heater (Jones Chromatography, Glamorgan, UK). The mobile phase was 
15mM orthophosphoric acid (pH 2.5), degassed using a DEG-1033 degasser 
(Kontron Instruments, Watford, UK). The flow rate was set at 0.5ml.min ' 1 using a 
Jasco PU-1580 pump (Great Dunmow, UK).
Following separation, GSH was detected using an ESA 5010 analytical cell 
(Aylesbury, UK). The signal was recorded as a chromatogram on a 
Thermoseparation Products Chromejet integrator (Anachem, Luton, UK). The chart 
speed was set to 25mm.min"1.
5pM GSH standards were dispersed among the samples to enable calculation of GSH 
concentrations and to ensure continuity o f  signal during a run.
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2.4.5 A IF and Smac concentration
2.4.5.1 SDS polyacrylamide gel electrophoresis
Untreated mitochondrial pellets were used as positive controls. Pellets were 
resuspended in lysis buffer (20mM Tris-acetate, ImM EDTA, ImM EGTA, IOitiM 
sodium (3-glycerophosphate, ImM sodium orthovanadate, 5% glycerol, 1% Triton X- 
100, 0.27M sucrose, ImM benzamidine, 4m g .m rl leupeptin, 0.1% (3-
mercaptoethanol, pH 7.4) to a concentration o f  2 m g .m rl. The suspension was then 
left on ice for 20 minutes with regular vortexing. It was centrifuged at lOOOOxg for 1 
minute to pellet the non-solubilized material. The supernatant was used as the sample 
for electrophoresis.
Supernatant samples from rotenone- or alamethicin-treated incubations were thawed 
from -70°C storage and vortexed before being used for electrophoresis.
15j.il o f  each sample was added to 8 pl Laemelli sample buffer (1% SDS, 10% 
glycerol, 2.5% |3-mercaptoethanol, 125mM Tris-HCl, 1% bromophenol blue, pH 6 .8 ) 
in eppendorf tubes. A hole was punched in the top o f  each tube with a needle, and the 
sample mixtures then boiled for 5 minutes. A solution o f  molecular mass markers 
was treated in the same way.
The samples were then loaded onto a Tris-HCl 12.5% pre-cast gel (Bio-Rad, Bucks., 
UK) and secured in a Bio-Rad Mini-Protean II electrophoresis cell. The molecular
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mass markers were run in the far left hand lane. The 30pl wells were filled to the top 
with running buffer (125niM Tris, 1M glycine, 0.01% SDS). The tank was also filled 
with running buffer and the electrodes secured. The gel was then run for 1 hour at 
180V.
2.4.5.2 Electrophoretic protein transfer
The gel was then carefully removed from the supporting glass plate, and equilibrated 
in transfer buffer (25mM Tris, 192mM glycine, 0.01% SDS, 20% methanol) for 20 
minutes. Meanwhile, a polyvinylidene fluroide (PVDF) membrane was activated in 
methanol at 4°C for 1 minute. The membrane was then washed in distilled water for 
5 minutes, and then equilibrated in transfer buffer for 20 minutes also.
The gel was then transferred to a fibre pad on a piece o f  filter paper. The PVDF 
membrane was layered onto the gel, and bubbles removed using a glass rod. A 
second piece o f  filter paper was layered onto the membrane, and the stack assembled 
into the transfer cassette, using fibre pads for support. A cooling pack was placed in a 
Bio-Rad mini trans blot electrophoretic transfer cell along with the cassette, and the 
cell filled with transfer buffer. A stirrer bar was positioned in the bottom of the tank, 
and the electrodes fitted. The proteins were then transferred to the membrane at 80V 
for 2  hours.
I l l
2.4.5.3 Immunoblotting
Following transfer, the membrane was washed for 10 minutes in Tween-20 Tris 
buffered saline (TTBS; lOmM Tris-HCl, 150mM NaCl, 0.5% Tween-20, pH 7.4) to 
remove SDS and methanol. It was then immersed in blocking buffer (TTBS with 5% 
non-fat dried milk) at room temperature for 90 minutes with shaking. The membrane 
was then probed with primary antibody diluted 1 in 500 into blocking buffer, for 1 
hour at room temperature. After removal o f  the antibody solution, the membrane was 
washed 3 times for 10 minutes each in TTBS. It was then incubated with a secondary 
antibody (donkey anti-goat) conjugated to HRP, diluted 1 in 1000 in blocking buffer, 
for 1 hour at room temperature. Finally, the membrane was washed 3 times more, for 
10 minutes each time, in TTBS.
The membrane was then drained o f  excess liquid by blotting the edge against a tissue. 
4m 1 ECL reagent (Bio-Rad, Bucks., UK) was then added to cover the membrane. It 
was dried quickly between two sheets o f  filter paper. The membrane was then fixed 
into an x-ray film cassette with tape and exposed to film. The exposure time was 
varied between 30 seconds and 10 minutes depending on the strength o f  the signal. 
The film was then soaked in developer for 1 minute, washed in acetone and finally 
fixed in fixer for 3 minutes.
Note that re-probing the gel to check for equal protein loading was not required in 
this case, since the protein content o f  the supernatant samples varied depending on the 
earlier rotenone treatment.
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2.5 Assessment o f  mitochondrial volume
2.5.1 Electron M icroscopy
Electron microscopy was carried out in collaboration with Professor David Landon 
and Mr. Brian Young (Electron Microscopy Unit, Institute o f  Neurology).
Samples from mitochondrial incubations were centrifuged at 17000xg for 5 minutes 
at 4°C (Sigma Laborzentrifugen 3K10, Osterode, Germany). The supernatant was 
then completely removed, and very carefully replaced with fixative (3% 
glutaraldehyde buffer, pH 7.4, with 0 .1M sodium cacodylate and 5mM calcium 
chloride). Mitochondrial pellets treated in this way were then kept at 4°C overnight.
The pellet was then subjected to 2 brief washes with distilled water. The pellet was 
exposed to 1 % aqueous osmium tetroxide for 2  hours, followed by a further 2  brief 
washes with distilled water. This treatment had further fixative properties, but also 
acted as an electron microscopy ‘stain’.
The pellet was then dehydrated in ascending grades o f  alcohol ( 2 x 1 0  minute washes 
in 70% and 90%, 4 x 1 0  minute washes in 100%). Following this, the pellet received 
2 x 1 0  minute washes in epoxy propane. This was replaced by a 1:1 mixture o f  epoxy 
propane and resin and left for 30 minutes. The resin consisted o f  agar 100, dodecenyl 
succinic anhydride (plasticiser), methyl nadic anhydride (hardener) and 2,4,6- 
tri(dimethyl aminomethyl) phenol (accelerator) in equal parts. This mixture was then
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replaced with neat resin and left for 3 hours. The resin was then polymerised by 
incubating at 60°C overnight.
An RMC MT6000 ultramicrotome with Diatome diamond knife was then used to cut 
ultra-thin (approximately 70nm) sections from the specimen. The sections were 
released into a dish o f  distilled water and then collected on 3mm mesh copper grids. 
The sections were stained with 25% uranyl acetate in 50% methyl alcohol for 20 
minutes, and then exposed to Reynold’s lead citrate for a further 20 minutes. The 
grids were washed 2 x 1 0  minutes in distilled water, and then examined in a JOEL 
1200EX electron microscope.
2.5.2 Determination o f  light scattering
A quantitative assessment o f  mitochondrial volume changes can be made by 
measuring the extent to which the mitochondria in suspension scatter light. As 
mitochondria swell, their refractive index decreases with the result that they scatter 
less light (Knight et al, 1981). If an incubation is carried out in a spectrophotometer, 
this reduced light scattering can be detected as a decrease in light intensity (Kluck et 
al, 1999; Kristian et al, 2000). The wavelength typically used as the incident beam in 
such an investigation is 540nm. This wavelength is almost isosbestic with respect to 
cytochromes h, c and c\, and therefore minimises potential complications by changes 
in the redox states o f  these proteins.
For the purpose o f  these experiments, mitochondrial incubations were carried out in a 
0.5ml quartz cuvette. This was placed in a Perkin Elmer Luminescence
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Spectrometer, and maintained at 37°C by means o f  a water jacket. Using FL WinLab 
version 3.00 software, an incident beam o f 540nm was passed through the cuvette, 
and the transmitted light detected at a 90° angle from the incident beam. Both slit 
widths were set to 2.5nm. The data was recorded as arbitrary light intensity units.
2.6 Assessment of neuronal apoptosis
2.6.1 Assav fo r  caspase-9 activity
Caspase-9 activity was measured using a colorimetric assay kit purchased from R&D 
Systems (Abingdon, UK).
Samples were stored as cell pellets at -70°C. In order to perform the assay, pellets 
were thawed and then resuspended in lOOpl lysis buffer (from kit). The lysing cells 
were kept on ice for 10 minutes, and then centrifuged at lOOOOxg for 1 minute. The 
supernatant was then removed and kept on ice.
The protein concentration o f  this pellet was measured as described in 2.7.1. A 1:50 
dilution o f  the lysates was appropriate for the protein concentration to fall within the 
standard curve.
The caspase assay was carried out in a 96-well plate. 50pl reaction buffer (containing 
lOmM DTT) was added to each well. The same volume o f  cell lysate was then 
added. Finally 5pl caspase-9 colorimetric substrate (Leu-Glu-His-Asp or LEHD
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peptide conjugated to p-nitroanilide) was added to each well. The plate was 
incubated in the dark at 37°C for 2  hours.
Following this incubation, the absorbance at 405nm was determined for each well 
using a plate-reading spectrophotometer (SpectraMaxPlus, Molecular Devices, 
Sunnyvale, CA). Caspase-9 activity was expressed as arbitrary absorbance units at 
405nm per milligram of protein in the lysate.
2.7 Validation of preparations
2.7.1 Assay fo r  protein concentration
Before any experiments could be carried out on isolated mitochondria, or enzyme 
activities measured in harvested cells, the exact protein concentration o f  the sample 
was required. This was determined using the DC Protein Assay from Bio-Rad 
(Bucks., UK). This assay is based on the Lowry method (1951), but is modified to 
allow for a shorter reaction time ( 2 0  minutes) and a more stable colour formation 
(stable for up to 2  hours).
The basis for the assay is as follows. In an alkaline medium, protein can form a 
complex with copper. This complex can reduce a Folin reagent, via the removal o f  1, 
2 or 3 oxygen atoms. The three different products from this reduction reaction are all 
coloured, due to the presence of  the amino acids tyrosine, tryptophan, cystine,
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cysteine and histidine. Furthermore, all three coloured products have a maximum 
absorbance at 750nm, which can be measured spectrophotometrically.
A set o f  protein standards are required for the assay, and these were made using fatty 
acid-free BSA in deionised water, at concentrations 10, 25, 50, 75 and lOOpg.ml'1. 
Deionised water served as a Opg.mf1 standard. The sample was diluted with 
deionised water to fit within this range o f  standards, according to the estimated 
concentration. For isolated mitochondria, a 1:200 dilution was always appropriate. 
For harvested neurons, the estimated concentration depended on the number of 
pooled wells.
40pl o f  standard or sample was added to a 96-well plate. To this was added 20pl 
Reagent A (alkaline copper tartrate solution) and then 160pl Reagent B (Folin 
reagent). Each standard or sample was assayed in triplicate in this way. The plate 
was incubated at room temperature in the dark for 2 0  minutes, and then the 
absorbance at 750nm o f  each well recorded using a plate-reading spectrophotometer 
(SpectraMaxPlus, Molecular Devices, Sunnyvale, CA). A standard curve was 
plotted, and the sample concentration subsequently determined.
2.7.2 Validation o f  isolated brain mitochondria preparations
2.7.2.1 Citrate synthase activity
Citrate synthase (CS) is a mitochondrial matrix enzyme which has been used 
routinely to indicate the extent to which the isolation procedure purifies mitochondria. 
It was used to validate both the non-synaptic and synaptic preparations.
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Remaining whole isolated mitochondria following an experiment were stored at - 
70°C. Following three freeze-thaw cycles, these mitochondria were assayed for citrate 
synthase activity as described in 2.4.2. The same was done for whole brain 
homogenates, samples o f  which were removed following the first 8  up and down 
strokes in the Dounce homogeniser as described in 2.2.1.2. The protein concentration 
o f  these homogenates was determined as described in 2.7.1.
The percentage purification o f  citrate synthase from the whole brain homogenate to 
the isolated mitochondria was then used to indicate the purifity o f  the mitochondrial 
preparation. The results o f  this validation procedure are shown in Table 2.4.
H NSM SM
CS specific activity
(nmoles.min'1.mg'1) 216.2 ± 1 2 . 6 1101 ± 8 0 .9 440.1 ±26.2
Purification of CS during 
mitochondrial isolation
(Multiple o f  activity in whole 
brain homogenate)
1 5.09 2.04
Table 2.4
Citrate synthase activity o f  whole brain homogenate (H), isolated non-synaptic 
(NSM) and synaptic (SM) mitochondria. Specific activities are given ± S.E.M., n = 
3. These data indicate that there is more than a 5-fold increase in citrate synthase 
activity during the isolation o f  non-synaptic mitochondria, and an approximate 
doubling o f  this activity during the isolation o f  synaptic mitochondria. These data 
represent the amount o f  non-mitochondrial contamination in the preparation, and 
suggest that there is more non-mitochondrial protein present in the synaptic 
preparation than the non-synaptic preparation. This should be taken into account 
when analysing subsequent data.
2.7.2.2 Lactate dehydrogenase activity
Lactate dehydrogenase (LDH, EC 1.1.1.27) is a cytosolic enzyme with no recognised 
mitochondrial isoform in brain. It can therefore be used to indicate the percentage 
cytosolic contamination o f  the mitochondrial preparations. It was used for this 
purpose for both non-synaptic and synaptic preparations.
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The reaction catalysed by LDH is as follows:
Lactate + NAD+ ^  Pyruvate + NADH + H+
In a reaction mixture which provides the substrates for the reverse reaction, the rate of 
LDH activity is monitored as the rate o f  disappearance o f  NADH, as determined by 
the change in absorbance at 340nm.
As for citrate synthase, whole isolated mitochondria and whole brain homogenate 
samples were freeze-thawed three times and then assayed for lactate dehydrogenase 
activity. This was measured in a Uvikon 940 spectrophotometer (Kontron 
Instruments Ltd., Watford, UK), by the method o f  Vassault (1983). 8 mM NADH 
was added into phosphate/pyruvate buffer (50mM K2 HPO4 , 8.3mM KH2 PO4 , 
0.345mM sodium pyruvate, 0.5% (v/v) Triton X-100, pH 7.5) in a cuvette to a total 
volume o f  and placed in the spectrophotometer. The cuvette was maintained at 30°C 
by means o f  a water jacket. After 2 minutes o f  equilibration, lOpg protein was added 
to the cuvette. The absorbance at 340nm was monitored for 5 minutes. Using the 
Beer-Lambert Law and an extinction coefficient o f  6.81 x 103 IVT'.cm"1, the rate of 
change in absorbance was then converted to LDH enzyme activity, expressed in 
nmoles NADH utilised.min'1.mg ’ 1 protein.
Mitochondrial LDH specific activity as a percentage o f  that measured in whole brain 
homogenate was used to indicate the extent o f  cytosolic contamination in the 
preparation. The results o f  this validation procedure are shown in Table 2.5.
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H NSM SM
LDH specific activity
(nmoles NADH.min '1.mg'1) 539.8 ± 18 13.7 ± 1 . 8 16.4 ±2 .9
Mitochondrial LDH 
contamination
(% o f whole brain homogenate)
- 2.5% 3.0%
Table 2.5
Lactate dehydrogenase activity o f  whole brain homogenate (H), isolated non-synaptic 
(NSM) and synaptic (SM) mitochondria. Specific activities are given ± S.E.M., n = 
3.
The low LDH activity in the isolated mitochondrial preparations as compared to the 
activity in the initial homogenate indicates that there is little cytosolic contamination 
o f  the preparations. The percentage contamination is very similar for isolated non- 
synaptic and synaptic mitochondria.
2.7.2.3 Respiratory control ratio
The respiratory control ratio (or RCR) is a recognised parameter which describes the 
extent to which the isolated mitochondria in a preparation are coupled. This is done 
by determining the increase in oxygen consumption rate o f  the mitochondria in 
response to the addition o f  ADP. Traditionally (Chance & Williams, 1956), the ratio 
is determined in the presence of  glutamate and malate as respiratory substrates. The
state 4 (in the absence o f  ADP) and state 3 (in the presence o f  ADP) oxygen 
consumption rates are measured potentiometrically as described in 2.3.1.1.
Mitochondria are subjected to three cycles o f  ADP addition, the concentration of 
ADP calculated such that it will be completely converted to ATP after around 30 
seconds. Each state 3 oxygen consumption rate is divided by the preceding state 4 
rate, and the mean o f  these three ratios taken as the overall RCR value. For brain 
mitochondria, an RCR of at least 5 is required to indicate sufficient coupling.
Following isolation from whole rat brains (2.2.1.2, 2.2.1.3) and measurement o f  the 
protein concentration (2.7.1), mitochondria were added at 0.5mg.mr' to respiration 
buffer (2.3.1.3) at 30°C (NB. This is the traditional temperature at which RCR values 
are measured (Chance & Williams, 1956). Although subsequent experiments are to 
be carried out at 37°C, this measurement is a validation process and must therefore be 
carried out under the traditional conditions). Fatty acid free BSA was added at 
2mg.mg‘l mitochondrial protein. The suspension was incubated for 5 minutes before 
state 4 respiration was induced using the substrates glutamate (lOmM) and malate 
(2.5mM). The mitochondria were then cycled three times through state 3/4 
respiration by the addition o f  300pM ADP for each o f  the three additions. The 
respiratory control ratio (RCR) was calculated as the average ratio o f  state 3: state 4 
respiration rates.
A typical RCR trace is shown in Figure 2.9. It can clearly be seen that the oxygen 
consumption rate increases very rapidly in response to ADP addition, and that there is
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a marked gradient change between state 3 and state 4 respiration. In the trace shown,
the RCR was calculated as > 8 . Mitochondria consistently demonstrated RCR>5.
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Figure 2.9
Typical Respiratory Control Ratio trace for isolated non-synaptic mitochondria. 
Similar traces were observed for isolated synaptic mitochondria. The RCR in this 
trace was calculated as > 8 .
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2.7.3 Validation o f  neuron-rich primary culture
2.7.3.1 Immunochemical assessment o f  purity
By staining a culture o f  primary neurons, the purity o f  the culture can be determined. 
A dye which causes all nuclei to fluoresce (DAPI) is used alongside an antibody for 
neuron-specific beta III tubulin. The percentage o f  the total number o f  cells which 
are neurons can then be estimated by observation through a confocal microscope.
In order to observe stained cell through the confocal microscope, the cells were 
required to be grown on glass coverslips. The culture procedure was very similar to 
that described for plastic wells (2.2.2.1). However, prior to the preparation, glass 
coverslips were immersed in 20% HNO 3 overnight at room temperature, washed 3 
times in distilled water, dried in acetone and then incubated at 180°C for 2 hours. 
Following cooling, the coverslips were placed one per well in a sterile 6 -well culture 
plate. 1 ml poly-D-lysine was added per well, and the plate incubated at 37°C for 1 
hour. The wells were then washed 3 times with sterile distilled water and dried under 
UV light. lOOpl coating solution (neurobasal with 5% horse serum, 5% FBS, 2mM 
L-glutamine, 62.5mM glutamate, 2% B27 with antioxidants) was added to each 
coverslip, and the plate then incubated at 37°C until the preparation was complete.
Following the preparation o f  the cells, they were resuspended to a concentration of 2 
x 106 .m r ' (double the concentration described in 2.2.2.1). lOOpl o f  cell suspension 
was added to into the coating solution on each coverslip. This was incubated for 1
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hour in the 37°C incubator described above (2 .2 .2 . 1 ). 2 ml neurobasal medium was 
then added into each well, and the cells cultured for 6  days as described in 2 .2 .2 . 1 .
At day 6  o f  culture, the neuronal medium was removed from cells and replaced with 
2ml.well -1 Tris-buffered saline (TBS; IO itiM  Tris-HCl, 150mM NaCl, pH 7.4). The 
TBS was removed after 5 minutes, and 2ml.well"1 ice cold methanol added in its 
place. The cells were fixed in this way for 10 minutes on ice. The cells were then 
rinsed twice with TBS as before, for 5 minutes each time. The cells were then 
permeabilised by the addition o f  4mM sodium deoxycholate for 10 minutes at room 
temperature. Following permeation, the cells were rinsed twice for 5 minutes each, 
this time with TBS containing 0.025% Triton X-100. The cells were then blocked 
using TBS containing 1% BSA and 10% goat serum for 2 hours at room temperature. 
After this time, the blocking solution was removed. Mouse anti-tubulin (1:500) was 
then added in TBS with 1% BSA. The cells were incubated with this primary 
antibody at 4°C overnight.
Following removal o f  the primary antibody, the cells were washed twice at room 
temperature with TBS for 5 minutes each. They were then incubated for 1 hour at 
room temperature with a FITC-conjugated secondary antibody, diluted 1:500 in TBS 
with 1% BSA. They were then washed twice with TBS for 5 minutes each, followed 
by incubation with 0.01% DAPI for 10 minutes at room temperature. Finally, the 
cells were washed once more with TBS for 5 minutes.
The coverslips were then removed from the TBS with forceps, and mounted face­
down on glass microscope slides using lOpl citifluor as a mounting solution.
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Three combinations o f  treatments were used on the coverslips: DAPI stain alone, 
DAPI with FITC-conjugated secondary antibody and finally DAPI, secondary 
antibody and the primary antibody anti-tubulin. The coverslips mounted on slides 
were observed under a Zeiss 510 laser scanning confocal microscope at x20 objective 
with numerical aperture 0.75. A 364nm line o f  argon UV laser was used to excite 
DAPI, and 488nm used to excite FITC. The emitted light was detected using a 
photomultiplier tube. The data was analysed using Zeiss LSM image browser 
software.
The DAPI stain alone and the DAPI stain with secondary antibody both showed the 
same result, with only nuclei visible. This demonstrated that the secondary antibody 
contributed no artefactual background signal. The cells which were treated with 
DAPI and both antibodies however clearly showed nuclei with surrounding tubulin 
stain. A typical field o f  view is shown in Figure 2.10. The apparently complete co­
localisation o f  nuclei with tubulin stain demonstrates the purity o f  the culture.
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Figure 2.10
Confocal micrograph o f  neuron-rich primary culture for foetal rat cortex, x20 
objective. The cells were treated with DAPI, primary anti-tubulin antibody and 
FITC-conjugated secondary antibody. Blue areas represent DAPI-stained nuclei, 
green regions represent neuron-specific tubulin, visualised with FITC. There are no 
nuclei which are isolated from the neuron-specific tubulin, demonstrating an 
extremely pure neuronal preparation. Scale bar represents 40pm.
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2.8 Statistical analysis
Statistics were calculated using GraphPad Prism IM Version 3.00 software (GraphPad 
Software Inc., CA, USA).
Data are presented as mean ± standard error o f  the mean (S.E.M.). Linear regression 
analysis and the Student’s t test were used for statistical comparisons. A p-value o f  < 
0.05 was considered significant.
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CHAPTER 3
Quantifying the release o f  cytochrome c from
brain mitochondria
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3.1 Introduction
3.1.1 The mechanism o f release
The release o f  cytochrome c is often taken as an indication o f  commitment to 
apoptosis. As such, it has tended to be thought o f  as a discrete event, with little 
consideration for any potential sophistication of  the signal itself
If postulated swelling-dependent mechanisms of  release are to be believed, it is quite 
understandable that the event should be o f  the all-or-none nature described in 
Goldstein et al (2000). Even taking into account mitochondrial heterogeneity, if a 
small number o f  more susceptible mitochondria were to lose integrity to the extent 
that the IM was ruptured, calcium homeostasis would be lost. An increased cytosolic 
calcium concentration would be likely to trigger MPT in further mitochondria, thus 
triggering a chain reaction.
However, the majority o f  recent investigations into mechanisms o f  CCR describe 
features more consistent with the OM channel hypothesis. Release has been reported 
in the absence o f  mitochondrial swelling, prior to dissipation o f  A\j/m and 
independently o f  release o f  any other soluble intermembrane proteins (SIMPs) 
(Andreyev et a l, 1998; Bossy-Wetzel et al, 1998; Brustovetsky et al, 2003b; Doran & 
Halestrap, 2000; Eskes et al, 1998; Jiirgensmeier et al, 1998; Kluck et al, 1999; Von 
Ahsen et al, 2000; Wiqckowski et al, 2001;). Furthermore, increasing awareness of 
the importance o f  quantitatively assessing CCR has led to demonstration of
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incomplete release (Brustovetsky et al, 2002). All o f  these features are more
consistent with the theory o f  release via an OM channel.
Bearing in mind the requirement for ATP in the apoptotic program, it is important for 
IM integrity to be maintained to a certain extent (especially in neurons, 1.3.5.3). For 
this reason, MPT is becoming increasingly regarded as an event downstream of CCR, 
possibly with the role o f  amplifying the signal for death (Marzo et al, 1998). A role 
for MPT is recognised in the necrotic death program, for which ATP is not required 
(Crompton et al, 2002; Kim et al, 2003).
3.1.2 The extent o f  release
There is growing interest in post-mitochondrial regulation o f  apoptosis. The IAP 
proteins (1.3.6.1) inhibit activated caspases, and it is suggested that this may serve to 
prevent ‘inappropriate’ apoptosis (Hengartner, 2000). There is now widespread 
recognition that such ‘inappropriate’ apoptosis contributes significantly to 
neurodegenerative cell loss (reviewed by Thompson, 1995). This regulatory system 
is therefore o f  particular interest in the brain.
The fact that this system exists implies that a certain amount o f  CCR can occur
without apoptosis proceeding. This calls into question the claim o f  Goldstein et al
(2000) that release is an all-or-none event. It makes little biological sense that such a 
crucial signal, which leads to an amplifying cascade o f  lethal protease activity, should 
be as strong in response to a mild insult as it is to a highly toxic one.
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The question o f  to what extent cytochrome c is released from mitochondria has been 
inadequately addressed. Studies tend to use strong and/or artificial stimuli (eg. 
Staurosporine, Bertrand et al, 1994) and measure release using methods with little 
quantitative value (Western Blotting, fluorescence labelling). Furthermore, the 
majority o f  studies involve whole cells. Increasing awareness o f  post-mitochondrial 
mechanisms for regulation o f  cytochrome c-induced apoptosis (1.3.6) highlight the 
uncertainty surrounding the fate o f  cytochrome c in the cytosol. Sequestration or 
degradation o f  the protein may hinder the detection o f  subtle changes in cytosolic 
cytochrome c concentration.
3.1.3 The model
In this initial section o f  the study, isolated mitochondria were used as the 
experimental subject, in order to eliminate the issues described above concerning the 
fate o f  cytochrome c in cytosol. The mitochondria were isolated from brain because 
o f  the particular interest in ‘inappropriate’ apoptosis and its regulation in this organ 
with respect to neurodegeneration. Both non-synaptic and synaptic mitochondrial 
populations were studied (see 1 . 1 .4.2).
The study aimed to titrate the severity o f  an insult to the mitochondria, to observe 
whether CCR was induced and whether it was an all-or-none phenomenon or 
sensitive to the severity o f  insult. It was central to this investigation that the 
treatment applied to the mitochondria modelled an effect which occurs naturally in 
vivo. The insult chosen was depletion o f  Complex I activity, since this is a 
recognised feature o f  several neurodegenerative disorders, particularly Parkinson’s
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disease (Schapira et a l, 1990). Inhibition o f  this enzyme complex was achieved using 
the specific inhibitor rotenone ( 1 . 1 .2 . 1 ).
The rate o f  oxygen consumption and A\|/m (1.1.2) were measured as respiratory 
parameters, and related to the amount o f  cytochrome c released by the mitochondria. 
This was measured using a quantitative and sensitive immunoassay method.
3.2 Aims
The aim o f  this initial study was to determine whether a mild respiratory insult, which 
models an early neurodegenerative disease state, induces isolated rat brain 
mitochondria to release cytochrome c. The use o f  a quantitative assay for measuring 
CCR made it possible to determine whether any release was sensitive to the severity 
o f  the insult.
3.3 Results
3.3.1 Titration o f  mitochondrial respiratory function using rotenone
Non-synaptic or synaptic mitochondria were isolated from whole rat brains (2.2.1.2, 
2.2.1.3). The protein concentrations were measured (2.7.1) and the mitochondria then 
incubated at 37°C in the electrode chamber according to Incubation Scheme 1
(2.3.1.3). Typically, a non-synaptic mitochondria] preparation provided sufficient
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protein for 7 incubations, whereas a synaptic preparation allowed 3 or 4. One 
incubation served as a control (ie. ethanol vehicle alone) for each preparation. The 
remainder were treated with a range of concentrations o f  rotenone. Thorough 
washing o f  the chamber with ethanol and water was carried out between each 
incubation. However, since rotenone is understood to have resilient binding 
properties (Ramsay & Singer, 1992), incubations were always performed in order of 
increasing rotenone concentration.
Once a suitable range o f  rotenone concentrations had been established (based on 
Davey & Clark, 1996; Davey et al, 1998) for either population o f  mitochondria, 
sufficient preparations were performed to provide n > 3 for each rotenone 
concentration.
Oxygen consumption rate and Avj/m were recorded (2.3.1 . 1 , 2.3.1.2) between t = 7 
minutes and t = 10 minutes. At t = 10 minutes, a 1 OOjlI was removed from the 
chamber and frozen immediately in liquid nitrogen, then stored at -70°C until being 
assayed for Complex I activity as described in 2.3.2.1. A 400j.il aliquot was also 
removed and centrifuged at 17000xg for 5 minutes at 4°C and then the supernatant 
frozen immediately in liquid nitrogen. This sample was also stored at -70°C until 
used for assay o f  cytochrome c concentration (these data are discussed in 3.3.2).
Non-synaptic mitochondria were treated with rotenone in the range 0 -  0.45 
nmoles.mg ' 1 mitochondrial protein. This produced a titration of  Complex I activity 
between (mean value o f  n > 3) 280.9 ± 25.0 nmoles.min’1.mg ' 1 protein and 6 6 . 8  ±
15.4 nmoles.min'1.mg ' 1 protein (100% to 23.8%), as shown in Figure 3.1. The
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corresponding oxygen consumption rates were found to be inhibited from 84.2 ± 3 .7  
nmoles.min'1.mg ' 1 protein to 6 . 6  ± 1.3 nmoles.min'1.mg ' 1 protein (100% to 7.8%), as 
shown in Figure 3.2. A\|/m was inhibited from 170.9 ± 5.2 mV down to 91.8 ± 8.1 mV 
(100% to 53.7%), as shown in Figure 3.3.
Synaptic mitochondria were treated with rotenone in the range 0 -  0.25 nmoles.mg ' 1 
mitochondrial protein. This produced a titration o f  Complex I activity between (mean 
value o f  n > 3) 103.3 ± 5.9 nmoles.min'1.mg ' 1 protein and 17.3 ± 4.3 nmoles.min' 
'.mg ' 1 protein (100% to 16.7%), as shown in Figure 3.4. The corresponding oxygen 
consumption rates were found to be inhibited from 51.7 ± 2.8 nmoles.min'l.mg ' 1 
protein down to 9.6 ± 2.6 nm oles.m in 1.mg ' 1 protein (100% to 18.6%), as shown in 
Figure 3.5. Measurement of A\|/m using synaptic mitochondria was found to be 
problematic. Only a very weak and unreliable TPP+ signal was obtained, 
unfortunately making the data unusable (discussed in 3.4.1.2).
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Figure 3.1
Concentration-dependent inhibition of non-synaptic mitochondrial Complex I activity 
by rotenone. n 3 for each rotenone concentration. Data shown ± S.E.M. The assay 
was carried out on mitochondria which had undergone three freeze-thaw cycles.
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Figure 3.2
Concentration-dependent inhibition of non-synaptic mitochondrial state 3 oxygen 
consumption rate by rotenone. n 3 for each rotenone concentration. Data shown ± 
S.E.M. Measurements were made in situ in the electrode chamber, in the presence of 
glutamate, malate and pyruvate as substrates.
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Figure 3.3
Concentration-dependent inhibition of non-synaptic mitochondrial state 3 Ai|/m by 
rotenone. n 3 for each rotenone concentration. Data shown ± S.E.M. 
Measurements were made in situ in the electrode chamber, in the presence of 
glutamate, malate and pyruvate as substrates.
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Figure 3.4
Concentration-dependent inhibition of synaptic mitochondrial Complex I activity by 
rotenone. n 3 for each rotenone concentration. Data shown ± S.E.M. The assay 
was carried out on mitochondria which had undergone three freeze-thaw cycles.
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Figure 3.5
Concentration-dependent inhibition of synaptic mitochondrial state 3 oxygen 
consumption rate by rotenone. n 3 for each rotenone concentration. Data shown ± 
S.E.M. Measurements were made in situ in the electrode chamber, in the presence of 
glutamate, malate and pyruvate as substrates.
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3.3.2 Relationship between respiratory function and cytochrome c release 
The 400pl supernatants from the incubations described in 3.3.1 were assayed for 
cytochrome c concentration (2.4.1). The assay was also performed on untreated 
isolated mitochondria which had been subjected to three freeze-thaw cycles, in order 
to determine total mitochondrial cytochrome c concentration. Released cytochrome c 
was then expressed as a percentage o f  total mitochondrial content.
It was found that in the case o f  both non-synaptic and synaptic mitochondria, as their 
respiratory function was inhibited, they released small amounts o f  cytochrome c to 
the surrounding buffer. The amount o f  cytochrome c released was proportional to the 
extent o f  the respiratory inhibition. This was determined by plotting the measured 
respiratory parameters (oxygen consumption rate and Avj/m) versus the percentage 
cytochrome c released. The results are as follows:
Non-synaptic mitochondria had a mean cytochrome c concentration o f  0.38 ± 0.015 
nmoles.mg ' 1 protein (n = 4). Oxygen consumption rate was plotted versus percentage
released cytochrome c, as shown in Figure 3.6. The linear regression line for this
scatter graph showed a significant deviation from zero slope (p < 0 .0 0 0 1 ), and had 
the equation y = -0.105x + 26.4. Similarly, A\|/m was plotted versus percentage 
released cytochrome c, as shown in Figure 3.7. The linear regression line for this 
scatter graph also showed a significant deviation from zero slope (p < 0 .0 0 0 1 ), and 
had the equation y = -0.101 x + 36.1.
Synaptic mitochondria had a mean cytochrome c concentration o f  0.14 ± 0.002
nmoles.mg ' 1 protein (n = 4). Oxygen consumption rate was plotted versus percentage
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released cytochrome c, as shown in Figure 3.8. The linear regression line for this 
scatter graph showed a significant deviation from zero slope (p < 0.005), and had the 
equation y = -0.127x + 26.3.
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Figure 3.6
Relationship between oxygen consumption rate and percentage release of cytochrome 
c in non-synaptic mitochondria. Linear regression line has equation y = -0.105x +
26.4 and is o f significant deviation from zero slope (p < 0.0001). Key indicates 
rotenone concentration (nmoles.mg ’ 1 protein) used to achieve inhibition.
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Figure 3.7
Relationship between Ai|/m and percentage release o f  cytochrome c in non-synaptic 
mitochondria. Linear regression line has equation y = -O.lOlx + 36.1 and is of 
significant deviation from zero slope (p < 0.0001). Key indicates rotenone 
concentration (nmoles.mg"1 protein) used to achieve inhibition.
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Figure 3.8
Relationship between oxygen consumption rate and percentage release of cytochrome 
c in synaptic mitochondria. Linear regression line has equation y = -0.127x + 26.3 
and is of significant deviation from zero slope (p < 0.005). Key indicates rotenone 
concentration (nmoles.mg ' 1 protein) used to achieve inhibition.
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3.3.3 ‘Background ’ release in the absence o f  rotenone
As can be seen in Figures 3.6, 3.7 and 3.8, approximately 15-20% total mitochondrial 
cytochrome c is released by the isolated mitochondria under control conditions, ie. 
where respiratory parameters are not subject to rotenone treatment and are therefore 
at their highest. In order to determine the trigger for this background level of release, 
mitochondria (0 .5m g.m r') were incubated according to Incubation Scheme 3
(2.3.1.3). At t = 10 minutes, a 400pl aliquot was removed and centrifuged at 
17000xg for 5 minutes at 4°C. The supernatant was frozen immediately in liquid 
nitrogen and then stored at -70°C until being used for assay o f  cytochrome c 
concentration (2.4.1).
In the case o f  both non-synaptic and synaptic mitochondria, there was no significant 
difference (unpaired t-test) between the percentage cytochrome c released after 
treatment with vehicle alone under Incubation Scheme 1 (see 3.3.2) and that released 
when mitochondria are simply added into buffer at 37°C with fatty acid-free BSA and 
incubated for 10 minutes (ie. Incubation Scheme 3). The data from these 
experiments are shown in Table 3.1.
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% CCR  
(experimental control)
% CCR  
(incubation control)
Non-synaptic mitochondria 15.3 ± 0.51 18.5 ±  1 . 1 1
Synaptic mitochondria 25.7 ±2 .98 19.6 ± 1.38
Table 3.1
Percentage CCR under experimental control conditions (treatment with vehicle alone 
under Incubation Scheme 1) and incubation control conditions (Incubation Scheme 
3). Data shown is mean of  n > 4, ± S.E.M. There was no significant difference 
(unpaired t-test, p > 0.05) between the two controls in either non-synaptic or synaptic 
mitochondria.
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3.3.4 'Background' release in the presence o f  rotenone
As described earlier, titration o f  respiratory function on each separate preparation of  
isolated mitochondria was carried out in order of increasing rotenone concentration. 
For this reason, a control experiment was required to demonstrate that the increasing 
CCR detected with increasing rotenone concentration was not purely an artefact o f  
deterioration o f  mitochondrial integrity over time.
The maximum time between completion o f  the isolation procedure and completion 
o f  the final incubation in a titration run was under 2  hours for non-synaptic 
mitochondria and under 90 minutes for synaptic mitochondria. Mitochondria 
therefore underwent a control incubation (vehicle alone, according to Incubation 
Scheme 1) at t = 0 and 1 2 0  minutes (non-synaptic mitochondria) or t = 0 and 90 
minutes (synaptic mitochondria). Both were then treated with rotenone (0.375 
nmoles.mg ' 1 protein for non-synaptic mitochondria, 0.25 nmoles.mg ' 1 protein for 
synaptic mitochondria), according to Incubation Scheme 1, at the appropriate upper 
time point. A 400pl aliquot was removed and centrifuged at 17000xg for 5 minutes 
at 4°C. The supernatant was frozen at -70°C and assayed for cytochrome c 
concentration as described in 2.4.1.
In the case o f  both non-synaptic and synaptic mitochondria, it was found that the 
120/90 minute delay (respectively) did not cause a significant increase in the 
percentage cytochrome c released. Rotenone treatment however caused a 
significantly greater amount o f  release than either o f  the control incubations. The 
data were analysed using a paired t-test and are shown in Tables 3.2 and 3.3.
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t = 0, 
[rotenone| = 0
t = 120 mins, 
[rotenone| = 0
t = 120 mins,
| rotenone] = 
0.375n nioles.mg’1
% Cytochrome c 
released 16.2 ±2.7 19.3 ± 1.1 26.0 ±1. 9
Table 3.2
Percentage cytochrome c released from non-synaptic mitochondria under Incubation 
Scheme 1 after treatment with vehicle alone at t = 0 and t = 120 minutes and with 
rotenone (0.375 nmoles.mg 1 protein) at t = 120 minutes. Only the final treatment 
shows an increase in released cytochrome c ( indicates p > 0.05, assessed by paired 
t-tcst). Data shown is mean of n > 3, ± S.E.M.
t = 0,
| rotenone] = 0
t = 90 mins,
| rotenone] = 0
t = 90 mins,
| rotenone] = 
0.25n moles.mg’1
% Cytochrome c 
released 17.1 ± 2 . 6 6 19.5 ±2.01 26.1 ± 1.74 *
Table 3.3
Percentage cytochrome c released from synaptic mitochondria under Incubation 
Scheme 1 after treatment with vehicle alone at t = 0 and t = 90 minutes and with 
rotenone (0.25 nmoles.mg ' 1 protein) at t = 90 minutes. Only the final treatment 
shows an increase in released cytochrome c (* indicates p < 0.05, assessed by paired 
t-test). Data shown is mean of n = 4, ± S.E.M.
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3.4 Discussion
3.4.1 Titration o f  respiratory function by rotenone
3.4.1.1 Non-synaptic and synaptic mitochondria
This study was carried out first on non-synaptic mitochondria, and subsequently on 
synaptic mitochondria. It was considered vital to the interpretation o f  the data that 
both populations be observed. Non-synaptic mitochondria originate from both 
astrocytes and neurons (excepting neuronal synaptic terminals). Although 
neurodegeneration is primarily concerned with a reduction in synaptic transmission 
(itself sufficient to justify the use o f  synaptic mitochondria in the investigation), the 
viability o f  the remainder o f  the neuron is o f  course equally crucial. Furthermore, the 
supporting role o f  glia, and astrocytes in particular, in the maintenance of  synaptic 
transmission has recently been highlighted (reviewed by Aschner, 2000). For 
example, it is thought that in vivo astrocytes provide precursors for neuronal 
glutathione synthesis (Dringen et al, 1999). These considerations support the use of 
non-synaptic mitochondria in this study.
From a more practical point o f  view, most clinical reports o f  reduced respiratory 
complex activity in cases o f  neurodegenerative disease rely on tissue homogenates or 
isolated non-synaptic mitochondrial populations (Schapira et al, 1990; Mutisya et al, 
1994). By far the majority o f  mitochondria in a tissue homogenate sample would be 
classified as 'non-synaptic'. Furthermore, the yield o f  non-synaptic mitochondria is 
significantly greater than that o f  synaptic mitochondria, relative to the original mass 
o f  brain tissue.
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Finally, although the range o f  rotenone concentrations used was based on Davey & 
Clark (1996), the incubation conditions in this study were not identical to those used 
in the 1996 report. (The incubations were carried out at 37°C and pyruvate was 
included as an additional substrate. Both changes created a more physiologically 
relevant environment). The treatments therefore needed to be re-defined for the 
altered incubation conditions. Although further 'fine tuning' was likely to be needed 
for the synaptic titrations, the initial 'broad tuning' was carried out in non-synaptic 
mitochondria, thus reducing the number o f  animals used for this preparatory stage.
It was determined that the range o f  rotenone concentrations required to suitably titrate 
non-synaptic respiratory activity was greater than that required to create a similar 
percentage change in synaptic mitochondria. In Davey and Clark (1996) and Davey 
et al (1998) the IC5 0 S for the effect o f  rotenone on oxygen consumption rates were 
comparable. This may be explained by the discrepancy in control Complex I 
activities measured: in this study the mean Complex I activity in non-synaptic 
mitochondria was 137% o f  that reported in Davey & Clark (1996), whereas in 
synaptic mitochondria, this study obtained a value only 76% o f  that in Davey et al 
(1998). The latter difference may be contributed to by a suspected contamination of 
the synaptic preparation by synaptosomal membranes (discussed later in this section). 
It is however recognised that control levels o f  non-synaptic Complex I activity are 
higher than those in synaptic mitochondria. Therefore the trend is as expected, even 
if the amplitude o f  the difference appears large.
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Mention should be made of the difficulty experienced in obtaining a reliable A\|/m 
measurement during incubations o f  synaptic mitochondria. The mV reading resulting 
from TPP+ distribution was extremely small, and highly unreliable. It should be 
noted that the volume used for these incubations (800pl) is lower than generally used 
for TPP+ measurements (Brand, 2002). However, the system did prove to be highly 
reliable for measuring Ai|/m in non-synaptic mitochondria. It is thought that the 
problem may have been due to contamination o f  the synaptic preparations by 
synaptosomal membranes. The second Ficoll gradient (see 2.2.1.3) is designed to 
remove such contamination, therefore further optimisation o f  this gradient may be 
required.
The presence o f  such membranes would contribute to the protein measurement. The 
assumption o f  synaptosomal membrane contamination is therefore supported by the 
observations o f  lower than expected measurements per mg of protein o f  citrate 
synathase (2.7.2.1), Complex I activity (3.3.1) and cytochrome c content (3.3.2). 
However, the titrations o f  oxygen consumption rate and Complex I activity were 
found to be highly reproducible for synaptic populations (see Figures 3.4 and 3.5). 
Any contamination is therefore either minimal or extremely consistent in terms of 
percentage contamination. It is possible that these low measurements per unit protein 
are due to an increased overall protein concentration per mitochondrion, as a result of 
the synaptic machinery.
Since measurements o f  CCR are to be relative to respiratory parameters and not 
protein content, this possible contamination does not affect the conclusions o f  this 
study.
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3.4.1.2 Profiles o f  inhibition o f  respiratory parameters
When the profiles o f  inhibition o f  non-synaptic mitochondrial complex I and 
respiratory parameters are compared (Figures 3.1, 3.2 and 3.3), there appears to be 
some inconsistency in the data. The profile o f  complex 1 inhibition appears almost 
flat at rotenone concentrations o f  0.075 nmoles.mg ' 1 mitochondrial protein and above, 
although the inhibition is not complete. However, the oxygen consumption rate and 
Avj/m continue to decrease throughout the range o f  rotenone concentrations used. It is 
recognised that complex inhibition and the resulting inhibition o f  respiration rate do 
not follow the same profiles. Indeed the curves for inhibition o f  respiratory 
complexes and respiration rate were observed to cross by Davey & Clark (1996) and 
Davey et a l, (1998). However, the apparent insensitivity o f  complex I activity to 
rotenone above 0.075 nmoles.mg ' 1 mitochondrial protein is inconsistent with the 
observed effects on oxygen consumption rate and A\|/m This suggests a problem with 
the assay for complex I activity. The three freeze-thaw cycles could perhaps be 
responsible for an artefactually high background rate o f  rotenone-sensitive NADH 
oxidation. This might be resolved if complex I activity could be measured in situ with 
the other respiratory parameters.
Interestingly, this inconsistency was not observed with the isolated synaptic 
mitochondria. Here, complex I activity decreased across the range o f  rotenone 
concentrations used. This was consistent with the resulting profile o f  inhibition of 
oxygen consumption rate.
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Nonetheless, despite this anomaly and aside from the differences described 
concerning thresholds for inhibition (3.4.1.1), the two populations of brain 
mitochondria displayed overall the same effect. Their respiration was titrated by 
increasing the concentration o f  the rotenone treatment. This concentration-dependent 
inhibition of  respiratory function by rotenone was simply a tool for observing a 
downstream effect.
There is one more observation, however, which is worthy of  discussion. As 
described, the non-synaptic mitochondrial incubations yielded measurements o f  both 
oxygen consumption rate and A\|/m. The relationship between rotenone concentration 
and oxygen consumption rate was clearly non-linear, instead displaying a pseudo­
exponential form (see Figures 3.2 and 3.5). Rotenone concentration versus A\|/m was 
however a near linear relationship (see Figure 3.3). It is not immediately clear why 
the profiles o f  the two parameters should differ.
One possible explanation involves the ‘proton leak’ across the IM. As described
(1.1.2), protons are pumped from the matrix into the IMS across the IM by 
Complexes I, III and IV, creating a A\|/m. This gradient is sacrificed in order to power 
the ATP synthase. However, a certain amount o f  protons ‘leak’ back into the matrix 
by other means. This means that some of the electron transport process, and so the 
oxygen consumption rate, is ‘wasted’, in counteracting the leaking protons. The 
dynamics o f  this proton leak are unclear, but it is quite possible that it may act in a 
regulatory manner, such that when the A\|/m is large (ie. very depolarised), the proton 
leak is great, but that if the Avj/m is dissipated, proton leak decreases accordingly. 
This would serve to ‘buffer’ the A\|/m against extreme change. If this were the case, at
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the more inhibited end o f  the curves, less oxygen consumption would be required to 
support the same A\|/m. This hypothesis is consistent with the recognised non-ohmic 
relationship between A\|/m and proton influx, and is demonstrated in Figure 3.9.
156
1 2
80
6 0 -Oxygen 
consumption rate 40.
2 0 -
0.0 0.2 0.5
150 -
Membrane
potential
100 -
5 0 -
0.0 0 30.2 0.5
>  Increasing rotenone 
inhibition
Figure 3.9
Hypothesised explanation for profiles of oxygen consumption rate and A\|/m with 
rotenone treatment. (Data shown is rotenone titration o f non-synaptic mitochondrial 
respiration; original figures 3.2 and 3.3). 1 Avj/m is high, therefore proton leak is high. 
A relatively high oxygen consumption rate is required to maintain Av|/m at this point. 
2 A\|/m is low, therefore proton leak is low. A relatively low oxygen consumption rate 
required to maintain Ai|/m at this point.
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3.4 .2  Effect o f  respiratory inhibition on cytochrome c release
3.4.2. ] Release proportional to severity o f respiratory deficiency 
In both populations o f  isolated brain mitochondria, there was a clear effect o f  
rotenone-induced respiratory inhibition on the distribution o f  cytochrome c. It was 
found that as respiratory function was reduced, cytochrome c was released from the 
mitochondria in a manner proportional to the extent o f  inhibition. A near linear 
inversely proportional relationship was found between the percentage CCR and both 
oxygen consumption (both populations of mitochondria) and Av|/m (only non-synaptic 
data available), despite these two parameters not showing a linear relationship 
themselves. There was no apparent threshold effect -  the relationship was linear from 
the control point. The possibility that the increased CCR detected was an artefact of 
mitochondrial deterioration over time (note that titrations were performed in order of 
increasing rotenone concentration - see 3.3.1) was eliminated by control experiments.
Since cytochrome c measurements were being made in a respiration medium of 
known composition and not in the cytosolic compartment o f  cells, the measurements 
can be taken as a direct indication o f  the extent o f  release. The maximum level of 
CCR detected was approximately 25-30% of the total mitochondrial content. This 
was true o f  both non-synaptic and synaptic mitochondria, despite the total 
mitochondrial content o f  the former being over double that o f  the latter (0.38 
nmoles.mg ’ 1 protein versus 0.14 nmoles.mg ' 1 protein).
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There was a certain level (approximately 15-20%) o f  CCR to the surrounding 
medium even under control conditions (ie. treatment with ethanol vehicle alone). 
Further investigation determined that this control level o f  release could be induced by 
simply adding the isolated mitochondria into the warmed buffer and incubating for 
the full ten minutes. In the absence o f  substrates and ADP, these mitochondria are in 
a quiescent state, and therefore this basal release is a result o f  incubation artefacts, 
rather than being related to any respiratory changes. Such artefacts may include 
temperature shock (the isolated mitochondria are stored on ice until used for 
experimentation at 37°C) and physical damage through centrifugation (performed 
after the incubation in order to separate the supernatant from the mitochondrial 
pellet).
The basal level o f  release essentially shifts the relationship down the y-axis by 10- 
15%, such that in both populations, rotenone treatment in the range selected induced a 
maximum release o f  approximately 10-15% total mitochondrial cytochrome c.
3.4.2.2 Implications o f  respiratory inhibition-induced release
The data from this study demonstrate that if Complex I activity is lowered using the 
specific inhibitor rotenone in isolated brain mitochondria, cytochrome c is released. 
Only small percentages o f  the total mitochondrial content are released, the extent of 
release being directly proportional to the extent o f  respiratory inhibition.
These findings are a clear contradiction to the claim o f  Goldstein et al (2000) that 
CCR is an 'all-or-none' event. The authors categorically state that the extent and time 
course o f  release is unaffected by the intensity o f  the pro-apoptotic stimulus. In direct
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challenge to that statement, it is concluded here that if  CCR is measured using a 
sensitive, quantitative assay and a physiologically relevant stimulus is used, then the 
release is indeed sensitive to the strength o f  the insult.
This 'physiologically relevant stimulus' models a recognised pathology in Parkinson's 
disease (Perier et a l, 2003; Schapira et al, 1990). By titrating the activity o f  Complex 
I, this study has modelled a physiological to pathological transition, rather than 
simply selecting a stimulus known to induce apoptosis. The observation that CCR 
was directly proportional to respiratory inhibiton, rather than showing a threshold 
effect, implies that low levels o f  CCR can occur before any symptoms o f  disease are 
apparent. If CCR can be induced by such mild insults, it appears likely that low 
levels o f  release would be insufficient to induce apoptosis.
This hypothesis is consistent with the growing understanding o f  post-mitochondrial 
regulation o f  apoptosis. Concannon et al (2001) claim that the molecular chaperone 
Hsp27 can sequester cytochrome c (in addition to pro-caspase 3) in the cytosol, 
preventing correct formation o f  the apoptosome complex. Hsp90 is thought to be 
associated with Apaf-1 in the cytosol with the same effect (Pandey et al, 2000). More 
widely recognised is the role o f  IAP proteins in inhibiting the action o f  activated 
caspases (Deveraux et al, 1997). These mechanisms o f  control have been suggested 
to prevent 'inappropriate' initiation o f  apoptosis in neurodegenerative disease 
(Hengartner, 2000; Kugler et al, 2000). These defensive mechanisms would only be 
in place if it were possible for cytochrome c to be released in small enough quantities 
for its pro-apoptotic action to be overcome. If CCR were an 'all-or-none' process, 
these levels o f  control would be redundant. Notably, physiological concentrations of
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potassium appear to set a threshold o f  cytosolic cytochrome c required to induce 
apoptosis (Cain et a l, 2001).
It is likely that a certain amount o f  cytochrome c is being released into the cytosol 
under normal physiological conditions. The 'trigger' for release is discussed in more 
detail in Chapter 5, but fluctuations in the activity o f  the ETC are inevitable and these 
data imply that as a result, so are fluctuations in CCR. Furthermore, cytochrome c 
may need to be translocated to the cytosol for degradation, as part o f  the normal 
turnover cycle (1.2.2.3). Reports have identified a basal cytosolic cytochrome c 
concentration under physiological conditions (Kluck et a l, 1997; Adachi et al, 1998). 
(It is interesting to note the confirmation that the sensitivity o f  the quantitative ELISA 
technique for measuring cytochrome c concentrations allows detection o f  low levels 
o f  the protein which cannot be picked up using Western blotting (Brustovetsky et al, 
2003b)). It is possible to regulate a system more tightly if there is a control level of 
signal which can be up- or down-regulated along a continuous scale. A system where 
the signal is simply on or off allows much less control. Bearing in mind the 
potentially lethal effect o f  releasing too much cytochrome c, such a strict level of 
control is vital. This is especially true o f  neurons, where the implications of 
'inappropriate' apoptosis have been discussed (3 . 1 .2 ).
Although it will be shown later (5.3.2) that the effect on CCR is not common to all 
respiratory inhibition, the data from this investigation indicate that the extent o f  CCR 
subtly reflects the extent o f  respiratory stress influencing the mitochondria. It is 
therefore possible that the presence o f  cytochrome c in the cytosol could have some 
signalling role more subtle than the initiation o f  apoptosis, perhaps indicating an
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imminent fall o f  ATP levels, and therefore the requirement for increased synthesis of 
respiratory proteins (the majority o f  whose subunits are encoded by nuclear and not 
mitochondrial DNA) or even increased mitochondrial turnover. It is interesting to 
note the claim of Ramasarma et al (1992) that cytochrome c has a molecular 
chaperone role. This could also be a feature o f  a cytochrome c-mediated stress 
response.
As described (1.2.3.3), low levels o f  cytochrome c external to the mitochondria 
appear capable o f  ameliorating ETC-mediated ROS generation. Bearing in mind the 
suggested importance o f  electron leak at the site o f  complex I in ROS generation
(1.1.3), the CCR detected here could be a defensive anti-oxidant mechanism.
These speculations are secondary, however, to the more strongly implied hypothesis 
that low levels o f  CCR do not necessarily lead to apoptosis. The post-mitochondrial 
mechanisms for preventing apoptosis could contribute to a threshold o f  cytochrome e 
required for activation o f  caspases (Waterhouse et al, 2002).
3.5 Conclusions
When the respiration o f  isolated brain mitochondria is inhibited at the level of 
Complex I by rotenone, the mitochondria release cytochrome c to the surrounding 
medium. The release is partial, and occurs to an extent directly proportional to the 
severity o f  respiratory deficiency.
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The data imply that CCR is a more common event than previously thought, but that it 
is also more subtle and tightly regulated than has been suggested (Goldstein et al, 
2000). It would seem likely that small amounts o f  CCR are a normal physiological 
occurrence, or at least occur upstream in the progression o f  neurodegenerative disease 
to the stage where symptoms become apparent.
The hypothesis which has arisen from this study is that small amounts o f  CCR can 
occur in brain cells without apoptosis proceeding.
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CHAPTER 4
Establishing the mechanism o f  release o f  
cytochrome c from brain mitochondria
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4.1 Introduction
4.1.1 The two categories o f  release mechanism
All o f  the current postulated CCR mechanisms fall into one o f  two categories. These 
are described in detail in 1.3.5. Briefly, release is thought to occur due to either 
physical rupture o f  the OM or formation of  channels in the OM. The former category 
includes release via MPT, where OM rupture occurs due to loss o f  osmotic balance, 
matrix swelling and outward force by the convoluted IM (Petit et a l, 1998; Scarlett & 
Murphy, 1997). Also, it is suggested that hyperpolarisation of  the membrane 
potential resulting from failure o f  the ATP/ADP exchange system leads to osmotic 
swelling with the same effect (Vander Heiden et a l, 1999). In contrast, postulated 
swelling-independent release mechanisms involve formation o fO M  channels, usually 
involving combinations o f  Bcl-2 family members and the VDAC (Andreyev et al, 
1998; Doran & Halestrap, 2000; Eskes et al, 1998; Jiirgensmeier et a l, 1998; KJuck et 
a l, 1999).
As described in 3.4.2.2, the data obtained thus far imply that a certain amount o f  CCR 
may be a normal physiological occurrence, or at least occur prior to onset o f  disease 
symptoms, and therefore be unlikely to lead to apoptosis. If this conclusion is to be 
drawn, it is crucial to determine the release mechanism. For low levels o f  release to 
be ‘safe’, not only must they be insufficient to induce apoptosis, but the release 
mechanism must leave the host cell energetically viable.
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Release via swelling-dependent mechanisms, particularly MPT, have debilitating 
effects on mitochondrial integrity. ATP synthesis by oxidative phosphorylation is 
prevented, and there is non-specific release o f  SIMPs (many o f  which have pro- 
apoptotic properties (Du et a l, 2000; Suzuki et al, 2001; Verhagen et al, 2000; Yu et 
al, 2002) to the cytosol. Such a dramatic loss o f  homeostasis in the cell is unlikely to 
be a normal physiological occurrence (Crompton, 2000). Formation of  channels in 
the OM, however, would be expected to allow controlled and specific release of 
cytochrome c. There is evidence to suggest that if  released in this manner, sufficient 
cytochrome e can remain associated with the IM for electron transport to continue 
(Cortese et al, 1995; Ott et a l, 2002). The capacity to synthesise ATP is therefore 
retained in this case and changes in levels o f  other SIMPs (note that the SIMP 
adenylate kinase, for example, is required for respiratory function) are not a 
consideration. These features may simply enable enough ATP synthesis for the 
apoptotic program to be completed (see 1.3.3.1). However, they may also allow 
retention o f  a cell’s energetic viability if the cytochrome c released was not to induce 
death o f  the cell.
Therefore if  low levels o f  CCR are indeed a normal physiological occurrence, the 
release mechanism would be expected to fall into the swelling-independent category.
4.1.2 M itochondrial enzymes
The distribution o f  mitochondrial enzymes can be a useful experimental tool for 
determining effects on the integrity o f  mitochondrial membranes.
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Adenylate kinase (EC 2.7.4.3, AK2 isoform, 23.6kDa) is found, like cytochrome c, in 
the IMS. Measurement o f  AK activity external to the mitochondria has been used as 
a method for establishing whether a release mechanism has been specific for 
cytochrome c or a general OM permeabilisation (Doran & Halestrap, 2000; Siskind et 
al, 2002; Crouser et a l, 2003).
Citrate synthase (CS, EC 4.1.3.7) is a matrix enzyme of 280kDa. It will only be 
released from mitochondria if both the IM and OM have been ruptured.
4.2 Aims
This investigation aimed to determine whether the CCR induced by respiratory 
inhibition, as described in 3.4.2, was associated with mitochondrial swelling. The 
distributions o f  AK and CS were then used to determine how IM and OM integrity 
were affected by the release mechanism. Inhibitors o f  the primary candidates for 
release mechanisms were also used to provide additional information on the 
specificity o f  the release process.
4.3 Results
4.3.1 Effect o f  rotenone on mitochondrial volume
Two methods were used for determining changes in mitochondrial volume during the 
release process. Electron microscopy was used to qualitatively demonstrate the
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effects, whereas changes in light scattering properties provided a quantitative
measurement.
4.3.1.1 Electron microscopy
Non-synaptic or synaptic mitochondria were isolated from whole rat brains (2.2.1.2,
2.2.1.3). The protein concentrations were measured (2.7.1) and the mitochondria then 
incubated at 37°C in the electrode chamber according to Incubation Scheme 1
(2.3.1.3). Three incubations were carried out for each population o f  mitochondria. 
Non-synaptic mitochondria were subjected to a control incubation (ethanol vehicle 
alone), treatment with rotenone (0.375 nmoles.mg"1 protein) and finally treatment 
with alamethicin (75pg.mg"' protein). Alamethicin is an antibiotic peptide, which 
non-specifically permeabilises membranes (Woolley & Wallace, 1992) and has been 
used to induce mitochondrial swelling as a positive control in volume studies (Kluck 
et a l, 1999; Kristian et a l, 2000). Synaptic mitochondria received the same three 
treatments, except that the rotenone used in the second incubation was o f  
concentration 0.25 nmoles.mg"1 protein.
After each incubation, a 700pJ aliquot was removed from the chamber, and 
immediately centrifuged at 1 7000xg for 5 minutes at 4°C (Sigma Laborzentrifugen 
3K10, Osterode, Germany). The supernatant was discarded, and the pellet was 
treated as described in 2.5.1. Electron microscopy images were generated and 
compared by observation.
Typical examples o f  mitochondria as seen by electron microscopy are shown in 
Figures 4.1 (A-C) and 4.2 (A-C). The rotenone treatment induced no observable
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change in the typical morphology o f the non-synaptic or synaptic mitochondria. The 
rotenone concentrations selected had caused a significant amount o f  CCR as 
compared to control conditions in each population (see Figures 3.6, 3.7 and 3.8). 
However, alamethicin treatment caused a marked change in morphology. All 
mitochondria now appeared swollen or burst. Again, this was the case for both non- 
synaptic and synaptic populations.
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Figure 4.1
Representative electron microscope images of isolated non-synaptic rat brain 
mitochondria after control incubation (A), treatment with rotenone (OJTSnmoles.mg1 
protein) (B) and treatment with alamethicin (TSpg.mg'1 protein) (C).
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Figure 4.2
Representative electron microscope images o f isolated synaptic rat brain 
mitochondria after control incubation (A), treatment with rotenone (OJSnmoles.mg'1 
protein) (B) and treatment with alamethicin (TSpg.mg'1 protein) (C).
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4.3.1.2 Light scattering
Non-synaptic or synaptic mitochondria were isolated from whole rat brains (2.2.1.2,
2.2.1.3). The protein concentrations were measured (2.7.1) and the mitochondria then 
incubated at 37°C in a 0.5ml quartz cuvette according to Incubation Scheme 1
(2.3.1.3). Between t = 7 and t = 10 minutes, the light intensity (540nm) at 90° was 
recorded as described in 2.5.2. Three incubations were carried out for each 
population, the treatments exactly as described in 4.3.1.1. Each set o f  three 
incubations was repeated three times, and the mean light intensity calculated for each 
treatment. This value was proportional to the extent o f  scattering, and therefore a 
reduction in light intensity represents an increased mean volume. These values are 
shown in Tables 4.1 and 4.2.
Light intensity values were unchanged between controls and rotenone treatment for 
both non-synaptic and synaptic mitochondria. Alamethicin however caused a 
significant reduction in intensity in both cases. This was determined using a paired t- 
test between treated and control mitochondria.
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c Rotenone Alamethicin
Light intensity 
(arb itra ry 90.1 ± 3.5 94.4 ±4.1 55.2 ± 5.1
Table 4.1
Effect o f rotenone (O.375nmoles.mg'' protein) and alamethicin (75pg.mg'' protein) on 
the detected light intensity (540nm) of isolated non-synaptic brain mitochondria. 
Values are mean ± S.E.M, n = 3. Indicates p < 0.01.
Control Rotenone Alamethicin
Light intensity 
(a rb itra ry  units) 152.212.6 145.310.7 116.1 1  1.3 **
Table 4.2
Effect o f rotenone (O.25nmoles.mg'1 protein) and alamethicin (75pg.mg"' protein) on 
the detected light intensity (540nm) of isolated synaptic brain mitochondria. Values 
are mean ± S.E.M, n = 3. Indicates p < 0.01
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4.3 .2  Enzyme distribution
Non-synaptic or synaptic mitochondria were isolated from whole rat brains (2.2.1.2,
2.2.1.3). The protein concentrations were measured (2.7.1) and the mitochondria then 
incubated at 37°C in the electrode chamber according to Incubation Scheme 1
(2.3.1.3). Titrations were performed using rotenone concentration exactly as in 3.3.1 
for both non-synaptic and synaptic mitochondria, n > 3 was obtained for each 
rotenone concentration. A 400pl aliquot was removed at t = 10 minutes, and 
centrifuged at 17000xg for 5 minutes. The supernatant was assayed for AK (see
2.4.3) and CS (see 2.4.2) activity.
The AK and CS activity o f  whole untreated non-synaptic and synaptic mitochondria 
was assayed after three freeze-thaw cycles. The mean values for these activities were 
calculated for n = 4. In non-synaptic mitochondria, AK activity was determined to be 
2088 ± 103.2 units.mg ’ 1 protein and CS to be 1101 ± 80.9 nmoles.min"1.mg ' 1 protein. 
In synaptic mitochondria, AK activity was determined to be 238.4 ± 39.6 units.mg"1 
protein and CS to be 440.1 ± 26.2 nmoles.min’1.mg ' 1 protein. Released enzyme was 
then expressed as a percentage of total mitochondrial content in all cases. The effect 
of  rotenone treatment on the release o f  AK and CS is shown in Figures 4.3 - 4.6. A 
range o f  rotenone concentrations seen earlier (3.3.2) to induce a significant change in 
CCR was found to have no significant effect on the distribution o f  AK or CS. This 
was true o f  both non-synaptic and synaptic mitochondria. There was a significant 
basal level o f  both enzymes in the supernatants (approximately 15-20% AK and 5-7% 
CS).
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Figure 4.3
Effect of rotenone concentration on adenylate kinase release from non-synaptic brain 
mitochondria. Data is expressed as AK activity in supernatant as a percentage of total 
mitochondrial activity. Analysis of the regression shows that the slope is not 
significantly deviant from zero (p > 0.05).
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Figure 4.4
Effect of rotenone concentration on citrate synthase release from non-synaptic brain 
mitochondria. Data is expressed as CS activity in supernatant as a percentage of total 
mitochondrial activity. Analysis of the regression shows that the slope is not 
significantly deviant from zero (p > 0.05).
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Figure 4.5
Effect of rotenone concentration on adenylate kinase release from synaptic brain 
mitochondria. Data is expressed as AK activity in supernatant as a percentage of total 
mitochondrial activity. Analysis of the regression shows that the slope is not 
significantly deviant from zero (p > 0.05).
177
<D(I)rea>
cu
.c
c>>c/>
cu
re
-4-1
o
55
0.0 0.1 0.2 0.3
Rotenone
(n m o les .m g  1 protein)
Figure 4.6
Effect o f rotenone concentration on citrate synthase release from synaptic brain 
mitochondria. Data is expressed as CS activity in supernatant as a percentage of total 
mitochondrial activity. Analysis of the regression shows that the slope is not 
significantly deviant from zero (p > 0.05).
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4.3.3 The use o f synaptic mitochondria
At this point in the study, the findings on non-synaptic mitochondria versus synaptic 
mitochondria were compared. Aside from a difference in sensitivity to rotenone, the 
effects observed had not differed between the two populations. Due to the 
particularly poor yield o f synaptic mitochondria considering the number o f animals 
used (3.4.1.1), it was decided that from this point onwards, non-synaptic 
mitochondria only would be used for investigations.
4.3.4 Inhibition o f  candidates fo r  release mechanism
Three different inhibitors were used in this investigation. The format o f the 
experiment was however the same in each case. Four incubations were carried out on 
each preparation of mitochondria. They were as follows:
Incubation Rotenone? In hibitor?
1 X X
2 X y
3 y X
4 y y
The incubation procedure is described in Incubation Scheme 2 (2.3.1.3). 
Mitochondria were allowed to incubate with the inhibitor for 10 minutes before 
treatment with rotenone.
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Where either or both rotenone and inhibitor were not being added, the appropriate 
vehicle was added in their place.
Results were expressed as rotenone-induced CCR in the absence and presence of the 
particular inhibitor. Rotenone-induced CCR in the absence of  inhibitor was 
calculated as measurement 3 minus measurement 1 above. Rotenone-induced CCR in 
the presence o f  inhibitor was measurement 4 minus measurement 2. Expressing the 
data in this way eliminated any effect o f  the particular inhibitor on the basal level of 
release seen without rotenone. The two calculated values were then compared using a 
paired t-test.
4.3.4 . 1  Cyclosporin A
Earlier it was observed that the respiratory inhibition-induced CCR was not 
accompanied by any mitochondrial volume changes. However, it has been suggested 
that MPT may cause CCR in a manner independent o f  volume changes (De Giorgi et 
al, 2002). Therefore it was desirable to further investigate whether MPT played a 
role by using the MPT inhibitor Cyclosporin A (CsA).
Non-synaptic mitochondria were isolated from whole rat brains (2.2.1.2). The protein 
concentrations were measured (2.7.1) and the mitochondria then incubated at 37°C in 
the electrode chamber according to Incubation Scheme 2 (2.3.1.3). The procedure 
described in 4.3.4 was carried out, using rotenone at 0.375 nmoles.mg ' 1 protein and 
CsA at lpM . Ethanol vehicles were used in place o f  both rotenone and CsA where 
appropriate.
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As can be seen in Figure 4.7, rotenone-induced CCR appears to be attenuated in the 
presence o f  lpM  CsA. However, the effect is not significant, as assessed by a paired 
t-test. This is likely to be due in part to the variability o f  the data. Hence no effect of 
CsA can be claimed.
Since MPT causes an inevitable dissipation of Av|/m, this parameter was also recorded 
during the CsA incubations. The TPP+ electrode was used (2.3.1.2) between t = 15 
and t = 18 minutes to record Ai|/m during all four incubations as defined in 4.3.4. The 
data are expressed in Table 4.3 as rotenone-induced dissipation of A\)/m in the absence 
and presence o f  CsA (rotenone at 0.375 nmoles.nig ' 1 protein). The lack o f  significant 
difference indicates that the dissipation o f  A\|/m induced by rotenone is not contributed 
to by any CsA-sensitive mechanism.
[CsA| = 0 [CsA] = lp M
Rotenone-induced Ai|/m (mV) 71.2 ± 12.9 74.7 ± 4 .6
Table 4.3
Dissipation o f  A\|/m (mV) induced by rotenone (0.375 nmoles.mg ' 1 protein) in the 
absence and presence of  1 pM CsA. Where CsA was absent, ethanol vehicle was 
substituted. There was no significant difference between the values (p > 0.05, paired 
t-test). Values are mean ± S.E.M., n = 4.
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Figure 4.7
Effect o f 1 jliM cyclosporin A on rotenone-induced CCR. Although CsA appears to 
attenuate the release, the effect is not significant as assessed by a paired t-test (p > 
0.05). Data is mean ± S.E.M., n = 4.
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4.3.4.2 Konig’s Polyanion
As discussed in 4.1.1, the hypothesis that low levels o f  CCR need not induce 
apoptosis would be supported by demonstration o f  release via an OM channel. The 
VDAC is thought to be a major OM component o f  the PTP, but has also been 
strongly implicated in allowing swelling-independent release o f  cytochrome c (see
1.3.5.2). If the release described in 3.3.2 was indeed occurring via an OM channel or 
pore, it was likely that the VDAC could be involved. For this reason, the 
experimental procedure described in 4.3.4 was repeated using Konig’s Polyanion 
(KPa). KPa is a lOkDa, 1:2:3 copolymer o f  methacrylate, maleate and styrene. By 
increasing the voltage dependence o f  VDAC more than five-fold, KPa blocks the 
channel (Colombini et al, 1987), and has been used previously to determine the role 
played by VDAC in CCR from isolated mitochondria (Brustovetsky et al, 2003b). 
The chemical is from an original and finite stock, synthesised by Tamas Konig 
(University o f  Maryland, USA). For the purpose o f  this study, it was generously 
donated by Professor Marco Colombini (University o f  Maryland, USA). KPa was 
used at 40 p g .m rl. A distilled water vehicle was used in place o f  KPa where 
appropriate.
The data are shown in Figure 4.8. Rotenone-induced CCR is significantly (p < 0.05) 
attenuated in the presence o f  KPa.
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Figure 4.8
Effect o f  40f.ig.mr' Konig’s Polyanion on rotenone-induced CCR. 
significantly attenuated in the presence of KPa (* represents p < 0.05). 
± S.E.M., n = 4.
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Data is mean
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4.3.4.3 Anti-Bak
As described (1.3.5.2), postulated OM channels which allow CCR nearly always 
incorporate pro-apoptotic Bcl-2 family members. In general, it is considered that 
anti-apoptotic members are localised to mitochondria and other membranes eg. 
endoplasmic reticulum and nuclear envelope (de Jong et al, 1994; Krajewski et a l, 
1993; Monaghan et a l, 1992). The pro-apoptotic counterparts, in contrast, are thought 
to constitutively reside in the cytosol, and translocate to the mitochondria in response 
to a pro-apoptotic stimulus (Wolter et a l, 1997). However, there are reports o f  a loose 
association o f  Bax with the OM, and detectable levels o f  Bax have been demonstrated 
in isolated rat liver mitochondria (Doran & Halestrap, 2000). Data obtained since this 
report has been contradictory (Polster et al, 2001; Brustovetsky et a l, 2003b). In 
contrast, and inconsistent with the generalisation described above, Bak is considered 
to have constitutive localisation to the mitochondrial OM (Eskes et al, 2000). 
Demonstration o f  the presence o f  Bak in isolated rat brain mitochondria appears to be 
a repeatable result (Polster et al, 2001; Brustovetsky et al, 2003b).
Since this study demonstrated CCR from isolated brain mitochondria, the 
considerations above presented Bak as a possible candidate for the release 
mechanism.
Bearing these findings in mind, the inhibitor experiments described above (4.3.4) 
were carried out using polyclonal anti-Bak (G23, Santa Cruz Biotechnology Inc., CA, 
USA). The antibody was used at 20i.ig.mg' 1 protein. A distilled water vehicle was 
used in place o f  anti-Bak where appropriate.
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The data are shown in Figure 4.9. Rotenone-induced CCR was significantly 
attenuated in the presence o f  anti-Bak (20pg.mg'' protein). This was assessed using a 
paired t-test (p < 0.05).
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Figure 4.9
Effect o f anti-Bak (20pg.mg'' protein) on rotenone-induced CCR. Release is 
significantly attenuated in the presence o f the antibody (* represents p < 0.05). Data 
is mean ± S.E.M., n = 4.
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4.4 D iscuss ion
4.4.1 Release via a swelling-independent mechanism
It has been demonstrated both quantitatively and qualitatively that the CCR induced 
by rotenone treatment is not associated with any significant change in mitochondrial 
volume. This was true o f  both non-synaptic and synaptic mitochondrial populations. 
This immediately rules out the 'swelling-dependent mechanisms' described in 1.3.5.1 
as being responsible for CCR in this case. It could be claimed that, given the data 
from 3.3.2, the release was proportional to the extent o f  the insult because the 
heterogeneous population o f  mitochondria were undergoing MPT at different times, 
due to their varying susceptibility (Gogvadze et al, 2001). However, if this were the 
case, it would be apparent both on the electron microscope images (where the 
proportion o f  swollen mitochondria would increase with rotenone treatment) and in 
the light scattering measurements (where the average mitochondrial volume would 
increase with rotenone treatment).
Release o f  cytochrome c, by means o f  MPT is generally considered to occur following 
non-specific OM rupture caused by matrix swelling. It can be argued that further 
downstream o f this, the IM would also lose integrity by the same process, causing 
complete breakdown o f  the mitochondrion as a discrete organelle. If 'weaker' 
mitochondria in a heterogeneous population were to undergo this process, the loss in 
mitochondrial number would mask the swelling o f  less susceptible mitochondria 
during light scattering measurements.
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Given Ihe mild nature o f  the stimulus, and other data contradicting involvement of the 
MPT (4.3.1, 4.3.4.1), this would be an extremely unlikely explanation for the lack of 
swelling observed in this study. The possibility has been conclusively eliminated, 
however, by the CS data. CS is a matrix enzyme o f  280kDa. It is therefore far too 
large to permeate via the PTP. However, if mitochondrial number were to decrease 
through complete IM breakdown, the CS concentration in the surrounding medium 
would increase. This was not the case, therefore the swelling data can be taken to 
truly indicate a lack o f  increased mitochondrial volume.
The fact that the rotenone-induced dissipation o f  Av|/m had no CsA-sensitive 
component further supports the conclusion that MPT was not responsible for the 
observed CCR. If rotenone was inducing MPT, even in only a fraction o f  the 
mitochondria, then the rotenone-induced drop in Avpm would exhibit a certain extent 
o f  CsA-sensitivity.
In conclusion therefore, the results o f  this investigation are inconsistent with the 
release having occurred via non-specific rupture o f  the OM due to matrix swelling. 
Instead, it can be hypothesised that release is occurring via an OM channel.
4.4.2 The nature o f  the OM release channel
Assaying for AK is a particularly useful tool because the enzyme is localised to the 
IMS like cytochrome c,. The fact that the distribution o f  AK was found, like that of 
CS, to be unaffected by rotenone treatment indicates that although CCR appears, by
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default, to be released through an OM channel, this channel does not allow non­
specific release o f  SIMPs. Either there is a size cut-off point between the two 
proteins in question, or the release channel is specific for cytochrome c. The size of 
AK has significance when compared to that o f  Sniac, another IMS protein known to 
have pro-apoptotic properties (see 1.3.6 .2). Smac is o f  almost identical size 
(23.7kDa) to AK (23.6kDa), and the AK data would imply that Smac might not be 
released along with cytochrome c in response to this rotenone treatment. This 
suggestion is to be strongly supported later by Western blotting (see Chapter 6 ). 
Bearing in mind the important (and possibly essential -  Deshmukh et al, 2002) role of 
Smac in the induction o f  apoptosis in neurons, this finding is consistent with the 
hypothesis (3.5) that low levels o f  CCR, induced by respiratory deficiency, may be 
insufficient to induce apoptosis.
It should be noted that although respiratory inhibition did not induce release o f  CS or 
AK, there were basal levels o f  both enzymes present in the supernatant samples. This 
could be interpreted as an artefact o f  the incubations, as discussed for the control 
level o f  CCR (see 3.4.2.1). However, there is a notably higher level o f  AK (15-20% 
total mitochondrial content) than CS (5-7%) present. There is a cytosolic isoform of 
AK (Ruan et a l, 2002), and this high basal activity in the supernatant could be due to 
cytosolic contamination o f  the mitochondrial preparation. However, validation of the 
preparations by means o f  LDH assay (2.7.2.2) suggested that this contamination was 
very low.
There is an alternative explanation which also has implications for the basal level of 
cytochrome c detected after control incubations. The variation in control rate of
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release o f  different proteins may lie in their constitutive rates o f  turnover. It is 
suggested (Bachmair et a l, 1986) that the N-terminal amino acid o f  a protein can give 
an indication o f  its physiological half-life. Using this theory, cytochrome c 
(methionine at N-terminal) is suggested to have an approximate f/> o f  30 hours, 
whereas AK (N-terminal alanine) is closer to 4 hours. These data are purely 
theoretical, but suggest that a relatively fast turnover rate for AK may help to explain 
the high background release.
The release mechanism therefore appeared to be specific for cytochrome c, or at least 
have a size cut-off which was smaller than other SIMPs which may contribute to a 
pro-apoptotic signal. Thus far, the findings are consistent with the hypothesis that 
low levels o f  CCR may not lead to apoptosis. The release mechanism was then 
further'characterised in order to gain as much information as possible about whether 
the CCR was an isolated event in response to rotenone treatment.
Although CsA looks to impact CCR, the effect was not statistically significant. CsA 
is known to have numerous targets other than cyclophilin d (Capano et al, 2002; Kim 
et al, 2003; Sanchez et a l, 2003; among others). However, the major alternative 
inhibitor is bonkrekic acid (which blocks MPT via the ANT), which was until 
recently difficult to obtain commercially. By far the majority o f  studies into MPT use 
CsA as an inhibitor, and it is notable that there appears to be very little concordance 
between studies on whether or not otherwise similar release mechanisms are CsA- 
sensitive. The lack o f  statistically significant effect o f  CsA on the CCR observed in 
this study support the conclusion that MPT is not the mechanism responsible.
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However, a recent report claims to reconcile much o f  the discordance over the role o f  
MPT in CCR (de Giorgi et a l, 2002). The authors argue that if reversible openings of 
the PTP are triggered, the consequent dissipation o f  Ai|/m signals for Bax translocation 
to the mitochondria, and subsequent release o f  cytochrome c via Bax-mediated OM 
channels. Whilst this provides possible resolution to claims o f  CCR which is 
independent o f  swelling, but appears to be sensitive to CsA, it is inconsistent with the 
data from this study on two counts. Firstly, the presence o f  CsA had no effect on the 
amplitude o f  the A\|/m after rotenone treatment (Table 4.3). If the mechanism 
proposed by De Giorgi and colleagues was responsible for release here, then rotenone 
would be inducing a dissipation of the A\|/m via reversible openings o f  the PTP, which 
would be prevented by the addition o f  CsA. Secondly, if a reduction in Av|/m was 
sufficient to trigger Bax translocation and channel formation, then CCR would have 
been observed in response to cyanide-induced respiratory inhibition (see chapter 5).
It seems most appropriate to conclude, therefore, that the release mechanism is not 
dependent on MPT. It is possible that a certain amount o f  sensitivity to CsA was 
conferred by other PTP components which may be involved in the release mechanism 
here, in a role independently o f  the rest o f  the PTP.
Such components were indeed confirmed to be involved by the use o f  KPa and anti- 
Bak. These inhibitors implicated the VDAC and Bak, since inhibition o f  the former 
and sequestration o f  the latter both significantly attenuated rotenone-induced CCR.
The study by Brustovetsky et al (2003b) promoted Bak to a primary role in regulating 
CCR from isolated brain mitochondria. Our data clearly demonstrated that inhibition
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of Bak attenuated respiratory deficiency-induced CCR. Bak and Bax are very closely 
related proteins, sharing sequence homology of  the BH1, BH2 and BH3 regions. The 
postulated role o f  Bax in associating with the VDAC to form a channel which is 
permeable to cytochrome c has been described (1.3.5.2). It is reported that Bak can 
induce the same effect (Shimizu et al, 1999). Combining the observed effect o f  anti- 
Bak with that o f  KPa in this study, an OM channel formed by the association o f  Bak 
and VDAC is strongly implicated.
These two channel-forming proteins are both postulated components o f  the PTP 
complex (see 1.3.5.1). However, arguments have been made against the involvement 
o f  MPT in the observed CCR. It can be hypothesised therefore that the channel is o f  
the VDAC-Bax/Bak formation which is being increasingly accepted. Previous work 
on this channel complex may therefore be used to aid in the understanding o f  the 
effect which its opening might have on mitochondrial viability.
VDAC-Bax channels have been reconstituted in liposomes (Shimizu et al 2000). 
This intriguing study demonstrated that a VDAC-Bax channel is nearly continuously 
in an open state, in contrast to VDAC alone, which rapidly fluctuates between open 
and closed formations. The pore diameter o f  the combined channel also appears to be 
four times larger than that o f  VDAC alone, thus overcoming suggestions that VDAC 
in isolation has too narrow a pore diameter to permit passage o f  cytochrome c 
(Manella, 1998). The VDAC-Bax channel was seen to have a size limit for 
permeation o f  less than 50kDa. Without further clarification o f  the size cut-off point, 
this information is o f  limited use, since other pro-apoptotic proteins (Smac, 23.7kDa; 
Omi, 38kDa) are smaller than this limit (although A1F, at 67kDa, is larger).
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However, studies which conclude CCR by means o f  a VDAC-Bax/Bak channel have 
claimed a lack o f  associated AK and Smac release (Brustovetsky et al, 2003b; Doran 
& Halestrap, 2000). This implies that the VDAC-Bax/Bak channel is either specific 
for cytochrome c. or at least has a pore diameter too small to allow the release o f  other 
recognised pro-apoptotic SIMPs.
Although there are significant benefits in the use o f  isolated mitochondria for this 
study (see 3.1.3), the data concerning the role o f  Bak highlight the importance of 
considering whole cells. As discussed (4.3.4.3), Bak is thought to be constitutively 
localised to the mitochondrial OM, but the majority o f  other pro-apoptotic Bcl-2 
proteins are considered cytosolic under control conditions. The discrepancy between 
two major studies (Brustovetsky et al, 2003b; Doran & Halestrap, 2000) in their 
findings on the presence o f  Bax in isolated mitochondria would be partly due to tissue 
heterogeneity, but may also be contributed to by a higher percentage cytosolic 
contamination o f  the preparation in the former study. Neither study provides LDH 
data to allow for accurate comparison o f  cytosolic contamination.
The LDH data used for validation o f  the isolated mitochondria preparations (2 .1 2 .2 ) 
demonstrated very low cytosolic contamination. It is likely, therefore, that in this 
case there was little contribution o f  cytosolic Bcl-2 proteins to the CCR mechanism. 
This demonstrates the only significant drawback o f  using isolated mitochondria for 
these experiments. The amplitude o f  the CCR event might be significantly altered if 
the experiment was carried out using whole cells, due to the added capacity for 
involvement o f  Bax, etc. There is no reason to suspect that CCR would no longer be 
proportional to complex I inhibition, but the gradient o f  the near-linear relationship
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might be altered. This limitation o f  the isolated mitochondria model therefore 
necessitates further investigation in whole cells. This is to be carried out in Chapter 
6 .
4.5 Conclusion
Previously, the demonstration o f  a subtle, controlled release o f  cytochrome c in 
proportion to respiratory inhibition presented the hypothesis that a certain amount of 
CCR may be tolerated by the host cell. For this hypothesis to be upheld, it was 
essential that the release mechanism did not impose any insurmountable damage to 
the mitochondria.
This study has now demonstrated that the release mechanism does not involve the 
swelling and non-specific rupture o f  the OM that has been described to be associated 
with CCR in some situations (Brustovetsky et al, 2002; Petit et al, 1998; Scarlett & 
Murphy, 1997). Rather, the mechanism appears to be dependent on two OM channel 
forming proteins, VDAC and Bak. Whether the channel is a complex composing 
both proteins, or whether Bak induces a conformational change in VDAC which 
allows cytochrome c. to permeate (Tsujimoto & Shimizu, 2000) is irresolvable at this 
stage. However, previous studies on the channel formed by the coordinate action of 
these two proteins would suggest that it may be specific for cytochrome c. (Doran & 
Halestrap, 2000; Brustovetsky et al, 2003b). This eliminates a number of important 
pro-apoptotic signals, in the form of other SIMPs.
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This investigation has supported the conclusion that, at the mitochondrial level, the 
cell will remain viable during partial CCR induced by respiratory inhibition. 
Concluding that this release is ‘safe’ however is subject to post-mitochondrial 
mechanisms ‘buffering’ low levels o f  CCR. This conclusion may only be drawn 
entirely if demonstrated in whole cells, since there is insufficient understanding o f  
these control mechanisms to be able to model them in an isolated mitochondrial 
system.
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CHAPTER 5
Determining the trigger for cytochrome c 
release from brain mitochondria
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5.1 In t ro d u c t io n
5.1.1 The 'bottom up ’ approach
It is common for studies on CCR to utilise stimuli selected for their recognised ability 
to induce apoptosis, eg. Staurosporine (Bertrand et al, 1994) or micro injection of 
cytochrome c (Deshmukh et al, 2002; Li et al, 1997; Zhivotovsky et al, 1998), rather 
than their capacity to model an underlying pathology. By diminishing Complex I 
activity, this study has, in contrast, modelled the pathology to determine whether 
there is an effect on apoptotic signals. This ‘bottom-up’ approach is a more 
interesting strategy with respect to elucidating molecular mechanisms o f  disease 
pathology.
The data obtained by using this strategy have suggested that low levels o f  CCR occur 
in response to changes in flux through the ETC. It has been hypothesised, 
considering this result, that small amounts o f  CCR may be harmless to the host cell. 
This is because fluctuations in electron flux are a physiological occurrence and there 
is no basis for expecting them to induce apoptosis.
The respiratory inhibition induced CCR showed a good correlation (p < 0.001) with 
A\|/m (see 3.8). Reduced amplitude o f  the Avj/m is a plausible candidate for the 
physical manifestation o f  respiratory inhibition which regulates CCR. If Ai|/m were to 
directly regulate CCR in this model, this would support the hypothesis that low levels 
of CCR are a normal physiological occurrence, since fluctuations in A\|/m are 
inevitable (Buckman & Reynolds, 2001).
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5.1.2 Dissipation o f mitochondrial membrane potential.
It has been suggested on many occasions that a reduction in the Av|/m is an obligatory 
event in the apoptotic pathway, occurring upstream o f  CCR (Barbu et al, 2002; 
Zamzami et al, 1995; among others). This was consistent with the theory that MPT 
was the underlying release mechanism, since MPT is both triggered by, and 
inevitably causes, a dissipation o f  Ai|/m.
However, the issue has since become hotly debated, with numerous reports 
concluding that a reduced A\|/m is a consequence, rather than a cause, o f  the CCR 
event. Dissipation o f  A\|/m which occurs secondary to CCR is suggested to be 
associated with opening o f  the PTP downstream o f  the initial caspase activation 
(Bossy-Wetzel et al, 1998), an event which may be involved in amplification o f  the 
initial pro-apoptotic signal (Marzo et ah 1998). Late dissipation of A\|/m is also 
suggested by some to be the simple result o f  reduced flux through the ETC due to 
limiting cytochrome c concentrations after CCR (Madesh et al, 2002; Mootha et al, 
2 0 0 1 ).
It is therefore unclear as to whether the reduced Ai|/m induced by complex I inhibition 
(see Figure 3.3) would act as a trigger for CCR. Although dissipation of Av|/m does 
not appear to be a prerequisite in all situations where cytochrome c is released, it may 
nonetheless be sufficient to induce it. Studies using uncouplers have attempted to 
resolve this issue, with mixed results (de Giorgi et al, 2003; Finucane et al, 1999; 
Niemenen et al, 1995).
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The debate may be reconciled when considering the claim of Marzo et al (1998) that 
an initial partial drop in A\|/m is sufficient to induce CCR and caspase activation. This 
protease activity then induces a secondary large amplitude dissipation of  Ai|/m. 
Bearing in mind the limited quantitative value o f  the fluorescent dye methods used by 
the majority o f  investigators, it is quite possible that a large proportion do not detect 
the initial partial change in potential. Considering this hypothesis, and the highly 
quantitative method used in this study for monitoring Av|/m, it appears possible that 
this parameter could be the link between Complex I inhibition and CCR.
5.1.3 Inhibition o f  Complex IV
In order to determine whether dissipation of A\|/m is indeed sufficient to trigger CCR, 
a second series o f  titrations was carried out on isolated non-synaptic mitochondria. 
By titrating Complex IV activity using potassium cyanide (KCN), Av|/,n would be 
reduced, and the effect on the extent o f  CCR could be determined. By comparing the 
relationship between Ai|/m and CCR in the two titrations (complex I and IV), the role 
of Ai|/m in triggering CCR could be assessed.
Cyanide is a recognised potent inhibitor o f  Complex IV. As described in 1.1.2.4, the 
final step in the function o f  complex IV is the donation o f  an electron from the heme 
a^/Cu^ complex to molecular oxygen to form water. Cyanide is thought to act by 
bridging the heme «.?-Cub bimetallic centre, with the result that electron transfer is 
arrested just prior to completion o f  the pathway (Gardner et a l, 1996).
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5.2 A im s
By repeating the titration o f  mitochondrial respiratory function by targeting complex 
IV rather than complex I, it was intended to investigate whether dissipation of A\|/m 
provides the link between respiratory inhibition and CCR. This link would be 
supported if the correlation between Avj/m and CCR was consistent between the two 
titrations.
This would either provide support or suggest modification o f  the hypothesis that CCR 
is a normal, physiological occurrence.
5.3 Results
5.3.1 Titration o f  mitochondrial respiratory function using potassium cyanide
Non-synaptic mitochondria were isolated from whole rat brains as described (2.2.1.2). 
The protein concentrations were measured (2.7.1) and the mitochondria then 
incubated at 37°C in the electrode chamber according to Incubation Scheme 1
(2.3.1.3). One incubation from each preparation served as a control (distilled water 
vehicle alone) and the remainder were subjected to a range o f  concentrations o f  KCN. 
Each titration was carried out in order o f  increasing KCN concentration.
It was established (based on Davey & Clark, 1996) that treatment with KCN in the 
range 0  -  400 nmoles.mg ' 1 protein caused inhibition o f  respiration in the order seen
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by the rotenone treatment (3.3.1). Sufficient preparations were then performed to 
provide n = 4 for each KCN concentration.
As before, oxygen consumption rate and mitochondrial Ai|/m were recorded (2.3.1.1,
2.3.1.2) between t = 7 minutes and t = 10 minutes. At 10 minutes, an aliquot o f  lOOpl 
was removed and frozen immediately in liquid nitrogen. A second aliquot o f  400pl 
was removed and centrifuged at 17000xg for 5 minutes at 4°C. The supernatant was 
removed and frozen immediately in liquid nitrogen. Both were stored at -70°C until 
assays were performed. The fonner aliquot was assayed for Complex IV activity as 
described in 2.3.2.2. The latter was to be used for assay o f  cytochrome c 
concentration (see 5.3.2).
Complex IV activity was found to be reduced from 27.6 ± 1.2 kmiiT'.mg ' 1 protein 
(mean o f  n = 4) to 9.7 ± 1.5 kmin'l.mg‘l protein (100% to 35.1%) by the range of 
KCN concentrations tested, as shown in Figure 5.1.
The corresponding oxygen consumption rates were inhibited from 97.5 ± 4.3 nmoles 
0 2 .min'l.mg ' 1 to 10.3 ± 0.62 nmoles C^.miiT'.mg ' 1 (100% to 10.6%) as shown in 
Figure 5.2. A\|/m was reduced from 175.1 ± 2.5 mV to 99.7 ± 3.5 mV (100% to 
57.0%) as shown in Figure 5.3.
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Figure 5.1
Concentration-dependent inhibition of non-synaptic mitochondrial Complex IV 
activity by potassium cyanide, n = 4 for each KCN concentration. Data shown 
± S.E.M. The assay was carried out on mitochondria which had undergone 
three freeze-thaw cycles.
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Figure 5.2
Concentration-dependent inhibition of non-synaptic mitochondrial state 3 oxygen 
consumption rate by potassium cyanide, n = 4 for each KCN concentration. Data 
shown ± S.E.M. Measurements were made in situ in the electrode chamber, in the 
presence o f  glutamate, malate and pyruvate as substrates.
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Figure 5.3
Concentration-dependent inhibition of non-synaptic mitochondrial state 3 Av|/m by 
potassium cyanide, n = 4 for each KCN concentration. Data shown ± S.E.M. 
Measurements were made in situ in the electrode chamber, in the presence of 
glutamate, malate and pyruvate as substrates.
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5.3.2 Relationship between respiratory function and cytochrome c release
Supernatants derived from the incubations described in 5.3.1 were assayed for 
cytochrome c concentration (2.4.1). The total mean cytochrome c content o f  isolated 
non-synaptic rat brain mitochondria had been determined as described earlier (3.3.2). 
Released cytochrome c was then expressed as a percentage o f  the total mitochondrial 
content.
Oxygen consumption rate and Ai|/m of the KCN-treated mitochondria were plotted 
against percentage CCR (see Figures 5.4 and 5.5). In both cases, respiratory 
inhibition did not appear to induce CCR. The regression did not show a significant 
deviation from zero slope in either case (p > 0.05). This is despite the extent o f  
inhibition o f  these parameters being similar to that induced by rotenone (see figure 
5.6).
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Figure 5.4
Relationship between oxygen consumption rate and percentage release of cytochrome 
c in non-synaptic mitochondria inihibited using potassium cyanide. Linear regression 
line has equation y = ().007x + 12.7 and is not of significant deviation from zero slope 
(p > 0.05). Key indicates cyanide concentration (nmoles.mg 1 protein) used to achieve 
inhibition.
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Figure 5.5
Relationship between A\j/m and percentage release o f cytochrome c in non-synaptic 
mitochondria inihibited using potassium cyanide. Linear regression line has equation 
y 0.02x + 10.4. Although the regression line suggests a reverse relationship (Av|/m 
and percentage CCR directly proportional), it does not have a significant deviation 
from zero slope (p > 0.05). Key indicates cyanide concentration (nmoles.mg ' 1 
protein) used to achieve inhibition.
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Figure 5.6
Collated data for rotenone and potassium cyanide-induced CCR. Ranges of oxygen 
consumption rate and A\|/m are the same for both inhibitors. However, both oxygen 
consumption rate and Avjtm display a significant inverse correlation with percentage 
CCR after rotenone treatment (A and B respectively), whereas inhibition of oxygen 
consumption rate and Avj/m using KCN has no effect on CCR (C and D respectively).
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5.3 .3  Rotenone-inducecl oxidative stress
Reducing A\|/m did not appear sufficient to induce CCR. It was hypothesised that the 
discrepancy between the effect o f  rotenone and cyanide on CCR could instead be 
explained by the synthesis o f  ROS. If superoxide was generated by the inhibition of 
Complex I, it would be rapidly converted to hydrogen peroxide by superoxide 
dismutase. H2 O 2 is then reduced by glutathione peroxidase, using reduced glutathione 
(y-glutamylcysteinylglycine, GSH) as an electron donor. As a result, GSH is oxidised 
to GSSG (glutathione disulphide) (see 1.1.3). If this system were at work, the 
mitochondrial glutathione would be increasingly present in the oxidised rather than 
the reduced form. This would be detectable as a reduction in the GSH level, which 
can be measured by HPLC.
Non-synaptic mitochondria were isolated from whole rat brains as described (2.2.1.2). 
The protein concentrations were measured (2.7.1) and the mitochondria then 
incubated at 37°C in the electrode chamber according to Incubation Scheme 1
(2.3.1.3). The titration o f  Complex I activity described in 3.3.1 was repeated. A 
lOOpl aliquot was taken at t = 10 minutes, and immediately acid extracted by adding 
to 0.5ml 15mM orthophosphoric acid. The mixture was vortexed and frozen 
immediately in liquid nitrogen. The samples were then stored at -70°C until GSH 
measurement.
GSH levels in the samples were measured by reverse-phase HPLC using 
electrochemical detection as described in 2.4.4.
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The data are shown in Figure 5.7. Increasing the concentration o f  the rotenone 
treatment had no effect on the GSH content o f  isolated non-synaptic brain 
mitochondria, as assessed by linear regression across the whole range o f  rotenone 
concentrations used (insignificant deviation from zero slope, p > 0.05). However, 
observation o f  the data shown in Figure 5.7 suggested that the GSH levels measured 
following milder rotenone concentrations (notably 0.150 nmoles.mg ' 1 protein) 
might be higher than those following stronger treatment ( 0.225 nmoles.mg ' 1
protein). This was confirmed using an unpaired t-test (p < 0.05). There is therefore 
some indication that GSH levels are reduced by concentrations o f  rotenone which 
cause CCR. Rather than demonstrating a linear trend across the range, GSH levels 
appear to show a form o f  threshold effect.
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Figure 5.7
Effect of rotenone treatment on GSH content of isolated non-synaptic rat brain 
mitochondria. There is no linear trend across the range o f rotenone concentrations 
tested, as assessed by linear regression. However, there is a significant difference 
between the GSH content of mitochondria treated with rotenone at 0.150 
nmoles.mg ’ 1 protein and that of mitochondria treated with rotenone at 0.225 
nmoles.mg ' 1 protein (p < 0.05, unpaired t-test).
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5.4 Discussion
5.4.1 Titration o f respiratory function by cyanide
This part o f  the study was carried out using isolated non-synaptic rat brain 
mitochondria only, for the reasons discussed in 4.3.3. Basing the treatment 
conditions on Davey and Clark (1996), the mitochondria were treated with cyanide in 
the range 0 - 400 nmoles.mg’1.
Increasing the concentration o f  the cyanide treatment resulted in a titration of 
mitochondrial oxygen consumption and A\|/m as expected. However, the same 
anomaly identified following the rotenone titration (3.4.1.2) was observed in this case 
also. Complex IV activity appeared insensitive to cyanide concentration above 50 
nmoles.mg ' 1 mitochondrial protein, although the inhibition was not complete. The flat 
profile o f  this region o f  the curve is inconsistent with the cyanide concentration- 
dependent inhibition o f  oxygen consumption rate and A\|/m across the entire range. If 
this problem is an experimental error which results from freeze-thawing o f  the 
samples, as suggested in 3.4.1.2, the issue could be resolved in this case by in situ 
measurement o f  complex IV activity. This can be done by isolating complex IV from 
the rest o f  the ETC, using ascorbate and TMPD (N,N,N',N'-tetramethyl-/>- 
phenylenediamine) as substrates and monitoring oxygen consumption rate.
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5.4 .2  Lack o f  effect o f  cyanide on cytochrome c release
Bearing in mind the marked effect o f  rotenone treatment on CCR from isolated non- 
synaptic brain mitochondria, it was surprising to observe that cyanide-induced 
respiratory inhibition caused no such effect. The relationship actually appeared very 
slightly reversed, ie. respiratory inhibition reduced CCR to below control levels. 
However, statistically, the regression line shows no significant deviation from zero, 
therefore it is concluded that there is no effect o f  cyanide treatment in this range on 
CCR.
The extent o f  release under control conditions was slightly lower (13.8 ± 0.8 % total 
mitochondrial cytochrome c) in this study than was observed during the rotenone 
titrations (17.3 ± 1.3 % total mitochondrial cytochrome c). This may indicate an 
effect o f  the presence o f  small amounts of ethanol in the rotenone titrations. If the 
ethanol was indeed responsible for some o f the basal CCR, this highlights the 
importance o f  adding the appropriate vehicle in the control incubations.
5.4.3 Rotenone versus cyanide treatment
This observation clearly demonstrates that dissipation o f  Ai|/m caused by reduced flux 
through the ETC is not sufficient to induce CCR from isolated non-synaptic brain 
mitochondria.
Also affected by respiratory inhibition are the ATP levels. ATP is thought to induce 
a conformational change in cytochrome c, which alters its association with
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cardiolipin, the IM ‘anchor’ (see 1.2.2.2) (Tuominen et a l, 2001). Although ATP 
levels were not measured in this study, Davey and Clark (1996, 1998) demonstrated 
that ATP levels follow an almost identical pattern to oxygen consumption rate during 
inhibitor titrations o f  isolated brain mitochondria. It can therefore be concluded by 
inference that lower levels of ATP were not the trigger in this case for the release of 
cytochrome c.
Rather than such parameters which are affected in the same way by rotenone and 
cyanide, the CCR must be induced by some factor/factors which are affected 
differently by the two inhibitors. There are two main candidates:
5.4.3.1 Oxidative stress
The ETC is recognised as a major generator o f  ROS. Electrons which are leaked 
from the chain can associate with molecular oxygen to form superoxide. The 
presence o f  mitochondrial superoxide dismutase allows the superoxide to be quickly 
converted to hydrogen peroxide, which is then subject to reduction to water by the 
glutathione peroxidase system (see 1.1.3). Due to the rapid dismutation of 
superoxide, increased superoxide production is not likely to be detectable (Forman & 
Azzi, 1997). However, changes in the oxidation state o f  glutathione can be detected 
as described (5.3.3), indicating an upstream alteration in superoxide levels.
Measurement o f  GSH levels by reverse phase HPLC initially suggested that there was 
no significant effect o f  rotenone treatement on the GSH concentration in isolated non- 
synaptic rat brain mitochondria. This was due to analysis o f  the regression line, 
which displayed no significant deviation from zero slope. However, observation of
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the data suggested a reduction in GSH levels when the rotenone concentration is 
raised to 0.225 nmoles.mg"1 protein. Indeed, when assessed using an unpaired t-test, 
mitochondria treated with rotenone o f  0.150 nmoles.mg ' 1 protein contained 
significantly more (p < 0.05) GSH than those treated with rotenone o f  0.225 
nmoles.mg"1 protein. The reason for this apparent threshold effect is unclear, and 
there is no correlating jump in the cytochrome c data at this point.
Therefore, despite the lack o f  linear trend between the concentration o f  rotenone used 
for treatment and GSH content o f  the mitochondria, there is some indication that 
rotenone can cause a reduction in GSH levels. This is consistent with the hypothesis 
that Complex I inhibition via rotenone is causing increased superoxide production, 
and that this may be the factor causing the increased CCR.
There has been considerable investigation into the generation o f  ROS by the ETC, 
particularly with respect to which complexes are primarily responsible. A number of 
studies have highlighted complexes I and III as the most important sites o f  superoxide 
production (Turrens et a l, 1985; Turrens & Boveris, 1980), but it is complex I which 
is emerging as the most physiologically and pathologically relevant site (Liu et al, 
2002; among others). This theory is consistent with the hypothesis that a discrepancy 
in ROS generation in response to rotenone versus cyanide treatment may underlie the 
differing effects on CCR.
A recent report on ETC-mediated ROS generation has particularly interesting 
implications for the interpretation o f  these data. Sipos and colleagues (2003) titrated 
the activities o f  complexes I, III and IV in a manner similar to that used in this study,
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although using synaptosomes rather than isolated mitochondria. The authors 
determined by monitoring superoxide and hydrogen peroxide levels that complexes 
III and IV demonstrated a threshold effect for ROS production. This effect was 
similar to that described in Davey and Clark (1996) and Davey et al (1998) with 
respect to changes in respiration rate and ATP synthesis. Notably, cyanide treatment 
was found not to induce ROS generation until complex IV was inhibited by more 
than 70%. In this study, the maximum cyanide treatment used only inhibited 
complex IV activity to approximately 35% of the control level. Although the study 
by Sipos et al (2003) was carried out using synaptosomes, and the differences 
between mitochondria from synaptic and non-synaptic origin are recognised, it might 
be expected that the extent o f  inhibition afforded by cyanide in this study was sub­
threshold with respect to ROS generation.
The findings o f  Sipos et al (2003) with respect to complex I inhibition by rotenone 
are even more interesting. Unlike complexes III and IV, complex I did not exhibit a 
threshold effect for ROS generation. Rotenone treatment caused proportional 
amounts o f  superoxide and hydrogen peroxide production from very low levels of 
inhibition. The extent o f  ROS generation was however very small when compared to 
that measured after super-threshold inhibition o f  complexes III or IV. This effect is 
remarkably similar to the profile o f  rotenone-induced CCR demonstrated in this 
study.
It would appear likely, therefore, that the CCR induced by mild rotenone treatment is 
mediated at least in part by a corresponding dose-dependent increase in superoxide 
generation. The inability o f  cyanide to induce CCR might be explained by the
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threshold effect described by Sipos et al (2003). The extent o f  inhibition o f  complex 
IV was probably insufficient to induce ROS generation. However, if the inhibition 
were to be increased to exceed the threshold, the large amplitude ROS generation 
described by Sipos et al (2003) would be predicted to induce a sudden and extensive 
cytochrome c translocation.
It is possible that generation o f  ROS proportional to the extent o f  Complex I 
inhibition may explain the effect of rotenone on GSH levels, as observed in 5.3.3 
Small amounts o f  superoxide could be ‘dealt with’ by the GSH system. However, if 
superoxide was increasingly generated as the concentration o f  the rotenone treatment 
increased, at a certain threshold level, the GSH system would be overwhelmed and 
GSH levels would start to decline without being replenished by glutathione reductase. 
This would explain the ‘lag’ effect observed in Figure 5.7, as low levels o f  oxidative 
stress can be effectively buffered by anti-oxidant mechanisms (reminiscent o f  the 
hypothesis concerning cytochrome c). Only once the limited capacity o f  the GSH 
regeneration system is exceeded do the GSH levels begin to decline. This is in 
contrast to the near-linear profile of induced CCR with rotenone treatment, and 
therefore implies that the release may not be induced purely by increased oxidative 
stress, but perhaps by a number o f  coordinate signals.
Despite claims that the transient nature o f  superoxide makes it less amenable to 
measurement than downstream indicators o f  oxidative stress (eg. hydrogen peroxide, 
change in GSH levels), the study by Sipos et a l, among others (Liu et al, 2002) have 
demonstrated that it is possible to reliably measure superoxide. Interpretation o f  the 
GSH data relies on certain assumptions, eg. mitochondrial SOD present in excess. A
more direct measurement o f  ROS production eg. assay for aconitase activity 
(Hausladen & Fridovich, 1996), might provide more informative data in this study.
Oxidative stress is recognised as a trigger for activation o f  the MPT (reviewed by 
Kowaltowski et a l, 2001). However, superoxide has also been linked with CCR by 
means o f  the VDAC (Madesh & Hajnoczky, 2001). This study used a human cell 
line rather than primary tissue, and demonstrated a number o f  difference results from 
this study (namely lack o f  involvement o f  Bax (see 4.3.4.3) and the concurrent release 
o f  Smac (see 6.3.1)). However, the report highlights the potential for an MPT- 
independent, VDAC-mediated release mechanism to be affected by an increased 
superoxide concentration.
As described (1.1.3), it has been suggested that if  generated at complex I, superoxide 
is released on the matrix side o f  the IM (St-Pierre et a l, 2002). Therefore if it is true 
that superoxide has a role in mediating CCR, there must be a mechanism for its 
translocation from the matrix across the IM to reach the OM release apparatus. An 
‘inner membrane anion channel’ (IMAC) has been described (Beavis, 1992) and 
appears to be capable o f  allowing such translocation o f  superoxide (Aon et al, 2003).
It is interesting to consider the claim of Korshunov et al (1999) that low levels of 
cytochrome c external to the mitochondria are capable o f  inhibiting hydrogen 
peroxide generation by complex I. As discussed (3.4.2.2), low amplitude CCR could 
serve as a defensive anti-oxidant system. This role o f  cytochrome c therefore 
supports ETC-mediated ROS generation as a trigger for CCR.
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It is believed that 1-3% of the total oxygen consumed at the ETC is converted to ROS 
due to electron leak (Boveris et al, 1972). If CCR is induced in proportion to 
mitochondrial ROS generation, this lends further support to the hypothesis that low 
levels o f  CCR can be tolerated and do not in all cases lead to apoptosis.
5.4.3.2 Redox status o f  cytochrome c
As described, there is a good case for the involvement o f  ROS in rotenone-induced 
CCR. However, there is also a more fundamental difference between rotenone and 
cyanide treated mitochondria which is implied by the basic features o f  the ETC. 
Rotenone prevents electron transfer at the stage o f  reduction o f  free ubiquinone. 
Therefore in the course o f  the rotenone titration, the redox components o f  the ETC 
which are downstream of the rotenone-sensitive site, including cytochrome c will be 
increasingly in the oxidised state. In contrast, cyanide halts electron transfer at the 
final stage o f  the ETC, where electrons are donated to molecular oxygen. In this case, 
redox components o f  the ETC which are upstream o f  the cyanide-sensitive site, 
including cytochrome c will be increasingly reduced during the course o f  the cyanide 
titration.
Is there a case for an increase in the ferriiferrocytochrome c ratio causing an increase 
in the amount o f  cytochrome c which is released? The cytochrome c immunoassay 
kit manufacturers (R&D Systems, Abingdon, UK) are unaware o f  any reason that the 
assay should differ in its sensitivity for ferri and ferrocytochrome c (personal 
communication). Therefore the data described in 5.3.2 would be consistent with a 
CCR mechanism which only permitted release o f  ferricytochrome c.
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It is understood that cytochrome c undergoes a conformational change on transition 
between redox states (Bret et a l, 2002; Calvert et al, 1997). It is conceivable that 
such a change could alter the extent to which cytochrome c is associated with the IM 
via cardiolipin (see 1.2.2.2). There has been suggestion that electrostatic associations 
o f  cytochrome c with the IM could be important in regulating its release (Ott et al, 
2002). It has also been reported that ferricytochrome c is generally more mobile than 
ferrocytochrome c. (Bartalesi et al, 2003). Ferricytochrome c is also thought to be 
subject to larger volume fluctuations than ferrocytochrome c (Eden et al, 1982). 
Effects on the redox state o f  cytochrome c. could therefore influence the potential for 
CCR. In addition, from a functional point o f  view, an increasing 
ferri:ferrocytochrome c ratio would be indicative o f  reduced work load on the ETC. 
It is possible that more cytochrome c would be released to the cytosol for degradation 
as an adaptive mechanism if a particular mitochondrion was less metabolically active.
It would be extremely interesting to investigate the relative apoptosis-inducing 
properties o f  ferri and ferrocytochrome c, perhaps using an in vitro caspase activation 
assay. However, similar approaches have so far yielded contrasting results (Hampton 
et al, 1998; Pan et al, 1999).
5.4.4 Implications o f  the lack o f  effect o f  cyanide on cytochrome c release
This study has demonstrated that although a controlled, dose-dependent increase in 
CCR is induced by rotenone, no such effect is observed in reponse to cyanide 
treatment. From the report by Sipos et al (2003), it can be hypothesised that a sudden 
increase in CCR may be induced by cyanide once the threshold for ROS generation is
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reached. This possibility has important implications for the physiological regulation 
o f  mitochondrial respiration.
It has been put forward that the inhibition o f  complex IV by nitric oxide may serve as 
a physiological mechanism for regulating the rate o f  respiration. Nanomolar 
concentrations o f  NO reversibly inhibit complex IV (Brown & Cooper, 1994; Stewart 
et al, 2000). Since the inhibition is o f  a competitive nature with oxygen, it has been 
suggested that NO may act as a physiological regulator o f  the sensitivity of the 
respiratory chain to oxygen (Brown, 1995).
The data from this study would suggest that such a form o f  regulation would be 
unlikely to lead to any CCR from the mitochondria. This is consistent with the 
concept o f  complex IV inhibition as a physiological mechanism. In contrast, 
physiological concentrations o f  NO do not appear to affect complex I activity 
(Bolanos et a l, 1994). The data from this study, describing CCR proportional to 
complex I inhibition, are consistent with mild complex I depletion as an early 
pathological rather than physiological event.
5.5 Conclusions
In this investigation, it was determined that CCR is not induced purely by reduced 
flux through the ETC and therefore reduced Ai|/m. The release has been dissociated 
from these measurable parameters via a cyanide-induced titration o f  respiratory 
function.
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The literature and, to a certain extent, data obtained in this study concerning 
mitochondrial GSH status, suggest that this discrepancy is mediated by the extent of 
oxidative stress imposed by the two inhibitors. It is likely that rotenone induces 
superoxide generation in a dose-dependent manner, which would then be expected to 
cause CCR. Cyanide is unlikely to be causing the same increase in ROS synthesis, 
indeed perhaps none at all, as suggested by Sipos et al (2003).
It is also possible that the release process may be affected by the redox state o f  the 
mitochondrial cytochrome c, although this study has not provided evidence for this 
hypothesis.
The discrepancy between the effects o f  complex I and complex IV inhibition with 
respect to CCR are consistent with the theory that modulation o f  complex IV activity 
(by NO) is a physiological process. No such role for complex I has yet been 
described. This consideration leads to a slight modification o f  the hypothesis arising 
from this study. Rather than suggesting that low levels o f  CCR are a normal, 
physiological event arising from any fluctuation in respiratory activity, it may be 
preferable to conclude that the event is indeed a pathological pro-apoptotic signal. It 
most likely results from increased levels o f  ROS generation. However, in very mild 
disease states where the CCR is at a low level, the signal is subject to buffering in the 
cytosol by IAPs, HSPs, GSH etc. Only once these other protective mechanisms are 
compromised (for example by increasing oxidative stress) or if  the CCR rises to a 
level above that which can be overcome by these systems, will apoptosis begin to 
implement the neurodegenerative process.
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CHAPTER 6
D oes cytochrome c release necessarily induce
apoptosis?
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6.1 Introduction
6.1.1 Progression from  isolated brain mitochondria to cultured neurons
It has been shown that very mild inhibition o f  complex I can induce a proportional 
amount o f  CCR from isolated brain mitochondria. This effect is not seen following 
complex IV inhibition, and it is suggested that the release induced by complex I 
inhibition is primarily mediated by ROS generation at this site. The release appears 
to occur via an OM channel and therefore the mitochondria probably remain 
energetically viable. The data imply that CCR induced in this manner is a pro- 
apoptotic signal which, instead of  being o f  an all-or-none nature, is subtly 
representative o f  the level o f  stress (perhaps oxidative stress). It is hypothesised that 
low amplitude CCR need not lead to apoptosis.
All o f  the data thus far originate from studies on isolated brain mitochondria. The 
reasons for using these organelles in isolation were explained in (3.1.3). This choice 
has yielded observations which may have simply been undetectable in whole cells. 
However, if  the hypothesis that low levels o f  CCR can occur in response to 
respiratory inhibition without apoptosis proceeding is to be proven fully, it is 
necessary to demonstrate that it is the case in whole cells. Uncertainty regarding the 
fate o f  released cytochrome c in the cytosol is a hindrance in detecting changes 
experimentally. Nonetheless the cytosolic effects on cytochrome c are crucially 
important in the interpretation o f  the results. The post-mitochondrial regulation 
events which occur in the cytosol determine whether or not apoptosis is allowed.
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6.1 .2  Post-mitochondrial control mechanisms
As has been alluded to several times, there are a number o f  reasons that released 
cytochrome c may not induce apoptosis:
6 .1.2.1 Insufficient release
The cytosolic IAPs (Crook et a l, 1993; Holcik et a l, 2001), the chaperone Hsps 
(Pandey et a l, 2000; Saleh et a l, 2000), physiological concentrations o f  K+ (Cain et al, 
2 0 0 1 ) and perhaps other, as yet unrecognised mechanisms, act to prevent 
‘inappropriate’ apoptosis. This implies that purely the amplitude o f  the cytochrome c 
signal determines whether or not it overcomes the regulatory mechanisms. Murphy et 
al (2003) have provided an interesting demonstration o f  the importance o f  the 
amplitude o f  the cytochrome c signal. It appears that in human neutrophils, which 
contain significantly less cytochrome c than other cells (and are largely incapable of 
mitochondrial respiration), the apoptotic pathway is adapted to exhibit dramatically 
reduced requirements for the protein in the formation o f  the apoptosome.
6 .1.2.2 Solitary release
It has been reported on numerous occasions that micro injection o f  cytochrome c into 
cell cytosol is sufficient to induce apoptosis (Li et al, 1997; Zhivotovsky et al, 1998; 
among others). However, it was noted that NGF-maintained sympathetic neurons are 
remarkably resistant to this insult (Neame et al, 1998). This observation has been 
taken further by Deshmukh et al (2002), who claim that in primary neurons, CCR is 
insufficient as an isolated event to induce apoptosis. The authors state that the cell 
only develops ‘competence to die’ when the pro-apoptotic protein Smac is present in
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the cytosol along with cytochrome c. It is implied that if  CCR occurs by a 
mechanism which does not also cause Smac release, the cell is safe from apoptosis. 
Since these conclusions were drawn from a study involving microinjection o f  the pro- 
apoptotic proteins, it is unlikely that an explanation of  insufficient cytochrome c to 
overcome the IAP defence is valid.
6 .1.2.3 Redox state o f  cytochrome c
As mentioned previously (1.3.6 .5, 5.4.3.2), it has been suggested that the redox state 
o f  cytochrome c determines whether or not it will cause apoptosis to proceed. 
Hancock et al (2001) suggest that cytochrome c acts in a pro-apoptotic manner only 
when in the ferri (Fe3+) form. Unless the GSH status is compromised, for example by 
increased ROS generation, GSH will serve to keep cytochrome c in a reduced, and 
therefore ‘safe’ state.
6.2 Aims
Due to particular interest in the claim of Deshmukh et al (2002) regarding the 
requirement for Smac release for apoptosis in cultured neurons, further experiments 
were carried out on isolated non-synaptic rat brain mitochondria to determine whether 
rotenone treatment caused Smac release in addition to CCR.
Crucial experiments were then carried out on primary cortical neurons to determine 
whether rotenone treatment could induce detectable CCR which was insufficient to 
induce apoptosis.
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6.3 Results
6.3.1 The effect o f  rotenone treatment on Smac and AIF release
It was decided to investigate the release o f  AIF (1.3.3) alongside Smac, since release 
o f  the former would induce death via a caspase-independent pathway, and so 
dramatically change the interpretation of the data thus far.
Non-synaptic mitochondria were isolated from whole rat brains (2.2.1.2). The protein 
concentrations were measured (2.7.1) and the mitochondria then incubated at 37°C in 
the electrode chamber according to Incubation Scheme 1 (2.3.1.3). Titrations were 
carried out as in 3.3.1, using the same range o f  rotenone concentrations. However, 
two additional incubations were made for the purpose o f  this experiment. Prior to the 
rotenone titration, mitochondria (O.Smg.inf1) were incubated according to Incubation 
Scheme 3 (2.3.1.3). The second additional incubation was made after the final 
rotenone titration was complete. This was earned out according to Incubation 
Scheme 1 (2.3.1.3), using alamethicin (75pg.mg~' protein) in place o f  rotenone, as a 
positive control for membrane rupture, as described in 4.3.1.1.
No recordings o f  oxygen consumption rate or Ai|/m were made, but a 400pl aliquot 
was removed after each incubation and centrifuged at 17000xg for 5 minutes at 4°C. 
The supernatant was frozen immediately in liquid nitrogen and then stored at -70°C. 
Preparations were repeated to obtain n = 3 for each rotenone concentration. Any 
remaining untreated mitochondria after each titration were centrifuged at 17000x,g for 
5 minutes at 4°C, and the supernatants removed. The mitochondrial pellet was then
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also stored at -70°C, to be used as a positive control when blotting for the released 
proteins.
The supernatant samples were thawed and loaded onto a Tris-HCl pre-cast 12.5% gel 
(Bio-Rad, Bucks., UK) as described (2.4.5.1). The mitochondrial pellet sample was 
resuspended in lysis buffer, and stored on ice for 1 0  minutes with regular shaking. 
The sample was then centrifuged at 17000xg for 1 minute at 4°C, and the supernatant 
loaded onto the gel also.
Once the gels had been run and transferred (2.4.5.1, 2.4.5.2), the membranes were 
probed for Smac and AIF (using V-17 anti-smac and D-20 anti-AIF, Santa Cruz 
Biotenhnology Inc., respectively) (2.4.5.3). Typical blots (from n = 3) for each of the 
two proteins can be seen in Figure 6.1a and 6.1b. Figure 6.1a. demonstrates the effect 
of rotenone treatment on AIF release. There is a very strong signal (somewhat 
difficult to resolve) resulting from the whole mitochondrial pellet and a clear band 
from the supernatant o f  alamethicin treated mitochondria. There is a very faint band 
arising from the control incubation (mitochondria in 37°C buffer with BSA) and this 
is unchanged throughout the rotenone titration.
Figure 6.1b demonstrates the effect o f  rotenone treatment on Smac release. The 
positive control (whole mitochondrial pellet) yielded a faint band, but no other 
treatments caused any detectable Smac signal. The background from the Smac blots 
was more variable than for the AIF blots, due to the longer exposure time required to 
visualise the positive controls.
229
aFigures 6.1a and b
Western blots demonstrating the release o f AIF (a) and Smac (b) from isolated non- 
synaptic rat brain mitochondria. In a, arrow marks 67kDa, in b, arrow marks 24kDa. 
Lane numbers indicate the following treatments:
Lane Sample type Incubation
Scheme
Rotenone
(nmoles.mg'1
protein)
Alamethicin
(Hg.mg'1
protein)
1 Lysed mitochondria 
(30pg)
N/A N/A N/A
2 Supernatant (15pl) 3 0 0
3 Supernatant (15pl) 1 0 0
4 Supernatant (15pl) 1 0.075 0
5 Supernatant (15pl) 1 0.150 0
6 Supernatant (15pl) 1 0.225 0
7 Supernatant (15pl) 1 0.300 0
8 Supernatant (15pl) 1 0.375 0
9 Supernatant (15pl) 1 0 75
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6.3.2 Treatment o f  primary cortical neurons with rotenone
Primary cortical neurons were grown in culture as described in 2.2.2.1. At day 6 , 
they were treated using neuronal medium containing ethanol vehicle or sterile 
rotenone. Experiments were carried out to determine the range o f  rotenone 
concentrations required for titration. A maximum concentration was sought which 
would be just sufficient to cause an observable deterioration o f  viability (as assessed 
by phase contrast light microscopy). Each preparation yielded approximately 20-30 
million neurons, and 8  million cells were to be required for each rotenone 
concentration in the experiments to follow (see 6.3.2.1 and 6 .3.2.2). Therefore, the 
‘titration’ would consist only o f  one control and two rotenone treatments. The 
treatment conditions selected from the preliminary experiments were OnM (ie. 
control, ethanol vehicle alone), lOnM and 20nM rotenone. The treatment was applied 
for 24 hours.
Phase contrast light microscope images o f  neurons following these treatments are 
shown in Figures 6.2a, 6.2b and 6.2c. There is no observable difference between the 
morphology o f  control treated neurons and those subjected to lOnM rotenone. 
However, the cells treated with 20nM rotenone are beginning to show marked 
deterioration o f  their connections and the density o f  viable cell bodies is reduced.
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Figure 6.2a
Primary cortical neurons following 24 hours treatment with ethanol vehicle alone. 
Phase contrast light microscope image at X20 objective, scale bar represents 40pm.
732
Figure 6.2b
Primary cortical neurons following 24 hours o f treatment with lOnM rotenone. The 
cells demonstrate no observable difference in morphology from control neurons (See 
Figure 6.2a). Phase contrast light microscope image taken at X20 objective, scale 
bar represents 40pm.
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Figure 6.2c
Primary cortical neurons following 24 hours o f  treatment with 20nM rotenone. The 
connections between the cells have visibly deteriorated, and there are less cell bodies 
apparent than control neurons (see Figure 6.2a) or those which have been treated 
with lOnM rotenone (see Figure 6.2b). Phase contrast light microscope image taken 
at X20 objective, scale bar represents 40pm.
6.3.2.1 Induction o f  caspase-9  activity by  ro tenone
Having established 0, 10 and 20nM rotenone as the treatment conditions (6.3.2), an 
experiment was carried out to determine the effect o f  rotenone treatment on caspase-9 
activity. Primary cortical neurons were cultured as described. On day 6 , each o f  the 
three treatments was applied to 8  million cells (ie. each treatment used on 4 wells of 
neurons). After 24 hours, 4 million cells from each treatment condition were 
harvested by scraping in HBSS (at 37°C). The cells were centrifuged at 500xg for 5 
minutes at 4°C, and the supernatant removed. The pelleted cells were then frozen 
immediately in liquid nitrogen and stored at -70°C. (The other 4 million cells for 
each treatment condition were to be used as described in 6 .3.2 .2 ).
The pellets were thawed and lysed by incubating with lysis buffer (from colorimetric 
caspase-9 activity kit, R&D Systems, Abingdon, UK) for 10 minutes on ice with 
gentle shaking. The lysed suspension was then centrifuged at lOOOOxg for 1 minute. 
50pl of the resulting supernatant was used to assay for caspase-9 activity as described 
in 2 .6 . 1 .
The results are shown in Figure 6.3. There was no significant change in caspase-9 
activity from control levels following 24 hours treatment with lOnM rotenone (p > 
0.05, paired t-test). However, following 24 hours o f  treatment with 20nM rotenone, 
there was a significant increase in caspase-9 activity as compared to control levels (p 
< 0.05, paired t-test).
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Figure 6.3
Effect o f rotenone treatment on caspase-9 activity, expressed in arbitrary units of 
absorbance (at 405nm) per milligram protein. lOnM rotenone does not affect the 
level o f caspase-9 activity, but 20nM rotenone significantly increases it (p < 0.05, 
paired t-test). Data shown ± S.E.M., n = 4.
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6.3.2.2 Induction o f  cytochrome c release by rotenone
The primary cortical neurons treated as described above (6.3.2.1) were also used to 
assay for CCR into the cytosol. The second 4 million cells from each treatment were 
harvested by scraping into HBSS (at 37°C), and then centrifuged at 500xg for 5 
minutes at 4°C. A cytosolic extract was then obtained by resuspending the cell pellet 
in lysis buffer (from colorimetric caspase-9 activity kit, R&D Systems, Abingdon, 
UK) for 10 minutes on ice with gentle shaking. This lysis buffer ruptures the cell 
membrane but leaves intracellular organelles eg. mitochondria, intact. After 10 
minutes, the suspension was centrifuged at 17000xg for 10 minutes at 4°C. The 
supernatant was removed and frozen immediately in liquid nitrogen. The sample was 
stored at -70°C.
The samples were collected and then thawed together and assayed for protein content 
(2.7.1). The cytochrome c content was then measured (2.4.1). The cytochrome c 
concentration expressed per milligram of protein is plotted against rotenone 
concentration in Figure 6.4.
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Figure 6.4
Effect o f rotenone treatment on the release of cytochrome c in primary cortical 
neurons. Cells treated with lOnM rotenone had a significantly (p < 0.05, paired t- 
test) greater cytochrome c concentration in the cytosolic fraction than control cells. 
Cytosolic fractions of cells treated with 20nM rotenone also contained significantly 
more cytochrome c than controls (p < 0.05, t-test), hut not significantly (p > 0.05, 
paired t-test) more than the lOnM treated cells. Data shown ± S.E.M., n = 4.
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6.4 Discussion
6.4.1 Specificity o f  rotenone-induced cytochrome c release
A recent study by Desmukh et al (2002) claimed that the presence o f  cytochrome c in 
the cytosol o f  neurons is insufficient to induce apoptosis. The authors state that in 
order to develop ‘competence to die’, a neuron must also overcome regulation of 
active caspases by the IAP system. This occurs when Smac is released from the 
mitochondrial IMS. It would have been interesting for the study to have investigated 
further into the effect o f  varying the amplitude o f  the microinjected cytochrome c 
signal, since it would be expected that if the concentration o f  cytochrome c were to be 
made high enough, the IAP system would be overwhelmed. Perhaps the coordinate 
release o f  Smac is only required if  the cytochrome c signal is especially weak. The 
threshold concentration o f  cytochrome c required may be higher in neurons due to the 
presence o f  extra IAP capacity, in the form of NAIP (1.3.6.1). Whether or not their 
hypothesis requires further validation, the authors o f  this intriguing study highlighted 
the important role o f  Smac in determining the fate o f  the host cell.
It was therefore considered important to investigate whether the rotenone-induced 
CCR detected in 3.3.2 was accompanied by Smac release. In contrast to cytochrome 
r, there is no commercially available immunoassay kit for Smac. Therefore the 
release o f  Smac was analysed by Western blotting. A positive Smac signal could 
only be detected in the lysed mitochondria. None o f  the supernatants, including that 
from the mitochondria treated with alamethicin, showed any detectable signal. 
Although alamethicin is known to be capable o f  causing CCR (Kluck et al, 1999), it
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has never been shown to induce Smac release. It is thought that Smac and 
cytochrome c are released by different mechanisms (Kandasamy et a l, 2003; Rehm et 
al, 2003), and so it is possible that additional events other than OM rupture are 
required for Smac release. Alternatively, the lack o f  evidence for Smac in the 
supernatant from alamethicin-treated mitochondria may simply indicate that the 
method has insufficient sensitivity for detection o f  the protein in these supernatant 
samples. Therefore, the conclusion that rotenone in the experimental range does not 
induce Smac release can only be drawn tentatively. This uncertainty highlights the 
considerable benefits of the quantitative immunoassay technique for assaying CCR.
In contrast, blotting for AIF proved more conclusive. AIF is another IMS protein 
which may be released to induce apoptosis (1.3.3). Western blotting demonstrated 
clearly that AIF was present in the mitochondrial control and in the supernatant from 
alamethicin-treated mitochondria. A much lower level was present in the supernatant 
from the mitochondria which were simply incubated in buffer at 37°C containing 
BSA. This level was consistent across the rotenone treatments, implying that 
rotenone in this range does not induce AIF release.
AIF is a much larger protein than cytochrome c (67kDa as opposed to 12.1kDa). It is 
therefore not very surprising that the CCR mechanism does not extend to AIF, 
bearing in mind the data obtained with respect to AK release (4.3.2). More 
interesting from this aspect is the tentative claim that Smac is not released with 
cytochrome c. As discussed (4.4.2), AK and Smac are almost identical sizes, both 
approximately double the size of cytochrome c. When it was determined that AK 
was not released with cytochrome c , it was hypothesised that the same might be true
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of Smac. The blotting data is supportive of the suggestion that the release mechanism 
is either specific for cytochrome c, or carries a size ‘cu t-off between 12.1 and 24kDa.
The fact that neither o f  these pro-apoptotic proteins appear to be released with 
cytochrome c is consistent with the hypothesis that low levels o f  CCR induced by 
rotenone may be ‘safe’. The lack o f  AIF release suggests that caspase-independent 
death will not be induced. The apparent lack o f  Smac release leaves the cytosolic 
IAP system with its full capacity for buffering low levels o f  CCR.
6.4.2 Rotenone-induced caspase-9 activity
Rotenone at lOnM had no effect on the caspase-9 activity in primary cortical neurons. 
However, increasing the intensity o f  the treatment to 20nM caused a significant 
increase in the measured caspase-9 activity. The important conclusion to be drawn 
from this part o f  the study is that there is a threshold concentration o f  rotenone 
treatment, above which early apoptotic events can be detected.
Ideally, several more measures o f  apoptosis would be made, eg. LDH distribution, 
Hoechst staining. However, the yield o f  neurons from each preparation was 
extremely restricted, and the caspase-9 and cytochrome c measurements alone were 
sufficient to limit the titration to three rotenone concentration points. Caspase-9 
activity was chosen as the most useful measurement o f  apoptosis for several reasons: 
Firstly, the only recognised means by which procaspase-9 is activated is via the
241
mitochondrial pathway . 2 Caspases later in the cascade eg. caspase-3, can be activated 
through the cell surface receptor route also. Therefore the use o f  caspase-9 activity as 
an apoptotic marker simplifies the model, and makes it easier to draw conclusions 
from the data. Secondly, caspase-9 is an ‘initiator’ caspase. It is the first one to be 
activated via the cytochrome oinduced pathway (Zou et al, 1999), and therefore is a 
marker o f  the early stages o f  apoptosis. This enabled a very sensitive analysis o f  the 
pro-apoptotic properties o f  cytochrome c , since cells which have not yet progressed to 
the later, more traditional markers of apoptosis, may nonetheless have committed to 
the pathway. Also, considering the amplification involved in the caspase cascade 
(Creagh & Martin, 2001), the activity o f  an early caspase such as -9  gives a purer 
indication o f  the direct effect o f  any released cytochrome c.
6.4.3 Rotenone-induced cytochrome c release
The benefits o f  modelling the recognised disease pathology rather than recreating 
downstream events were discussed in 5.1.1. Here, the same principle has been 
applied. Rather than microinjecting cytochrome c into cells, an approach often 
followed (Deshmukh et al, 2002; Li el al, 1997; Zhivotovsky et al, 1998), the 
experiment was carried out using a model o f  an underlying disease cause, ie. complex
1 deficiency (Perier et al, 2003).
A discrepancy was observed in the data resulting from lOnM rotenone treatment. A 
significant increase in CCR was detected at 10nM rotenone, whereas a significant
2 (F o o tn o te :  a n  e x tr e m e ly  r e c e n t  p u b lic a tio n  h a s r e p o r te d  c y to c h r o m e  c - in d e p e n d e n t  p r o c a s p a s e -9  
a c tiv a tio n  -  M c D o n n e ll  e t al, 2 0 0 3 . Th is is o b v io u s ly  y e t  to  b e  c o n fir m e d  o r  r e fu te d  b y  su b s e q u e n t  
w ork).
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increase in caspase-9 activity was not detected until the rotenone treatment was raised 
to 20nM.
6.4.4 The discrepancy between caspase-9 activity and cytochrome c release
As discussed (1.3.6), there are a number o f  recognised post-mitochondrial 
mechanisms for regulating the commitment to apoptosis. O f  these, the IAPs have 
featured heavily in the literature. Crucially, in the context o f  this study, it has been 
demonstrated that X1AP can inhibit the activation o f  procaspase-9 (Shiozaki et al, 
2003). The authors demonstrate that XIAP sequesters procaspase-9 in a monomeric 
state. Since homodimerisation drives the activation o f  procaspase-9 (Renatus et al, 
2001), this mechanism serves to inhibit progression down the caspase cascade. It can 
therefore be hypothesised that the discrepancy in rotenone concentrations required for 
increased caspase-9 activity and CCR might be explained by this action of XIAP and 
perhaps other IAP family members.
It is likely that the other post-mitochondrial regulatory mechanisms might also 
contribute to the caspase-9 activity versus CCR discrepancy observed. However, as 
yet, there is insufficient understanding o f  the mechanism o f  sequestration o f  
cytochrome c by Hsps, or the prevention of apoptosome formation by K+ to be able to 
conclude whether or not the immunoassay would detect cytochrome c which had 
fallen subject to these regulatory processes. Provided that the monoclonal antibody 
binding site on cytochrome c had not been altered or obstructed, the assay would still 
detect the protein, but it cannot at this stage be concluded that this is the case.
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As discussed previously (5.3.4), cytochrome c which is released in response to 
complex 1 inhibition will be primarily in the ferri state. According to the hypothesis 
presented by Hancock et al (2001), this cytochrome c has pro-apoptotic potential due 
to its redox state, but can be made ‘safe’ by the action o f  cytosolic GSH, which will 
reduce the cytochrome c to the ferro form. This could also help to explain the 
‘delayed’ increase in caspase-9 activity. It is interesting to note that the neuronal 
culture method uses media which has been ‘conditioned’ by incubating with 
astrocytes for 24 hours. It has been suggested that astrocytes lend important support 
to their neuronal neighbours in the form o f transmitted GSH (Gegg et al, 2003), and 
this would have been modelled by the use o f  conditioned media. It would be 
interesting to determine the level o f  protection afforded by astrocytic GSH with 
respect to maintaining the cytosolic cytochrome c pool in a reduced state.
It could be argued that the discrepancy at lOnM rotenone is due to a difference in 
sensitivity o f  the two assays. However, both methods are highly quantitative. 
Conclusions regarding caspase activation have been drawn in the literature using data 
from Western blotting (eg. Gu et a l, 1999), which has limited quantitative value, as 
has been discussed (3.1.2). A sensitive activity assay, as has been used in this study, 
is preferable for determining very small changes. An explanation o f  insufficient 
sensitivity is therefore unlikely to be valid, but is worth taking into consideration.
6.4.5 Implications o f  the effect o f  rotenone on neurons
This experiment has demonstrated that when CCR is induced by rotenone-induced 
complex I inhibition, there is a threshold rotenone concentration at which the
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apoptotic pathway is triggered. It would appear that below this threshold, caspase 
activity is not induced.
In contrast to this apparent threshold effect for rotenone-induced caspase-9 activation, 
it has been shown using experiments on isolated mitochondria (3.3.2) that rotenone- 
induced CCR shows no such threshold effect. Rather, CCR is increased in proportion 
to complex I inhibition. It can therefore be concluded that low levels o f  cytochrome c 
present in the cytosol can be buffered, and ‘made safe’ with respect to caspase 
activation. This conclusion is relevant to CCR induced by complex I inhibition, but 
may not apply to CCR induced by other mechanisms, which may perhaps be more 
detrimental to mitochondrial integrity.
The findings are particularly relevant in the understanding o f  the pathology o f  
Parkinson’s disease. In early disease states, where complex I activity would be 
expected to be only marginally reduced, it is likely that the cytochrome c signal is 
already being increased. However, the cells’ natural defences are able to buffer its 
pro-apoptotic activity up to a point. Only once these defences are overcome does 
neurodegenerative cell loss ensue.
It would appear to be the case that it is primarily the amplitude o f  the cytochrome c 
signal which is the important factor. Rotenone is known to be capable o f  inducing 
apoptosis provided that the concentration is sufficient (Gao et al, 2002; Pei et al, 
2003). From our preliminary blotting data, it would appear that Smac is not required 
to induce this death, in contrast to the claim o f Deshmukh et al (2002). However, 
direct measurement o f  Smac levels in the cytosol o f  treated neurons would be
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required to confirm this suggestion because it is difficult to equate the strength of 
rotenone treatment between the isolated mitochondria and the cultured cell 
experiments. It is intuitive that Smac should only be required in the initiation of 
apoptosis if the cytochrome c signal is too weak to overwhelm the IAP inhibition 
alone.
Taking account o f  these considerations, the IAP system presents itself as a very 
promising therapeutic target. If this family o f  proteins could be clinically exploited, 
the threshold level o f  CCR could be raised to effectively delay onset of 
neurodegenerative symptoms in Parkinson’s disease patients.
6.5 Conclusions
This final section to the study has lent considerable support to the hypothesis that 
CCR induced by complex I inhibition need not necessarily lead to apoptosis. 
Neuronal cells appear to be able to tolerate a low level o f  CCR without undergoing a 
detectable increase in the activity o f  the first caspase to be affected by cytochrome c. 
Further investigation would ideally include a number o f  other assays for apoptotic 
markers, to confirm this conclusion.
There are a number o f  possible mechanisms by which cytosolic cytochrome c can be 
made ‘safe’. It would be interesting to investigate further in order to determine the 
relative importance o f  such mechanisms. The IAP system, in particular, is of 
potential therapeutic use with respect to early treatment for Parkinson’s disease and
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perhaps other neurodegenerative diseases. Work in this area i 
some interesting results (Crocker et al, 2003; Kugler et a l, 2000).
already providing
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CH APTER 7
General D iscussion
The discovery o f  the role which cytochrome c plays in the apoptotic pathway has 
opened up a huge field o f  research. There has been considerable interest in the 
mechanism by which the protein is liberated, with recent advances increasingly 
claiming release via channels in the mitochondrial OM. Another rapidly emerging 
field is that o f  post-mitochondrial mechanisms for regulation o f  apoptosis, such as the 
IAP system.
These two advances in particular are consistent with the hypothesis that CCR need 
not be complete within a cell, but may occur at low levels. CCR o f  small amplitude 
is often described as ‘accidental’. If this occurs, there are mechanisms in place to 
prevent the amplifying caspase cascade from being induced.
The data in this study provide the first complete demonstration that CCR can be 
induced in proportion to the severity o f  an insult to the mitochondria, and that low 
levels o f  release induced by a minor insult do not appear to induce apoptosis. This 
low amplitude release is probably not ‘accidental’ as often described, but instead a 
weak pro-apoptotic signal, which appears to be sub-threshold with respect to the 
activation o f  procaspase-9.
These findings can be attributed largely to the careful selection o f  methods for the 
study. It was vital to the hypothesis that the stimulus used to induce CCR was a 
recognised model o f  a naturally-occuring pathology, and that the severity could be 
titrated. This ‘bottom-up’ approach was used to determine the dynamics of CCR in a 
disease state. This is in contrast to the often used approach which uses a stimulus
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chosen because o f  its recognised ability to cause the CCR event, but with little or no 
relevance to the underlying cause. Comparatively, this is much less useful with 
respect to determining mechanisms of  disease.
The second methodological advantage was the immunoassay used for measuring 
CCR. There were no published reports using an ELISA assay for this purpose when 
this study commenced. This method has now been used in published work on a 
number o f  occasions (Brustovetsky et al, 2003b, Jemmerson et al, 2002), and 
cytochrome c ELISA kits are now available from several manufacturers. The method 
affords significant advantages over the more traditional means for measuring CCR, 
such as Western blotting or fusion with green fluorescent protein. The former method 
has comparatively little quantitative value; even using densitometry readings, the data 
is subject to background variation. Use o f  the GFP fusion protein is claimed to have 
quantitative value, but it has been shown that when fused to GFP, cytochrome c 
displays altered properties with respect to release from mitochondria due to the size 
increase (Roucou et a l, 2000). The immunoassay method, in contrast, is highly 
quantitative, can be used to measure large numbers o f  samples simultaneously and is 
not subject to the same experimental variation as other methods. These advantages 
probably underlie the recent surge in utilisation o f  the technique.
This study was carried out primarily on isolated brain mitochondria. The use of 
isolated mitochondria enabled a sensitive and accurate determination o f  CCR, 
eliminating the effects o f  cytosolic regulation mechanisms, which would be very 
difficult to quantify. Brain mitochondria were used due to the particular importance 
o f  controlling the induction o f  apoptosis in mature neurons. Apoptosis is a major
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mechanism o f  neurodegenerative cell loss, and the incidence o f  ‘unnecessary’ 
apoptosis in neurons clearly has severe implications.
There is no immediately obvious reason that proportional release o f  cytochrome c, in 
response to an insult which is increasing in severity, should be a phenomenon 
restricted to the brain. The gradient o f  the respiratory inhibition versus CCR curve 
may exhibit tissue variation due to the extent o f  ETC-mediated ROS generation or 
pro:anti-apoptotic Bcl-2 protein ratio for example. However, the proportional 
relationship itself does not present any clear basis for tissue specificity.
However, even if this proportional relationship were true o f  mitochondria in general, 
there is considerable potential for tissue heterogeneity with respect to the threshold 
cytochrome c concentration required for apoptosis. It might be expected that neurons 
would exhibit a higher threshold than hepatocytes, for example, which are highly 
proliferative cells. It is interesting to note that there is a neuronal specific IAP, NAIP 
(1.3.6.1). This protein could convey added security onto a neuron to raise the 
threshold for apoptosis.
Crucial to the conclusion that low amplitude CCR need not lead to apoptosis were the 
features o f  the release mechanism. The retained integrity o f  the IM and lack o f  non­
specific rupture o f  the OM would leave the mitochondria energetically viable, and 
therefore capable o f  supporting a host cell if it were to survive. These findings cannot 
however be extended to situations beyond those tested in this study. It is likely that 
MPT is responsible for CCR in other situations, for example in response to raised 
intracellular calcium levels. The mechanism o f  CCR induced by complex I inhibition
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is however o f  great interest in isolation from other apoptotic scenarios due to the 
implications for the pathology o f  Parkinson’s disease.
This study has demonstrated that primary cortical neurons can tolerate low levels of 
CCR which result from inhibition of  complex I activity, implying that there is a 
threshold level at which CCR becomes sufficient to induce caspase-9 activity. 
Considering heterogeneity between neurons, this could cause a gradually increasing 
proportion o f  the cells to commit to apoptosis, underlying the slow progression of 
Parkinson’s disease or other neurodegenerative disorders. This could be mediated by 
the age-related increase in ROS generation resulting from mitochondrial DNA 
mutations (Lee & Wei, 1997), given the suggestion that CCR is induced by 
mitochondrially-generated ROS (5.4.3.1).
Possibly the most important implication o f  this study concerns potential directions for 
therapy in neurodegenerative disorders. The threshold effect described for 
cytochrome c-mediated induction o f  apoptosis reinforces the considerable interest in 
IAPs as therapeutic targets. Bearing in mind the uncertainty regarding the molecular 
details o f  the CCR mechanism, it is important to have determined that cytochrome c 
presence in the cytosol need not be eliminated completely for therapy to be effective. 
(Indeed if low levels o f  CCR are in fact a defensive anti-oxidant mechanism in 
response to ETC-generated ROS -  see 3.4.2.2, 5.4.3.1 -  then complete elimination of 
cytosolic cytochrome c may actually be detrimental). Rather, from the apparent 
threshold effect, it would seem feasible to aim to increase the threshold at which 
caspase activity is induced. The findings from this study imply that this strategy 
would be sufficient to prolong onset o f  neurodegenerative symptoms without
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additional problems arising from mitochondrial deficiencies. Indeed it has been 
shown previously that substantial complex I inhibition is possible before ATP 
synthesis is compromised (Davey & Clark, 1996; Davey et al, 1998).
The therapeutic potential o f  lAPs is already being probed for use in conditions where 
dysregulation o f  apoptosis is a primary part o f  the pathology. This includes cancer, as 
well as neurodegenerative disorders. O f particular interest with respect to this study 
is the finding that over-expression o f  XIAP can protect CA1 hippocampal neurons 
from ischaemia-induced apoptosis (Xu et al, 1999). The protection was o f  both a 
histological and, importantly, a functional nature. Surprisingly, perhaps, over­
expressed XIAP has also been shown to be capable o f  rescuing retinal ganglion cells 
from apoptosis induced by axotomy o f the optic nerve, even when the therapy was 
only applied subsequent to the insult (Kugler et a l, 2000). Use o f  XIAP or other IAPs 
in gene therapy may therefore be o f  real therapeutic value in delaying the symptoms 
of  neurodegenerative disorders.
A major hindrance in therapy for neurodegenerative diseases is the lack o f  official 
diagnosis until post mortem. Symptoms only become apparent once significant 
‘inappropriate’ apoptosis has occurred. Therefore, therapy would initially be aimed 
at delaying further degeneration rather than preventing onset o f  the disease. 
However, screening for individuals at risk, and methods for early detection o f  these 
diseases would be o f  considerable benefit for this strategy.
There are o f  course potential complications associated with using up-regulation of 
IAPs as a therapeutic strategy. Upsetting the balance o f  pro- and anti-apoptotic
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proteins carries huge risks in terms o f  tumourigenesis. Normal apoptotic potential is 
also essential for development, although this is less likely to be o f  concern in the 
treatment o f  neurodegenerative diseases, which are associated with aging. However, 
if these complications can be overcome, the strategy o f  raising the threshold for 
cytochrome c mediated induction of apoptosis could prove extremely fruitful. The 
support lent to this line o f  research by this study is extremely important. The study 
has demonstrated on a number o f  levels using the relevant subject material (brain 
mitochondria and primary neurons) and a recognised model o f  the disease pathology 
(complex I inhibition to model Parkinson’s disease) that the strategy is feasible.
The data reported here have highlighted the sophisticated mechanisms employed by a 
cell to regulate commitment to apoptosis. Consistent with the tightly controlled 
apoptotic program, whereby cellular contents are neatly packaged and damage 
limitation is paramount, the initial ‘decision’ as to whether or not to commit to the 
program is not made rashly. However, the considerable amplification and positive 
feedback loops involved in the caspase cascade ensure that apoptosis itself is a 
definite all-or-none event. This contrast between the ‘reluctance’ to commit to 
apoptosis and the amplification o f  an initially small pro-apoptotic signal is an 
intriguing feature o f  the cell death program, and one which needs to be carefully 
considered when attempting to regulate the incidence o f  apoptosis for therapeutic 
benefit.
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Future work
Given the considerable implications o f  the data from this study, it would be 
interesting to extend the project in a number o f  directions.
1 This study was carried out using isolated mitochondria and cultured cells 
from rat brain, the reasons for which were described in 3.1.3. As 
described in Chapter 7, there is no clear reason that CCR occurring in 
proportion to complex 1 inhibition should be a feature restricted to 
mitochondria from brain. However, the amplitude o f  the signal might be 
expected to vary.
It would therefore be interesting to repeat this part o f  the study using 
mitochondria isolated from tissues other than brain. Given the readiness 
o f  hepatocytes to undergo apoptosis, liver mitochondria would be 
particularly useful subjects.
2 There are a number o f  other inhibitors which could be used to further 
elucidate the CCR mechanism discussed in Chapter 4. Bonkrekic acid is a 
more specific inhibitor o f  the MPT, acting on the IM ANT. There are 
considerably fewer reports in the literature o f  the effects o f  this inhibitor, 
and it has only recently become readily commercially available. The use 
o f  this tool would, however, provide information on whether additional 
components o f  the PTP are involved in this case. It would also be 
interesting to investigate the role o f  other Bcl-2 proteins, eg. Bax.
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3 Further investigation is required to conclusively demonstrate whether 
ETC-generated ROS are responsible for inducing the observed CCR. Use 
o f  exogenous GSH in isolated mitochondrial incubations would 
demonstrate whether this was the case.
4 The preliminary data obtained in Chapter 6  from cultured neurons would
benefit from more extensive investigation. In particular, markers of 
apoptosis additional to increased caspase-9 activity would add to the 
validity o f  the conclusions. Control experiments could also be carried out 
to confirm the manufacturer’s claim that the effect o f  the lysis buffer is 
limited to the cell membrane and does not disrupt mitochondrial integrity. 
The very limited yield o f  neurons from each preparation prevented these 
experiments from being done in the course o f  this study.
5 Affinity chromatography could be used to identify new candidates for
cytochrome c-binding proteins in the cytosol. This study has yielded 
results highly consistent with the concept o f  cytosolic ‘buffering’ o f  low 
levels o f  cytochrome c in the cytosol, and so provides a good basis for 
such an investigation.
6  In the same vein, it would be extremely interesting to determine the
‘buffering power’ o f  cytosols from different cell types. It might be 
determined that CCR occurs in proportion to complex I inhibition in 
tissues other than brain (see point 1). However, it is known that there is a 
neuronal specific IAP (NAIP), and this could contribute to a higher
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cytosolic buffering capacity in neurons than other cells from other tissues. 
This might be expected as an evolutionary adaptation considering the 
critical implications o f  neuronal apoptosis in mature brain. Determination 
o f  the relative level of IAPs, HSPs, etc. in neurons and other cell types 
would demonstrate whether the threshold cytosolic cytochrome c 
concentration required for apoptosis exhibits tissue heterogeneity.
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